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ABSTRACT
An increased concentration of insulin-like growth factor-1 (IGF-1) is recognized 
to be an independent risk factor for pre-menopausal breast cancer. Tamoxifen 
is thought to initially reduce IGF-1 concentrations and increase levels of the IGF 
binding proteins 1 and 3. Isoflavones are oestrogen-like plant compounds, 
which may, because of their structural similarities to tamoxifen, also alter IGF 
status.
This thesis first compares IGF-1, IGF binding protein 1(BP-1) and IGF binding 
protein 3 (BP-3) levels in breast cancer patients (n=14) compared with control 
subjects (n=23) and then assesses the effect of tamoxifen on IGF status after 9, 
18 and 27 months of treatment. Concentrations of IGF-1, BP-1 and BP-3 at 
baseline did not differ between cases and controls. However on tamoxifen 
treatment, BP-1 and BP-3 were both significantly increased after 18 and 27 
months while the IGF-1/BP-3 ratio was significantly decreased after 9 and 18 
months.
A feasibility study was then conducted to compare the effects of acute (single 
80 mg load) versus chronic (80 mg/day for 7 days) administration of isoflavone- 
containing soy and linseed cereal bars on IGF-1, IGFBP-1 and IGFBP-3 in 
healthy female volunteers (n=10). Assays were established for the analyses of 
serum IGF-1, BP1 and BP3 concentrations and GCMS analysis of isoflavones 
in urine. Concentrations of IGF-1 were unchanged following the single 80 mg 
load. However, IGF-1 and BP-3 concentrations were significantly elevated after 
a week of supplementation with the soy and linseed bar.
A larger study was then carried out to assess the effect of one-month isoflavone 
supplementation (80 mg/d) in tablet form, on IGF status in healthy pre- (n=16) 
and post-menopausal (n=7) women. This was a randomized, placebo-controlled
crossover study with a minimum two-month washout period. Hormonal, 
antioxidant and lipid altering effects of the supplement were also examined, as 
was background diet. For pre-menopausal subjects, while there was an effect of 
time on IGF-1 (p=0.005), BP-1 (p=0.004), and BP-3 (p<0.001) confirming that 
IGF profile is influenced by menstrual cycle, this did not differ between placebo 
and isoflavone supplement. When the change in IGF-1 over the whole 
supplementation period was compared between the supplement and placebo 
phases, there was a non-significant reduction in change in IGF-1 (p=0.06) on 
isoflavone supplement compared to placebo. However, this may have been 
due to the non-significantly higher baseline concentrations of IGF-1 during the 
supplement phase. In post-menopausal subjects, there was no effect of 
Isoflavone supplementation in comparison with placebo on IGF-1, BP-1 or BP-3. 
Finally, experiments were done in vitro to study the effect of isoflavones on DMA 
synthesis and proliferation in ERa positive MCF-7 and ERa negative MDA-MB 
231 human breast cancer cells. In MCF-7 cells, low concentrations of 
isoflavones (O.IpM-IOpM) stimulated DMA synthesis while high concentrations 
of genistein and equol were able to inhibit DMA synthesis with IC50 values of 
93pM and 55pM respectively compared with 1.17pM tamoxifen. In MDA-MB231 
cells the Isoflavones did not stimulate DMA synthesis at any concentrations but 
significantly inhibited DMA synthesis with 1050 values of 114pM, 14.1 pM and 
14.55pM for daidzein, genistein and equol respectively compared with 1.35pM 
tamoxifen.
This work suggests that isoflavone supplementation may alter IGF profile in pre­
menopausal women, and could suggest a role for these dietary compounds in 
breast cancer prevention. This should be further investigated in long term 
intervention studies with isolated isoflavone supplements.
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CHAPTER ONE -  INTRODUCTION
Breast cancer is one of the most important public health problems facing 
women in the UK and other Western populations today. With over 40,000 new 
cases diagnosed in the UK in 2000 alone, the disease accounts for 17% of 
female cancer mortality with almost 13,000 deaths in UK each year (Toms,
2004). Incidence rates have increased by 70% since 1971 with one in ten 
women developing breast cancer at some point in their lives (ONS, 31 October
2003). Breast cancer is a complex, multifactorial disease, but established risk 
factors include nulliparity, late first pregnancy, early menarche, late menopause, 
oral contraceptive use, hormone replacement therapy (HRT), obesity, increased 
alcohol consumption, exposure to ionising radiation and inheritance of 
mutations in the BRCA1 and BRCA2 genes (McPherson et al., 2000).
1.1 Role of dietary factors
There is strong epidemiological evidence that environmental factors such as 
diet have a role in breast cancer aetiology (Miller et al., 1994). This evidence 
initially came from population and migrant studies where Chinese, Japanese or 
Filipino’s who had lived in the United States for a decade or longer had a risk 
80% higher than more recent migrants (Ziegler et al., 1993). The timing of 
immigration to the US was also important in determining breast cancer risk and 
when migration occurred later in life, rates for breast cancer were substantially 
lower than when migration occurred early, although they were still much higher 
than in the homeland populations (Hunter & Willett, 1996; Shimizu et al., 1991).
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Subsequently, cohort and case-control studies have been carried out, mainly 
focussing on the hypothesis that a diet rich in fat can increases the risk of 
breast cancer (Hunter & Willett, 1996). Assessing this relationship is 
complicated and study design, dietary methodology and choice of study 
population is important (Miller et al., 1994). The results of prospective studies 
have largely been equivocal (Hunter & Willett, 1996), while fat-reducing 
intervention studies have shown some effects on total and free oestradiol in 
post-menopausal but not pre-menopausal women (Bingham et al., 1998). Other 
studies suggest that olive oil may be protective for its high levels of 
monounsaturated fatty acids and/or phenolic compounds (Hashim et al., 2005). 
However recent findings from large prospective studies in the UK and Europe 
(EPIC) suggest that risk of breast cancer is associated with intake of saturated 
fat (HR 1.22, 95% Cl 1.06-1.4), with 35g /day vs 10g/day approximately 
doubling risk (Bingham et al., 2003) in peri and post-menopausal women 
studied. While total or specific fruit and vegetable intake was not found to be 
associated with risk of breast cancer in pre or postmenopausal women in the 
initial analysis of data in women across 10 countries in Europe (van Gils et al.,
2005), the UK women's cohort study (n= 35,792) has found that for pre­
menopausal women, total fibre is significantly protective against breast cancer, 
especially fibre from cereals and possibly fruit (Cade et al., 2007), while high 
consumption of meat, especially processed meat, significantly increased risk of 
breast cancer (Taylor et al., 2007). It is possible that specific components of 
dietary fibre such as lignans present in seeds and wholegrains are responsible 
for reducing risk of breast cancer (McCann et al., 2004). There is also interest in 
the protective effect of other dietary factors, such as vitamins, other 
micronutrients and phytochemicals (Bingham et al., 1998).
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1.2 Isoflavones
Plants contain a large number of potential antioxidant/anticancer type 
compunds, known as phytoestrogens (Bingham et al., 1998), many of which 
can be classed as phenols, as they contain an active benzene ring with a 
hydroxyl group attached. An example of such compounds is the flavonoid family 
which are present in fruit and vegetables as the biologically inactive phenolic 
glycosides. The aglycone (sugar free) part of the compund is characterised by a 
C6-C3-C6 backbone. Sub groups such as Isoflavones and Flavanols have been 
classified to encompass differences in the position of ring B and varying 
degrees of oxidation and saturation of the pyrone ring (Figure 1.2.1). 
Isoflavones are found predominantly in legumes (peas, beans, lentils, etc). 
Soybeans and soy products are perhaps the most common food source of 
isoflavones and contain large amounts of the isoflavones genistein and daidzein 
(Coward et al., 1993). But other legumes, especially clovers, contain higher total 
levels and, in addition to genistein and daidzein, also contain formononetin and 
biochanin (Francis et al., 1967). Interest has focused on isoflavones and breast 
cancer due to the relatively low breast cancer mortality rates in Asian countries 
where soy foods are commonly consumed. In Japan and China, for example, 
the breast cancer mortality rate is about one quarter of that in the United 
Kingdom (Society, 2006). In addition, a lower proportion of breast biopsies from 
Asian women contain hyperplasia, atypical hyperplasia, and apocrine 
metaplasia than breast biopsies from American women (Sasano et al., 1975; 
Schuerch et al., 1982). The evidence linking isoflavone or soy intake with breast 
cancer risk comes from a number of sources and these will be considered in 
turn.
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Figure 1.2.1: Chemical structure of isoflavones and oestradiol.
Basic structure comprised of two benzene rings (A and B) linked through a 
heterocyclic pyran or pyrone (with a double bond) ring (c) in the middle
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1.2.1 In vitro evidence
Isoflavones have been considered weak oestrogenic compounds in vitro, 
binding to both oestrogen receptors a and p with a relative binding affinity of 4 
and 87 respectively for genistein (compared to 100 for oestradiol) (Kuiper et al., 
1997; Kuiper et al., 1998). Numerous studies In breast cancer cells show that 
Isoflavones stimulate growth at low concentrations but inhibit both hormone 
dependent and independent cells at high concentrations with genistein IC50 
between 5 and 40pM (Messina, 1999) (Magee & Rowland, 2004). Studies 
suggest that these biphasic effects are a result of estrogen dependent and 
independent mechanisms (Chen et al., 2003) (Chen et al., 2004).
Apart from anti-oestrogenic activity the mechanism whereby isoflavones reduce 
cell growth, particularly in oestrogen receptor-negative cells, is still to be fully 
elucidated. Other possible mechanisms include; antioxidant properties observed 
in vitro, and sitmulating several antioxidative enzymes like glutathione 
reductase and catalase (Ruiz-Larrea et al., 1997; Sierens et al., 2001; Sierens 
et al., 2002; Wei et al., 1993), inhibitory actions on several enzymes including 
aromatase and those involved in signal transduction, like tyrosine protein 
kinases (Akiyama et al., 1987), MAP kinase (Thorburn & Thorburn, 1994) and 
ribosomal S6 kinase (Linassier et al., 1990). Genistein has been shown to 
inhibit the activity of DNA topoisomerase I and II (Constantinou et al., 1990), 
inhibit angiogenesis (Fotsis et al., 1995) and metastasis (Li et al., 1999), 
increase apoptosis (Shao et al., 1998a) (Sarkar & Li, 2003), increase the in vitro 
concentrations of transforming growth factor p (Kim et al., 1998) and increase 
protein and mRNA expression of the IGF-1 receptor and IRS-1 (Chen & Wong,
2004). Genistein can also regulate signalling pathways involved in cell 
proliferation (NFKB and AKT) (Davis et al., 1999; Li & Sarkar, 2002), and has
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recently been shown to increase expression of all genes involved in cell cycle 
control apoptosis and DNA repair including BRAC1, p53, p21, Rad51, BARD, 
Bax GADD45 and RF1 (Gaetano et al., 2006). Genistein can also regulate 
many genes for which roles are still being discovered (Barnes, 2004; Naciff et 
al., 2002). It is also possible that phytoestrogen effects are mediated via their 
action on growth factors and growth factor binding proteins (Adlercreutz, 2002a; 
Chen & Wong, 2004) with vegetarian diets rich in phytoestrogens associated 
with low plasma concentration of insulin, insulin Like Growth Factor-1 (IGF-1) 
and higher levels of IGF-1 binding proteins and SHBG (Giovannucci, 1999). 
Although most of these studies have been carried out with genistein, daidzein 
also exhibits anti-cancer properties (Scholar & Toews, 1994), although it has 
received less attention (Jing et al., 1993), and biochanin produced greater 
growth inhibition than genistein in MCF-7 breast cancer cells (Peterson et al., 
1996) and has potent anti-mutagenic activity (Chae et al., 1991). The 
metabolite equol has also received greater attention recently with superior 
oestrogenic and antioxidant activity (Setchell et al., 2002).
In vitro studies suggest that physiological levels of oestrogen may also impact 
on the effect of isoflavones in vivo (Messina et al., 2006) and some findings 
suggest that the clinical relevance of these genomic and non-genomic effects 
found in vitro may not actually be significant (Santell et al., 2000). Thus caution 
is warranted in the interpretation of some of these studies because some of the 
effects may have been observed at higher concentrations than would be found 
in vivo.
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1.2.2 Animal evidence
Approximately 70% of early studies in rat and mice models (Barnes, 1995) have 
found that feeds of soy protein or whole soy beans had protective effects, 
lowering the number of carcinogen induced tumours when compared with 
standard diets. Isoflavone-depleted soy was found to be inactive in these 
models (Barnes, 1995). A recent review (Messina et ai., 2006) also found that 
the majority of rodent studies showed inhibition of tumour development with soy 
or isoflavone supplementation prior to carcinogen- induced tumours (Magee & 
Rowland, 2004) (Constantinou et al., 2001; Yan et al., 2002) or implanted 
cancer cells (Gallo et al., 2006; Zhou et al., 2004). However there were 
exceptions to this (Allred et al., 2004a; Cohen et al., 2000; Day et al., 2001 ; 
Thomsen et al., 2005) and a review (Cooke, 2006) suggests that isoflavones 
have limited benefit once cancer is established in animal models.
Studies using overectomized mice injected with MCF-7 cells and implanted with 
estrogen pellets found that diets rich in genistein (Hsieh et al., 1998), isoflavone 
rich soy protein (Allred et al., 2001), or isoflavone extracts (Allred et al., 2004b) 
stimulated tumour growth compared with standard diets once implanted 
estrogen pellets were removed. Although this model is more inclined to show 
growth with weak estrogenic compounds, dietary genisten was still able to 
stimulate tumour growth in the presence of low levels of plasma estradiol 
mimicking conditions in postmenopausal women (Ju et al., 2006a).
The outcome of these studies are not only affected by the model used, but the 
type of soy product (Allred et al., 2004b; Constantinou et al., 2001) and specific 
isoflavone, with equol showing no stimulation of tumour growth when compared 
to daidzein (Ju et al., 2006b). Others have found that combinations of 
isoflavones with green/black tea (Zhou et al., 2004) or flaxseed (Thompson &
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Ward, 2005) give even greater benefit than either alone. Furthermore, the 
timing of exposure to the carcinogen compared with ovarectomy and isoflavone 
intake can also affect outcomes, with genistein increasing tumours under 
certain conditions (Allred et al., 2004a) (Ueda et al., 2003).
Stuides exposing pre-pubertal rats to genistein (Cotroneo et al., 2002; 
Lamartiniere et al., 2002a; Lamartiniere et al., 1995; Lamartiniere et al., 2002b) 
also reduced the number of tumours later induced by administering DMBA 
carcinogen to adults. It is thought that in this model genistein promotes cellular 
differentiation thereby causing breast epithelial cells to be less vulnerable to 
carcinogen initiation. Other studies have also shown that subcutaneous 
injection of genistein in newborn rats can protect against DMBA induced 
tumours while increasing tumour resistant biochemical markers (Cabanes et al., 
2004; Hilakivi-Clarke et al., 1999; Lamartiniere et al., 1995).
Certainly there are limitations with rodent studies and the large quantities of 
equol produced by rat gut flora vs human should be considered when using 
rodent models given that equol’s oestrogenic activities are comparable to 
genistein but with preferential binding to Er(3 (Cooke, 2006; Gu et al., 2006; 
Setchell et al., 2002; Setchell et al., 2005).
1.2.3 Epidemiological evidence
1.2.3.1 Soy/lsoflavone intake
Although there is supportive evidence from in vitro and animal studies that 
isoflavone intake may influence the risk of breast cancer, this clearly requires 
confirmation in human studies. Epidemiologic studies indicate that in 
populations with a high isoflavone intake the risk of breast cancer is reduced 
(Adlercreutz, 1990; Ingram et al., 1997; Wu et al., 1998), and that within ethnic
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groups whose diets are traditionally high in isoflavone intake, change in diet due 
to adoption of western lifestyle has led to an increase in breast cancer incidence 
(Buell, 1973; Lee et al., 1988).
Epidemiological studies of human dietary soy intake and breast cancer risk 
have recently been reviewed (Adlercreutz, 2002a; Adlercreutz, 2002b; Peeters 
et al., 2003) and include case control and prospective studies (Table 1.2.3.1).
To date, case control studies have assessed intake by dietary questionnaire 
(Hirose et al., 1995; Lee et al., 1991; Witte et al., 1997; Wu et al., 1996; Yuan et 
al., 1995) (Dai et al., 2001; Hirohata et al., 1985; Shu et al., 2001) and/or 
plasma/urine concentrations (Adlercreutz et al., 1986; Adlercreutz et al., 1982; 
Ingram et al., 1997; Pietinen et al., 2001). Those that have assessed intake 
through dietary questionnaires include the following:
Of studies conducted in China, (Yuan et al., 1995) found no association 
between intake of soy and risk of breast cancer in either pre or post 
menopausal women but did see a strong protective effect from fibre rich foods, 
while (Dai et al., 2001) did find a dose-response relation between soy food 
intake and breast cancer risk in women with high BMI (p=0.02). (Shu et al., 
2001) found that soy intake during adolescence (age 13-15) was associated 
with lower risk of breast cancer in later life.
In Singapore, high intake of soy was associated with a reduced risk in pre­
menopausal women but not in post-menopausal women (Lee et al., 1991) (Lee 
et al., 1992). In pre-menopausal women, high daily consumers (>55.0 g soy 
product) showed a 60% (95% 01 0.2, 0.9) reduced risk compared with low daily 
consumers (<20.3 g). Similarly, in Japan, a high intake of soybean curd (tofu) 
was associated with a statistically non-significant reduced risk of breast cancer 
in pre-menopausal but not in post-menopausal women. However, in both
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groups of women, there was no association between intake of miso soup, which 
was categorised in the food frequency questionnaire as daily or occasional-to- 
never, and breast cancer risk (Hirose et al., 1995). A recent smaller case control 
study in Japan, by the same author, found a statistically significant inverse 
association between tofu or isoflavone intake and risk of breast cancer in 
Japanese pre-menopausal women, but again this was not found with post­
menopausal women (Hirose et al., 2005).
A study In the USA and Canada (Witte et al., 1997) found that tofu intake was 
associated with lower risk of pre-menopausal bilateral breast cancer. Among 
Asian Americans, intake of tofu was associated with a lower risk of breast 
cancer both overall and separately in pre- and post-menopausal women. Similar 
results were obtained after adjustment for relevant menstrual and reproductive 
factors and selected dietary factors (Wu et al., 1996). Asian American women in 
the highest intake group (>120 times/y) showed a 30% reduced risk (95% Cl 
0.4, 1.0) compared with women in the lowest intake group (<12 times/y). 
Analysis by migrant status showed a significant protective effect in migrants but 
not in Western-born Asian Americans. Another case control study in a similar 
population of Asian Americans found that the risk of breast cancer was 
significantly inversely associated with soy intake during adolescence and adult 
life [OR=0.53, 95% CI=0.36-0.78], with women who reported soy intake at least 
once per week during adolescence showing a statistically significantly reduced 
risk of breast cancer (Wu et al., 2002). A recent case control study in Canada 
restrospectively assessed phytoestrogen intake during adolescence of breast 
cancer patients vs controls and also found that higher phytoestrogen intake 
(both isoflavones and lignans) during adolescence was associated with reduced 
risk of breast cancer, with a trend observed from the lowest to the highest
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quartile [OR =0.91, 95% Cl= 0.79-1.04, OR=0.71, 95% 01=0.62-0.82, p 
trend<0.001] (Thanos et al., 2006).
Recently a large case control study In Italy analysed intake of the six principal 
classess of flavonoids and found that only increased intake of flavones gave a 
significant reduced risk of breast cancer [OR=0.81, highest vs lowest quintiles, 
p-trend=0.02] (Bosetti et al., 2005). This appears to be in line with an earlier 
case control study done in Greece (Peterson et al., 2003).
Case Control studies that have assessed intake by plasma or urine 
concentrations include the following:
Two studies in Australia have looked at levels of isoflavones or their metabolites 
in biological fluids. (Ingram et al., 1997) carried out a case-control study of 144 
breast cancer patients and an equal number of age-matched healthy controls in 
Australia. When examining isoflavone and metabolite excretion in quartiles, as 
equol excretion increased, the relative risk of breast cancer was significantly 
reduced. The risk for the highest quartile of excretion of equol, after adjustment 
for confounding variables, was one quarter that of the lowest quartile. Similar 
effects were seen with respect to the lignan, enterolactone. Daidzein showed a 
similar pattern, but the trend was not significant. Unfortunately, the laboratory 
assay for genistein was not reliable enough to report results. These results were 
surprising as the total phytoestrogen intake of the study subjects, as estimated 
from the urinary phytoestrogen excretion, was very low (Messina et al., 1997).
A similar, preliminary study, also carried out in Australia but this time in post­
menopausal women and controls, found that those with breast cancer had lower 
24-h urinary daidzein excretion than controls (p=0.03) and a trend towards 
lower genistein (p=0.08) (Murkies et al., 2000). A study in China (Zheng et al.,
1999) showed that breast cancer cases had substantially lower levels of
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isoflavones in urine than age matched controls, while studies in Finland 
(Adlercreutz et al., 1986; Adlercreutz et al., 1982; Pietinen et al., 2001) have 
also found lower urinary and plasma enterolactone concentrations in women 
with breast cancer vs controls.
Two recent nested case control studies examining phytoestrogen 
concentrations from women participating in the large European Prospective 
Investigations into cancer (EPIC) have had conflicting results. In the UK 
population, where 333 women who developed breast cancer, higher equol and 
daidzein in serum and urine significantly Increased breast cancer risk (Grace et 
al., 2004). In this population the majority of women were post-menopausal, 
although analysis was combined. Analysis of the Dutch cohort of 383 women 
who developed breast cancer found that high levels of all isoflavones were 
associated with lower breast cancer risk and this was significant for plasma 
levels of genistein. These results were the same in pre and post-menopausal 
women (Verheus et al., 2007).
A number of larger prospective studies (den Tonkelaar et al., 2001; Hirayama, 
1992; Horn-Ross et al., 2002; Keinan-Boker et al., 2004; Key et al., 1999; 
Nomura et al., 1978; Yamamoto et al., 2003) have also been conducted using 
dietary assessments of intake as a marker for isoflavone status. Only one found 
significant results (Yamamoto et al., 2003), with consumption of miso soup and 
isoflavones (not soy foods) inversely associated with risk of breast cancer in 
Japanese women aged 40-59 years. Compared with those in the lowest quartile 
of isoflavone intake, the adjusted RRs for breast cancer for women in the 
second, third, and highest quartiles were 0.76 (95% Cl = 0.47 to 1.2), 0.90 (95% 
Cl = 0.56 to 1.5), and 0.46 (95% Cl = 0.25 to 0.84), respectively (P for trend =
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.043). This association was stronger in post-menopausal women (P for trend = 
.006) (Yamamoto et al., 2003).
Prospective studies that have examined plasma and urine concentrations of 
isoflavones include a study in pre-menopausal German women, which found a 
non significant positive association between isoflavones and breast cancer risk 
(Piller et al., 2006) and a study in Dutch postmenopausal women which found a 
weak but non-significant negative association between genistein urine 
concentrations and breast cancer risk (den Tonkelaar et al., 2001).
More recently meta-analyses have been conducted to assess soy intake and 
breast cancer risk. (Trock et al., 2006) analysed 12 case control and 6 cohort 
studies taking original measures of soy (soyfood intake or urinary isoflavone 
excretion) and converting them to an estimate of grams of soy protein 
consumed daily. They found high soy intake was modestly associated with 
reduced breast cancer risk [OR =0.86, 95% Cl =0.75-0.99] and this association 
was stronger in pre than post menopausal women [OR=0.7, 95% 01= 0.58-0.85] 
vs [OR=0.77, 95% 01=0.6-0.98]. (Qin et al., 2006) looked at 14 case-control and 
7 cohort studies, including studies published in Japanese and Chinese. They 
also found an inverse association with soy food/isoflavone intake and breast 
cancer [RR=0.75, 95% 01=0.59-0.95], with isoflavone intake resulting in a 20% 
decrease in risk [RR-0.81, 95% 01=0.67-0.99].
1.2.3.2 Hormone levels and breast cancer risk
Reviews of epidemiological and clinical data confirm that lifetime exposure to 
increasing concentrations of oestrogens and androgens significantly increases 
breast cancer risk (Clemons & Goss, 2001 ; Key, 1999; Peeters et al., 2003; 
Thomas et al., 1997). A review of data from prospective studies has found that 
levels of endogenous sex hormones are strongly associated with breast cancer
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risk in post-menopausal women (Key et a!., 2002), whilst a recent case control 
study nested within the European Prospective Investigation into Cancer and 
Nutrition cohort, found that elevated blood concentrations of androgens were 
associated with an Increased risk of breast cancer from 370 pre-menopausal 
women who subsequently developed breast cancer vs 726 matched cancer free 
control subjects (Kaaks et al., 2005).
Breast cancer patients have been shown to have shorter menstrual cycle 
lengths than control subjects (Olsson et al., 1983), while Asian women have 
longer cycle lengths than those in Western populations (Treloar et al., 1967). 
Women with shorter cycles will have a greater lifetime exposure to oestrogen, 
and also spend more of their reproductive lifetime in the luteal phase, where the 
mitotic rate for breast tissue is almost fourfold greater than during the follicular 
phase. Isoflavone supplementation, by increasing the length of the follicular 
phase, may therefore reduce the risk of breast cancer. Thus soy isoflavones 
may reduce risk of breast cancer by changing levels of endogenous hormones 
and altering the menstrual cycle (Adlercreutz, 2002a) (Bingham et al., 1998).
1.2.4 Intervention studies examining effect of isoflavone supplementation 
on hormone levels
A number of studies have looked at the effect of isoflavone supplementation on 
hormonal endpoints, in both pre and post-menopausal women, with varying 
results, and these are summarised in Tables 1.2.4.1 and 1.2.4.2.
In the controlled environment of a metabolic unit, studies have shown that 
consumption of isoflavone-rich soy extends the length of the follicular phase 
and therefore overall menstrual cycle and decreases serum follicle-stimulating 
hormone and luteinizing hormone concentrations (Cassidy et al., 1995; Cassidy
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et al., 1994). However, 36 oz of soy milk had no effect on LH or FSH levels in 
10 pre-menopausal women with no change in mean menstrual cycle length (Lu 
et al., 2000a; Lu et al., 2001). Only two studies have shown a significant 
reduction in oestradiol concentrations (Lu et al., 1996a; Wu et al., 2000). All of 
the studies reviewed (Table 1.2.4.1) showed a reduction in total progesterone 
concentrations measured in the luteal phase but only (Lu et al., 1996a) found 
this to be a significant reduction. SHBG levels measured in these intervention 
studies also varied with only two studies showing increases, and they were in 
the follicular (Nagata et al., 1998) and luteal phase respectively (Wu et al.,
2000). In a more recent randomised intervention study with 220 pre­
menopausal women (Maskarinec et al., 2004), there appeared to be no 
significant difference in the oestrone, oestradiol, progesterone and SHBG levels 
of the intervention group consuming ~50mg isoflavones daily vs control group in 
samples taken in the luteal phase (day 19) after 3,6,12 and 24 months. The 
authors concluded that the effects of soy on the breast, if they exist, are 
mediated by mechanisms other than the lowering of circulating estrogen levels 
in pre-menopausal women.
In post menopausal women Intervention studies have also produced mixed 
results (Table 1.2.4.2). In post menopausal women most soy intervention 
studies reviewed have produced no difference in levels of oestradiol, LH, or 
FSH (Baird et al., 1995; Berrino et al., 2001; Brooks et al., 2004; Brzezinski, 
1997; Duncan et al., 1999b; Foth & Nawroth, 2003; Murkies et al., 1995;
Nicholls et al., 2002; Persky et al., 2002; Petrakis et al., 1996; Pino et al., 2000). 
In the large EPIC Oxford cross-sectional study (Verkasalo et al., 2001), there 
were no differences seen in oestradiol or SHBG levels of 456 postmenopausal 
women consuming daily soy milk. Another centre in the EPIC study (Norfolk)
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found that urinary and serum levels of daidzein and genistein were negatively 
correlated with plasma oestradiol (Low et al., 2005) but that when women with 
certain genotypes were excluded these correlations were no longer significant. 
The author concluded that polymorphisms in genes encoding for enzymes 
involved in oestradiol metabolism (i.e. ESR1 Pvull CC genotype) may affect the 
concentration of plasma oestradiol, suggesting diet-gene interactions. Recent 
cross-sectional studies of post-menopausal women (Shoff et al., 1998),
(Thomas et al., 1999),(Verkasalo et al., 2001), (Low et al., 2005) assessing 
phytoestrogen intakes through dietary questionnaires found correlations with 
SHBG and oestradiol levels were not significant.
Results from a number of human studies suggest that soy consumption may 
exert oestrogenic effects on breast tissue and highlight the fact that caution is 
necessary at this stage. In a 6-month study (Petrakis et al., 1996), breast fluid 
secretion in both pre- and post-menopausal women in response to soy protein 
isolate consumption (containing 37.4 mg genistein/day) increased 2-6 fold, as 
did the number of atypical cells in breast fluid. However, this was a pilot study, 
which did not include a control group.
In another study, this time in pre-menopausal women, (McMichael-Phillips et al., 
1998), the rate of DNA synthesis by breast cells taken from biopsies of normal 
breast tissue from women with benign or malignant disease was enhanced by 
14 days of soy feeding (60 g/day equivalent to 45 mg isoflavones) prior to 
surgery. (Hargreaves et al., 1999) also found nipple aspirate levels of 
apolipoprotein D were significantly lowered and pS2 levels raised in response to 
soy supplementation (P < or = 0.002), after two weeks of soy supplementation, 
which they suggest is indicative of an oestrogenic stimulus. However, in a more 
recent pilot study with 17 surgical patients, after two week isoflavone
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supplementation, there appeared to be a statistically non-significant trend 
towards cancer growth inhibition in the isoflavone treatment group, as 
manifested by higher apoptosis/mitosis ratios in tumour biopsies compared with 
those from the control untreated group (Sartippour et al., 2004).
1.3 Insulin like Growth Factor -1 and binding proteins
Insulin like growth factor-1 (IGF-1) originally termed somatomedin (Daughaday 
et al., 1972) (Van Wyk et al., 1980) is structurally homologous to the hormone 
insulin and, like insulin, is involved in stimulating the anabolic processess 
needed for growth during puberty and adult life (Juul, 2003; Ranke et al., 1999). 
Much of the IGF-1 found in plasma is hepatically produced upon the stimulation 
of growth hormone released by the pituitary. Like the growth factor itself, the 
receptors for insulin and IGF-1 are structurally very similar, creating the 
potential for cross affinity and binding. Indeed, many tissue types, including 
those of the ovaries and breast, express receptors for both growth hormones. 
Target tissues also have the capacity to produce IGF-1 locally when needed 
(D'Ercole et al., 1980) as it is invoved in the paracrine control of the tissue's 
cellular proliferation. This includes normal breast tissue (Paik, 1992), where it is 
required for mammary development (Ruan & Kleinberg, 1999). Expression of 
IGF-1 in recent studies assessed by RT-PCR, show that levels tend to be 
higher in non-neoplastic breast tissue than in adjacent cancerous tissue 
(Voskuil et al., 2004) (Chong et al., 2006b) (Chong et al., 2006a) providing 
evidence fora paracrine relationship between IGF-1 producing stromal 
fibroblasts and neighbouring epithelial cells (Ellis et al., 1994).
Concentrations of IGF-1 in plasma are at least a hundred fold greater than that 
of insulin. However, IGF-1 is bound to a family of six binding proteins (IGFBP-1
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to 6) (Baxter et al., 1998), produced by many tissues and found in plasma.
Again growth hormone is responsible for the regulation of these binding protiens 
and is regulated by the nutritional status of the individual. Binding proteins are 
also produced locally within the target tissues
More than ninety percent of IGF-1 is bound to IGFBP-3 and an associated acid- 
labile subunit, forming a high molecular weight complex, which is not available 
to the tissues (Juul, 2003). Clinical studies suggest that individuals with IGFBP- 
3 levels in the upper range of normal may have decreased risk of breast cancer 
while in vitro and animal studies show that IGFBP-3 can also regulate cell 
growth and apoptosis through IGF independent mechanisms (Ali et al., 2003). 
IGFBP-1, on the other hand, binds only a small fraction of circulating IGF-1, with 
hepatic production regulated through the portal supply of insulin, with insulin 
inhibiting its production in the liver (Brismar et al., 1994). Thus, regulation of this 
binding protein is sensitive to food intake and has been shown to correlate 
inversely with the secretion of insulin (Kaaks & Lukanova, 2001; Lee et al., 
1997b).
1.3.1 IGF-1 and breast cancer risk
Next to oestrogen, Insulin-like growth factor-1 is one of the most potent mitogen 
for breast cancer cell lines in vitro (Karey & Sirbasku, 1988). It can rescue cells 
from cytotoxic chemotherapy through induction of proliferation and inhibition of 
apoptosis, stimulating both MAPKinase and PI3Kinase pathways (Gooch et al., 
1999; Laban et al., 2003).
In Vivo, antibody blockade of the IGF-1 Receptor inhibits growth of human 
breast cancer cells in mice (Arteaga et al., 1989) while liver specific gene 
deletion knockout of IGF-1 gene results in mice with reduced circulating IGF-1
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levels and reduced rates of cancer growth and metastasis (Yakar et al., 2005). 
Lower circulating levels of IGF-1 also delay the onset of induced mammary 
tumours in vivo (Wu et al., 2003).
In humans, significantly elevated concentrations of IGF-1 have been found in 
breast cancer patients when compared with healthy controls (Bruning et al., 
1995; Peyrat et al., 1993). Healthy subjects with high IGF-1 concentrations, 
when controlled for binding proteins, have been shown to have an elevated risk 
of breast cancer (RR 7.28, highest vs. lowest quintile (Hankinson et al., 1998). 
High concentrations of IGF-1 in serum have now been associated with an 
increased risk of breast cancer, in case control studies (Bohlke et al., 1998; 
Bruning et al., 1995; Del Giudice et al., 1998; Johansson et al., 2004; Li et al., 
2001 ; Peyrat et al., 1993; Vu et al., 2002) and more recently in prospective 
studies (Allen et al., 2005; Hankinson et al., 1998; Krajcik et al., 2002; Muti et 
al., 2002; Rinaldi et al., 2005a; Rinaldi et al., 2006; Schernhammer et al., 2005; 
Toniolo et al,, 2000). It is therefore now accepted that elevated levels of IGF-1 
are an independent risk factor for pre-menopausal breast cancer, and this has 
been confirmed by meta-analysis (Renehan et al., 2004) while a review of 
recent cohort studies show that associations with IGFBP-3 are less clear 
(Renehan et al., 2006).
The first study to show a difference in IGF-1 between breast cancer cases and 
controls compared 44 primary breast cancer patients with 92 controls all over 
the age of 35. This showed significantly higher levels in the patients, with 
median concentration of IGF-1 of 152 ng/ml as apposed to 115ng/ml (Peyrat et 
al., 1993). In a larger study done by (Bruning et al., 1995), 150 Stage I- II breast 
cancer patients between the ages of 38 to 75 had serum levels analysed for 
IGF-1 and BP3 just prior to or one month after surgery. These were compared
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with 441 women from a population base control group. Pre-menopausal cases 
showed increased IGF-1, decreased IGFBP-3 and increased IGF-1/BP-3 ratios. 
The relative risk was 7.34 for the highest compared with the lowest quintile of 
IGF-1/BP-3.
A more recent study examined levels in 94 patients with pre-menopausal ductal 
carcinoma-in-situ vs 76 controls and found that women in the two highest 
tertiles of IGF-1 and the lowest tertile of IGFBP-3 were at 3.7-fold higher risk 
than women in the lowest tertile of IGF-1 and highest two tertiles of IGFBP-3 
(Bohlke et al., 1998).
A prospective study conducted with data obtained in the Nurses Health Study 
cohort, analysed plasma concentrations of IGF-1 and IGFBP-3 from samples 
collected in 1989-1990 in women who went on to develop breast cancer after 
this date up to 1994. They compared these 397 women with 620 aged matched 
controls. Among pre-menopausal women younger than 50 years, the mean 
IGF-1 concentration was significantly higher in the cases than in the controls 
(p=0.009) with a relative risk of 4.58 (Hankinson et al., 1998).
Most reviews agree that this relationship is more prominent in pre-menopausal 
women (Fletcher et al., 2005; Renehan et al., 2004; Schernhammer et al., 2005; 
Shi et al., 2004; Sugumar et al., 2004) but not all studies have found this (Kaaks 
et al., 2002; Rinaldi et al., 2006; Rinaldi et al., 2005b), with a recent prospective 
analysis of the Nurses Health Study II cohort study finding no associations in 
pre or post-menopausal women (Schernhammer et al., 2006).
The reasons for this discrepancy may be related to the age of participants at 
recruitment (Rollison et al., 2006) or genetic differences in subpopulations (Al- 
Zahrani et al,, 2006). Polymorphisms of IGF-1 and BP genes have been shown 
to change risk of breast cancer although authors conclude they do not play a
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major role in altering breast cancer risk in Caucasian populations (Canzian et 
al., 2005) (Canzian et al., 2006).
However the effect of differences in time between blood collection and tumour 
diagnosis cannot be ruled out given the possibility of tumour influence on IGF 
levels (Schernhammer et al., 2006). A recent updated meta-analysis of all 
these studies concludes that there is a modest association between IGF-1 and 
breast cancer risk in pre-menopausal and young women but no discernible 
associations between IGF-1, IGFBP-3 and post menopausal breast cancer risk 
(Renehan et al., 2006).
1.3.2 IGF-1 and oestradiol
Oestradiol and IGF-1 appear to work together in the proliferation of breast 
cancer cells with increasing support for cross talking between the ER and IGF- 
1R signalling pathway (Kato et al., 2000; Laban et al., 2003). Oestradiol has 
been shown to stimulate expression of IGF-1, the IGF-1 R, IRS-1 and down- 
regulate expression of IGF binding proteins (Huynh et al., 1996b; Lee et al., 
1999; Ruan et al., 1995; Stewart et al., 1990), while genistein has been shown 
to enhance the IGF-1 signalling pathway in proliferation of MCF-7 cells at low 
concentrations (Chen & Wong, 2004).
1.3.3 IGF-1 and Tamoxifen
The cytotoxic effects of tamoxifen are also partially mediated through IGF-1 R 
signalling (Guvakova & Surmacz, 1997). Tamoxifen has been shown to lower 
circulating IGF-1 levels by approximately 30% in breast cancer patients 
(Campbell et al., 2001; Colletti et al., 1989; Helle et al., 1996; Lonning et al..
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1992; Poliak et al., 1990) and healthy women (Bonanni et al., 2001; Decensi et 
al., 1998; Decensi et al., 2003).
The mechanism by which tamoxifen alters IGF status remains to be fully 
elucidated. However, tamoxifen can alter IGF-1 levels by reducing the 
production of GH from the pituitary (Tannenbaum et al., 1992) thereby lowering 
the amount of IGF-1 released into circulation (Bonanni et al., 2001 ; Poliak et al., 
1990) and in \n vivo models, directly inhibits the expression of the IGF-1 gene in 
common target organs for breast cancer metastasis (Huynh et al., 1993). It also 
has direct action as an antiestrogen on breast cancer cells and appears to 
reduce the number of IGF-1 receptors (Huynh et al., 1996a) and up-regulates 
expression of binding proteins released by the cells themselves (Huynh et al., 
1996b; Winston et al., 1994).
1.3.4 IGF-1 and diet
Although numerous epidemiological and in vitro studies positively associate 
IGF-1 and it binding proteins with increased cancer risk (Renehan et al., 2004) 
the major determinants of inter-individual variability in circulating IGF-1 levels 
are not yet fully understood. Studies show that genetic (Fletcher et al., 2005) 
and nutritional factors, such as energy and protein restriction, play an important 
role in the regulation of IGF-1 (Thissen et al., 1994).
Reports examining the IGF and diet relationship have mostly been 
observational and cross sectional human studies are summarised in table 
1.3.4.1. These studies have reported associations between IGF-1, BP-3 and 
BP-1 levels and a range of dietary variables including calcium/dairy foods, fibre, 
vegetables, fat, carbohydrates and micronutrients, and are discussed in further 
detail in chapter 5.
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1.3.5 IGF-1 and isofiavone/soy intake
A few of the more recent epidemiological studies have also examined the 
association between IGF-1 and intake of soy/phytoestrogens (Nagata et al., 
2003; Probst-Hensch et al., 2003; Vrieling et al., 2004). No correlations were 
seen between soy product intake and IGF-1 or BP-3 levels in 261 Japanese 
pre-menopausal women (Nagata et al., 2003) or 386 pre and post menopausal 
Dutch women (Vrieling et al., 2004) assessed using food frequency 
questionaires. However there was a positive association found between soy 
intake and IGF-1 in 321 Chinese men studied (Probst-Hensch et al., 2003) and 
a positive association with plant lignans and BP-1 concentrations in 162 
postmenopausal Dutch women (Vrieling et al., 2004).
Prior to reports on the cross-sectional associations between isoflavone intake 
and IGF, two intervention studies were conducted between 1997-9, the results 
of which are presented in this thesis. These have now been published 
(Woodside et al., 2006) (Campbell et al., 2004). Since conducting these 
isoflavone supplementation studies, other intervention studies have also 
published their findings on the effects of soy or isoflavone supplementation on 
IGF-1 and binding proteins (these are summarised inlable 1.3.5.1). Of the 
studies published to date, only our study (Campbell et al., 2004) and to our 
knowledge one subsequent study published very recently (Vrieling et al., 2007) 
have looked at the effects of isoflavone supplementation alone. Further 
discussion of these intervention studies can be found in chapter 5.
1.4 Conclusion
In vitro and animal evidence suggests that dietary isoflavones may be protective 
against the development of breast cancer. Epidemiologic evidence remains
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largely inconclusive, and while case-control studies have produced some 
convincing evidence that increased dietary isoflavone intake correlates with 
reduction in breast cancer risk, early intervention studies have produced 
conflicting results. In light of the emerging role for IGF-1 and Its binding proteins 
in breast cancer aetiology, this thesis aims to examine the effects of Isoflavones 
on IGFs, to determine whether, like other antiestrogens, this may be a possible 
mechanism of action, which could further explain the possible protective effects 
of these compounds in the diet.
We propose to do this by first examing the effects of the SERM tamoxifen on 
levels of IGF-1 and its binding proteins In breast cancer patients, then by 
looking at the short-term effects (single dose or one week supplementation) of a 
phytoestrogen-rich bar and then a placebo-controlled isoflavone 
supplementation study over one month on IGF-1 and binding proteins, in 
healthy pre and post-menopausal women. Finally we examine the effects of 
isoflavones on DNA synthesis in breast cancer cell lines in vitro to compare 
their actions with tamoxifen in the presence or absence of IGF-1 and oestradiol.
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Table 1.2.3.1. Studies on the association between phyto-oestrogens in plasma 
and urine or phyto-oestrogen-rich diet and breast cancer risk.
42
Table 1.2.4.1: Interventions with soy foods/supplements in premenopausal women-effects on hormones
Table adapted from (Maskarinec et al., 2004)
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Table 1.2.4.2: Interventions with soy foods/supplements in postmenopausal women- effects on hormones.
Author Isoflavone dose; 
type of food
Length 
(mo)_ .
Type n E1 (%) E2 (%) SHBG (%) LH (%) FSH (%)
Baird et al. 1995 165mg; soy foods 1 Rl
RC
66
25
NO ND -6.8
-5.7
-2.5
-2.0
-4.4
-2.8
Murkies et al. 1995 45g soy or wheat flour 3 Rl (soy)
RC (wheat)
23
24
ND ND ND ND -1.6
-9.8**
Petrakis et al. 1996 75 mg; soy protein 
isolate
6 CO 10 ND -0.94 +44.4 ND ND
Brzezinski et al. 1997 -375 mg; tofu, soy 
drink, miso and flax 
seed
3 Rl
RC
78
36
ND -22.2
-13.6
+27.6*
-7.5
ND ND
Duncan et al.1999 10, 65, 129 mg; 
soy protein Isolate
3 CO (10VS129) 18 -5.6 -11.9 +5.6* +5.5 +3.04
Knight etal. 1999 40 or 160 mg 3 Rl (40) 
(160)
37 ND ND -11.7
-16.3
ND -6.3
-16
Pino et al. 2000 69mg; soy milk lOwks Interven 20 -8.59 +0.17 +15.7* ND -10.2
Berrino et al. 2001
-45  mg; fibre and 
phtoestrogen rich diet
5 RlRC
49
50 ND
-18.0
-5.5
+25,2*
+3.6
ND ND
Persky et al. 2002 56, 90 mg; isolated soy 
protein
6 Rl
Rl
RC
24 
23
25
ND +40
+10.2
-18.6
-12.8
-5,2
-17.2
ND -7.3
-0.68
-1.4
Foth et al. 2003 20mg; soy protein 6 Interven 16 ND -15.2 ND +3.6 +2.2
Brooks et al. 2004 41.9mg; soy flour In 
muffin
4 Rl
RC
16
15
+40
+5.25
+89.6
-24.7
ND ND ND
Nicholls et al. 2002 60mg; textured soy 
protein
14 days Interven 7 ND +25.6 ND -6.9 -3.3
Arjamandi et al. 2005 60mg; 25g protein from 
soy products or control 
protein with no soy or 
isoflavones.
12 Rr
RC^
35
27
+14.3
-2.8
+39.4
-11.1
-14.5*
-12.4
ND -3.6
-11.2
44
Table 1.3.4.1: Epidemiological studies- Dietary correlations with IGF-1, BP3 and BP1 concentrations
Author n Subjects Results
IGF-1 IGFBP-3 IGF-BP-1 other
Devine et al 
1998
119 Postmenopausal
women
Zinc +ve 
Protein +ve
Riboflavin +ve ND Baseline-prior to controlling for age and 
weight, IGF-1 correlated with Calcium, 
Cholesterol, Energy, Iron, potassium, 
magnesium, sodium, niacin, phosphorous, 
protein, riboflavin, thiamine and zinc.
Kaklamani et 
al. 1999
115 73%female and 27% 
male; age 30-84
Red meat +ve 
Fat +v6 
Oils +ve
Energy from lipids 
+ve
Energy from 
carbo +ve
Saturated fat -ve ND
Ma et al. 
2001
193
vs
318
Men, Cases with 
colorectal cancer vs 
controls; age 40-84 
(physicians health 
study)
Dairy food +ve Dairy food +ve ND
Mucci et al 
2001
112 Men, control group for 
liver cancer study. 
Greek population; all 
ages.
Alcohol -ve  
Cooked tomatoes 
-ve
Not shown ND IGF1/BP3 ratio: Cooked tomatoes -ve
Allen et al 
2002
292 Women, age 20-70, 
Meat eaters vs 
vegetarians vs vegans
Animal protein 
+ve
Animal plus soy 
protein +ve 
Nonsoya plant 
protein -ve  
NSP -ve
None Nonsoya 
plant protein 
+ve
SFA -ve  
NSP +ve 
Zinc +ve
IGF1 13% lower in vegan woen than Meat 
eaters of vegetarians (p=0.006). BP1 20- 
40% higher in vegans than ME and 
Vegans(p=0.005). Significant increase in 
IGF-1 in vegan women who drink s % pint 
of soya milk daily.
Holmes et al 
2002
1037 Women, age 43-69, 
526 pre & 456 
postmenopausal
B-cryptoxantine
+ve
Animal protein 
+ve
Alcohol +ve 
Sat fat intake -ve  
Lycopene +ve 
Vitamin C +ve
ND Cereal, pasta, milk and total dairy +ve 
associated with IGF-1
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Vitamin D +ve 
Vitamin A +ve 
Calcium +ve 
Zinc +ve 
Energy +ve 
(with BMI <25)
Energy +ve
Baibas et al 
2003
620 225 men & 395 women, 
age 35-65, Greek EPIC 
study
Ethanol -ve  
Saturated lipids 
+ve
Not showen ND
DeLellis et al 
2004
1000 Multiethinc; age 45-75; 
50% male/female
Men; fat from 
meat -ve  
Low fat milk -ve
Men: total fat -ve  
Saturated fat -ve  
Fat from meat -  
ve
Low fat milk -ve 
Women; alcohol 
+ve
ND
Giovanucci 
et al 2003
753 Men; age 40-75; health 
professionals follow up 
study
Animal & 
vegetable protein 
+ve (milk, fish & 
poultry)
Potassium +ve 
Zinc +ve 
Magnesium +ve 
Calcium +ve 
Phosphorous +ve 
Energy intake 
+ve(men with BMI 
<25)
Not shown ND IGF1/BP3 ratio: Vitamin E 
Phosphorous had the strongest association 
with IGF-1 probably because a good 
marker of both meat and dairy intake.
Gunnell et al 
2003
344 Men; age 50-70 PU FA +ve 
Calcium +ve 
Dairy products 
+ve
PUFA +ve ND IGF1/BP3 ratio; inversely related to 
vegetable intake and tomato containing 
products. Carbohydrate had a +ve trend 
with IGF-1 levels but not significant.
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Milk +ve
Heald et al 
2003
257 Multiethnic; age 25-78; 
-50% men/women
Fat intake +ve 
Sat fat +ve 
Protein +ve 
Carbohydrate +ve 
Starch +ve 
Energy +ve
ND Total fat -ve 
PUFA -ve 
Total protein 
-ve
Nagata et al 
2003*
261 Premenopausal 
women; age 20-54; 
Japanese
Vitamin D +ve Total fat -ve ND No correlations seen with soy product 
intake and IGF-1 or BP-3 levels
Probst- 
Hensh et al 
2003*
338 321 men and 326 
postmenopausal 
women; age >50; 
Singapore Chinese
Soy +ve (men) 
Calcium +ve 
Cholesterol +ve 
LDL +ve 
Triacylglyceroi 
+ve
Total Chol/HDL 
+ve
Sat Fat -ve  
Omega 3 PUFA 
+ve
Fibre +ve 
Cholesterol +ve 
LDL +ve 
Triacylglyceroi 
+ve
Total Chol/HDL 
+ve
ND Inverse trend with Alcohol intake and IGF-1 
levels
Vrieling et al 
2004*
286 224 pre & 162 
postmenopausal 
women; age 49-69; 
EPIC study in 
Netherlands
Alcohol -ve 
(premen)
Alcohol +ve 
(premen)
Postmen: 
alcohol -ve  
Plant lignans 
+ve
Cereals -ve
No correlations seen with soy 
intake/phytoestrogens and IGF-1 or BP-3 
levels
Larsson et al 
2005
226 Men; age 42-76; 
Sweden
Protein +ve 
Zinc +ve 
Red meat +ve 
Potassium +ve
ND ND Fish & seafood +ve trend with IGF-1
Maskarinec 
et al 2005
258 Premenopausal 
women; age 34-46; 
multiethnic
Dietary fibre +ve 
Vitamin A +ve
Zinc +ve ND IGF1/BP3 ratio: Iron +ve 
Calcium +ve 
Saturated fat +ve trend. 
No ethinc differences.
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Norat et ai 2109 Women; age 35-70; Protein +ve Calcium +ve ND Adjustment of IGF-1 for BPS;
2006 EPIC study in Europe Calcium +ve 
Magnesium +ve 
Phosphorus +ve 
Potassium +ve 
Vit B6 +ve 
Vit B12 +ve 
Beta- carotene-ve
Phosphorus +ve PUFA -ve
Zinc not analysed as could not standardise 
estimates across countries.
Food correlations w\ih IGF-1 were Milk +ve, 
Cheese +ve and Vegetables -ve
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Table 1.3.5.1 : Interventions with soy foods or supplements -  effects on insulin like growth factors and binding proteins
Author Isoflavone dose; Length Type n Results
%change
type of food (mo) IGF-1 IGFBP-3 IGF­
BP-1
other
Maskarinec et al 2005 50mg;soy foods 24 Rl
RC
97®
99®
+0.48
+0.26
-1.47
-0.33
ND Iso excretion +ve 
assoc with IGF-1 
(p=0.04)
Wangen et ai. 2000 10, 65,129mg soy protein 
isolate
3 CO 14®
17*^
+10.8(PO)* 65 
-6.54(129)*
+5(EF)65
^.5(129)
ND
ND
Adams et al. 2003 3 vs 83mg; soy protein 12 Rl (3) 
RC (83)
58^
65^
+8.1*
+7.7*
0
+1.0
ND
ND
Khalil et al. 2002 88mg; soy protein vs 
milk protein control
3 Rr
RC"
24
22
Inc*
Inc
(figures not 
given)
ND ND N.B Only Soy protein 
supp significantly 
increased IGF-1 from 
baseline (<0.0001 )
Kaaks et al. 2003 -45  mg; fibre and phytoestrogen rich diet 5 Rr
RC^
50
49
-5.9
-4.4
-4.5
-2.2
+12.2*
-6.4
Campbell et al. 2004 86mg; isoflavone supplement (no protein) & 
placebo
1 CO 16®
t
+1.5 (sVsP)  
+2.77
+2.5
-1.1
+13.2
+12.3
Woodside & 
Campbell et al. 2006
80mg; soy and linseed bar (18g protein) 1
week
interven I Q a b +71* 18.3* -40.7
Arjamandi et al. 2003 88mg; soy protein vs 
milk protein control
3 Rl^
RC^
20
22
+68.6**
+36.4**
ND ND Increases in IGF-1 
greater for women on 
HRT.
Arjmandi et al. 2005 SOmg; 25g protein from soy products or control 
protein with no soy or isoflavones.
12 Rl"
RC^
35
27
+26.3**
+12.8**
+1.85
+5.2**
ND Both significantly 
increased IGF-1 but 
IGFBP-3 only sig 
increased on soy.
Spentoz et al. 2003 114mg; soy protein supp on low fat diet 2 Interven" 15 +22 -1 ND Increase in IGF-1 of 
9% after low fat diet 
then increase by 22 
% from baseline on
49
soy protein p=0.02
Gann et al 2005 88mg: soy protein powder with or without 
Isoflavones (subjects on both LFHF and UD)
3 Rr
RC^
153 2.9
1.2
-1.2
-3.4*
7.5
6.3
Small but significant 
decrease in BP3 of 
2.3% when both 
groups analysed 
together.
Vrieling et al 2007 84mg; isoflavone supplement (no protein) & 
placebo
2 CO 37" -25 +0.43 -6.4 Change in IGF-1 and 
serum Equol were 
negatively correlated 
post supplement.
a =premenopausal 
b=postmenopausal 
c=men
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CHAPTER TWO -  METHODS
2.1 Collection and preparation of biological samples
Urine samples (24 h) were stabilised with 1-2 g/i ascorbic acid and sodium 
azide (0.1 g/L) and stored at -80°C until analysis. Spot urine samples were not 
stabilised but immediately frozen after collection. Blood samples either kept at 
4°C for a maximum of 30 min (plasma) or were allowed to clot for 30 minutes in 
the dark (serum) and then centrifuged at 3000 rpm for 10 min. Serum or plasma 
was aliquoted and stored at -80°C until analysis. Lymphocytes were collected 
into a Vacutainer Cell Preparation Tube (Becton Dickinson, New Jersey), 
extracted and washed according to manufacturer's instructions and stored at - 
80°C.
2.2 Endpoint measurements
2.2.1 Diet
Food frequency questionnaires (from EPIC) and food diaries were analysed 
using DietPlan 5 for Windows 98 using standardised composition (McCance et 
al., 1978) and food portions established by MAAF (Crawley et al., 1988) to 
assess background diet through out the studies.
2.2.2 Phytoestrogens
Urine samples were analysed for the isoflavonoids genistein and daidzein, the 
isoflavan equol and the lignans enterolactone and enterodiol levels, using gas 
chromatography-mass spectrometry following enzyme hydrolysis, extraction 
into ether and silylation according to Morton et al. (Morton et al., 1994).
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2.2.3 Ascorbic acid
Ascorbic acid concentrations were determined as described by Vuiilemier & 
Keck (1989) (Vuiilemier & Keck, 1989). The procedure is based on the 
enzymatic oxidation of ascorbic acid and subsequent quinoxaline formation to 
generate a fluorescent derivative measured on the Cobas Fara centrifugal 
analyser. The whole blood sample, stabilised with dithiothreitol (Fisher 
Scientific), was centrifuged and separated upon arrival at the laboratory. The 
plasma was precipitated by adding 100 pi of plasma to 900 pi of 5% 
metaphosphoric acid (Fisher Scientific) in a conical microcentrifuge tube and 
vortex mixed. Once precipitated the sample was stable for 1 year at -70°C.
Our samples were assayed within 6 months of collection. Working standards 
(0, 1,5, 10, 15, 20 pmol/l) were prepared for each run from a freshly made 
stock standard of 20 pmol/l ascorbic acid in 5% metaphosphoric acid. 
Approximately 200 pi of standards and samples were placed in Cobas cups, 
and oxidising reagent (9.9 ml, 2 mol/l acetate buffer and stock ascorbate 
oxidase) and coupling reagent (20 mg of 1,2-phenylenediamine dissolved in 20 
ml deionised water) added to appropriate reagent wells. The assay was then 
started. The intra-assay CV was calculated for several different serum 
samples. At a mean concentration of 4.2 pmol/l, the inter-assay CV was 6.80% 
(n=9), at 50.6 pmol/l the inter-assay CV was 0.72%, while at 151.0 pmol/l the 
inter-assay CV was 1.50%. Antioxidant malondialdehyde (MDA) levels in serum 
were analysed using HPLC method (Young & Trimble, 1991).
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2.2.4 Retinol, a-tocopherol and carotenoids
Concentrations of serum a-tocopherol and 6-carotene were measured by HPLC 
according to the method of Catignani etal. (1983)(Catignani & Bieri, 1983) and 
Thurnham et al. (1988) (Thurnham et al., 1988). They were monitored by 
ultraviolet detection following extraction into heptane. The assay also measures 
serum concentrations of retinol. Ivcopene and a-carotene. Serum or standard 
(200 pl) was pipetted into 4 ml glass tubes. Internal standard, a mixture of 
retinol acetate and a-tocopherol acetate in ethanol (400 pi - Labscan) was 
added to each tube and the ethanol precipitated the protein from the serum. 
Heptane (Analar or 99% - 700 pi (Labscan)) containing 0.5 g/l butylated 
hydroxytoluene (BHT) was added to the tubes which were then vortexed 
vigorously for 1 minute. The tubes were then centrifuged for 10 minutes at 
1200 g and 500 pi of the resulting top heptane layer transferred to a set of 
identically labelled glass tubes. The complete contents (1300 pi) of the 
standard tube contents were dried. These tubes were evaporated to dryness in 
a rotary evaporator under vacuum for 1 - 2 hours. The samples were either 
assayed immediately or stoppered and stored dry in a -70°C freezer. For HPLC 
analysis, the samples were reconstituted in ethanol (100 pi), vortexes and 
assayed using UV detection. A 45% methanol:45% acetonitrile;10% 
dichloromethane (200 ml, not filtered, degassed for exactly 5 minutes using 
Romil HPLC grade solvents, (Analab, Dromore, Co. Down) mobile phase was 
used with a flow rate of 1.8 ml/min. The column used was Hypersil CDS 5 pm 
(Alltech), with changing wavelengths of 325 nm, 292 nm and 450 nm to pick up 
the retinol, tocopherol and carotenoid peaks respectively. A Thermo Separation 
Products Constametric 4100 pump was coupled with a Spectra-Physics 
AS 1000 autosampler and a Spectra-Physics Analytical UV2000 ultraviolet
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detector. The system was controlled using a Spectra-System SN4000 interface 
and operated using PC1000 software from Thermo Separation Products.
A quality control serum sample was assayed at the start of every batch of 
samples. The inter-assay CV for a-tocopherol was 5.4% (n=7) and 10.0% (n=7) 
for p-carotene. The CVs for retinol, lycopene and a-carotene were similar to 
those for p-carotene. The addition of internal standard allowed the calculation of 
an intra-assay CV of 4.9% (n=29).
2.2.5 Serum Lipids and lipid peroxidation
Serum lipids were assessed, again at the start and end of each 
supplementation phase, using standard spectrophotometric assays.
Serum total cholesterol, was estimated using an enzymatic CHOD-PAP kit, 
while serum triglycerides were measured using the Peridochrom GPO-PAP kit 
(both Boehringer Mannheim). Precipitation for HDL-cholesterol estimation 
employed phosphotungstic Mg^  ^ reagents (Lopes-Vi relia et al., 1977). All 
cholesterol assays were carried out on the Cobas Fara auto-analyser. As well 
as employing internal quality control procedures, total cholesterol and HDL- 
cholesterol were subject to external quality control through the World Health 
Organisation reference laboratory in Prague. LDL-cholesterol was estimated 
using the Friedewald formula:
LDL cholesterol (mmol/l) = total cholesterol - HDL cholesterol - 0.45 x 
triglyceride
Levels of aqueous phase lipid hydroperoxides were assessed in plasma by the 
FOX 1 (ferrous oxidation in xylenol orange) assay according to Wolff (Wolff,
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1994). Susceptibility of LDL to oxidation was assessed according to McDowell 
et al. (McDowell et al., 1995).
2.2.6 COMET Assay
DNA damage was analysed by the COMET assay in both lymphocytes 
according to Spanswick et al. (Spanswick et al., 1999).
2.2.7 Creatinine
Creatinine concentrations from 24 hour urine collections were measured using a 
Sigma colorimetric assay.
2.2.8 Hormones
17 p-oestradiol, Progesterone, LH, FSH and SHBG were measured in serum 
using routine IRMA/RIA methods as follows:
17 p-oestradiol was measured directly using the DiaSorin Clinical Assays™ 
Oestradiol-2 Radioimmunoassay. The standards, controls and samples were 
incubated with oestradiol tracer and antiserum raised in rabbits for 2 hours at 
37°C in a water bath. After a second incubation for 15 min with a precipitating 
reagent, containing antibody to rabit IgG the samples were centrifuged for 15 
min at 2000G to separate free tracer from antibody-bound tracer. The tubes 
were then decanted and the supernatant discarded. The pellet was counted in a 
gamma counter. A standard curve was then prepared from the standards 
ranging from 10 to 2000pg/ml. The unknown values were obtained from the 
standard curve by interpolation.
Progesterone was measured using the DiaSorin Clinical Assays™ 
GammaCoat™ Progesterone-^^ l^ RIA Kit for the quantitative determination of
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progesterone levels in serum. This was a competitive binding 
radioimmunoassay whereby the amount of [^^ l^]-labeled progesterone bound to 
the antibody on the plastic coated tube was inversely proportional to the 
concentration of progesterone present in the serum. The samples, standards 
and controls were added to the Anti-Progesterone pre-coated tubes in 
duplicate. Progesterone tracer was then added and the tubes were incubated at 
37°C for 60 minutes. The tubes were then decanted and counted in a gamma 
counter. A standard curve was then prepared from the standards ranging from
0.3 to 60ng/ml. The unknown values were obtained from the standard curve by 
interpolation.
Serum Luteinizing Hormone (LH) and Follicle-stimulating Hormone (FSH) were 
measured using the NETRIA Immunoradiometric assay (IRMA). The samples, 
standards and controls were added to the tubes along with the solid phase 
(sheep) Anti-LH or FSH, the f  ^ ]^-iodine labelled Anti-LH or FSH (monoclonal) 
and the assay buffer. These were vortexed and placed on a rotary mixer 
overnight. The next morning, 2ml of wash buffer were added to the tubes and 
after centrifugation at 1000G for 5 minutes, the supernatant was decanted. This 
washing step was repeated before the tubes were decanted and counted in a 
gamma counter. A standard curve was then prepared for LH and FSH from the 
standards ranging from 1-260 U/L or 0.5-200 U/L respectively. The unknown 
values were obtained from the standard curve by interpolation.
Sex Hormone Binding Globulin was measured in serum using the [^ ^^ 1] 
Immunoradiometric Assay kit from Orion Diagnostica. This procedure was 
based on the principles of a non-competitive “liquid-phase” immunoradiometric 
assay. Samples, standards and controls were diluted in assay buffer and added 
in duplicate to the test tubes. Equal volumes of SHBG Antiserum (Rabbit) and
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anti-SHBG (Mouse monoclonal) were added to all tubes. Tubes were 
vortexed and incubated at room temperature for 60 minutes. The separation 
reagent, containing goat anti-rabit IgG covalently bound to solid particles, was 
then added and tubes were vortexed and incubated for a further 15 minutes at 
room temperature. Two ml of 0.9% saline was added and the tubes centrifuged 
at 2000G for 15 minutes. The tubes were decanted and counted in a gamma 
counter. A standard curve was then prepared from the standards ranging from 
6.25, 200 nmol/L. The unknown values were obtained from the standard curve 
by interpolation.
2.2.9 IGF-1, BP-1 and BP-3
Levels of IGF-1, IGF-BP1, IGF-BP3 were measured in serum using ELISA 
methods (Diagnostic Systems Laboratories). The DSL-10-5600 IGF-1 ELISA kit 
was an amplified “one step” sandwich-type immunoassay. This assay included 
an extraction step in which IGF-1 was separated from its binding protein in 
serum by acidification followed by ethanol precipitation of the IGFBP fraction. 
The standards, controls and extracted samples were then incubated with anti 
IGF-1 antibody labelled with the enzyme horseradish peroxidase (HRP) in 
microtitration wells coated with another anti-IGF-1 antibody. After incubation 
and washing, the wells were incubated with the substrate tetramethylbenzidine 
(TMB). An acidic stopping solution was then added and the degree of enzymatic 
turnover of the substrate was determined by dual wavelength absorbance 
measurement at 450nm with background wavelength correction set at 620nm. 
The absorbance measured was directly proportional to the concentration of 
IGF-1 present. The IGF-1 standards were used to plot a standard curve of 
absorbance versus IGF-1 concentration and the IGF-1 concentrations were
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then calculated using the line of best fit plotted using the MINITAB statistical 
package. Controls were assayed at the beginning and end of the plate while 
samples were assayed in duplicate.
IGFBP-3 and total IGFBP-1 were measured using the DSL-10-6600/7800 
ELISA kits. In these “two-step” immunoassays, standards, controls and samples 
were incubated in microtitration wells which had been coated with an anti- 
IGFBP-3/1 antibody. After incubation and washing, the wells were treated with 
another anti-IGF-3/1 antibody labelled with HRP. After a second incubation and 
washing step, the wells were incubated with TMB. After adding the acidic 
stopping solution, the enzymatic turnover was measured at 450 and 620nm as 
above. The absorbance measured was directly proportional to the concentration 
of BP present. The standards were used to plot a standard curve of absorbance 
versus BP concentration and the BP concentrations were then calculated using 
the line of best fit plotted using the MINITAB statistical package.
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2.3 Development of an Enzyme Linked Immunosorbant Assay 
(ELISA) for the quantitative measurement of IGF-BP3 in Human 
Serum.
Work carried out under supervision of Dr Brian Rafferty at the National Institute 
for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, 
Hertfordshire EN6 3QG, UK.
2.3.1 Introduction
Prior to commencing the intervention studies described in this thesis, an attempt 
was made to develop an in-house assay for IGFBP-3. IGFBP-3 is the major 
binding protein for IGF-1 in human serum, and the best indicator of clinical 
conditions involving Growth Hormone deficiencies (Kim et al., 2001) and is also 
potentially useful as an anti cancer molecule/biomarker (Ali et al., 2003).
ELISAs are the preferred method for measuring Insulin Like Growth Factors and 
their binding proteins (Rutanen & Pekonen, 1991). At the time of this research, 
ELISA kits were only commercially available from Diagnostics Systems 
Laboratories (Diamandi et al., 2000). These were expensive, therefore the 
development of an in-house ELISA would be have been useful. This work 
would also allow a better theoretical understanding of ELISAs and could 
hopefully be used as an alternative to commercial kits in future.
2.3.2 Method
An antibody to IGF-BP3 had previously been raised in White Long Eared 
Rabbits in the Animal House at NIBSC. IGF-BP3 was human recombinant DNA
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(non glycosylated) and was from the standardised stock made at NIBSC. Both 
the Antibody and the Binding protein had been previously assessed using 
Radio-iodination and Fast Protein Liquid Chromotography (FPLC).
The assay development involved;
• Coating the 96 well microtitre plate with antibody over night (optimal 
concentration and volume to be determined).
• Coating the Plate with samples and standards (optimal concentration and 
volume to be determined).
• Addition of Biotinylated Antibody (optimal concentration and volume to be 
determined).
• Addition of Avid in Horse Radish Peroxidase and Substrate Reagent for 
colour development (optimal concentration and volume to be determined).
•  Incubation (optimal number of steps time and temperature to be determined 
between each stage).
Assays which attempted to optimise the assay as detailed above are described 
below in results.
2.3.3 Results 
Assay 1 :
Aim: To determine the concentration of the coating antibody needed to give 
adequate binding of the substrate and to establish the dilution of biotinylated 
antibody needed to give an adequate signal.
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Method:
COATING ANTIBODY (FPLC-RBP3/3) 200pl @ 0.5|xg/ml
200pl @ 1.0 pg/ml
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5jag/ml) 
SERUM POOL 
DSL STD 
MAELI'S SERUM
100pl @ 100ng/ml LJl.5625ng/ml (2 
fold dilns)
BIOTINYLATED ANTIBODY fFPLC- 100pl @ 1/1000 diln
RBP3#5) 100pL@ 1/2000 diln
INCUBATION STEPS 1 step, 3hr
Results:
Assay 1
fe
?
m-
♦  0.5mcg/ml, 1 /2000  
BioAb
- - *  - -0.5mcg/m l,1/1000 
BioAb
 A —  1 .Omcg/ml,1/2000
BioAb
 1- - -1 .Omcg/ml,1/1000
BioAb
0.1
1 10 100
IGFBP-3 (ng/mi)
Findings: Absorbance readings using 1.0g/ml coating antibody and 1/1000 diln 
of biotinylated antibody are consistently greater as would be expected.
Assay 2 & 3:
Aim: To determine the effect of halving the volumes used in Assay one.
Method:
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COATING ANTIBODY (FPLC- 100^L@0.5nG/ML 
100pL @ I.O^iG/MLRBP3/3)
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL 
DSL STD 
MAELI’S SERUM
50|il @ 100ng/ml □ 1.5625 ng/ml (2 
fold dilns)
BIOTINYLATED ANTIBODY fPPLC- 50pl @ 1/1000 diln 
50pl @ 1/2000 dilnRBP3#5)
INCUBATION STEPS 1 step, 3hrs
Results:
Assay 2
10
Ec
I
s
<
1
0.1
+ '
 ♦ —  0.5mcg/ml, 1 /2000BioAb
- - *  - -0.5mcg/ml,1/1000 BioAb 
— A— 1.Omcg/ml,1/2000 Bio Ab
- '  +  - -1 .Omcg/ml, 1/1000 BioAb
10
BP3 ng/mi
100
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Findings: Halving the volumes used gives an adequate signal if maximal
parameters are used. (See assay one) The control (MSB) values were 
consequently lower in Assay 2.
Assay 4 & 5
Aim: To assess the effects of altering incubation times from 3 hours to one. 
Method
COATING ANTIBODY (FPLC- 100pL@ 1.0pG/ML
RBP3/3)
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL 
DSL STD 
MAELI’S SERUM
60pl @ 20ng/ml □ 0.3125ng/ml (2 
fold dilns)
50fil @ 40ng/ml □ 0.6125ng/ml (2 
fold dilns)
BIOTINYLATED ANTIBODY fPPLC- SOpI @ 1/1000 diln
RBP3#5) 50pl @ 1/2000 diln
INCUBATION STEPS Assay 4: 1 step, 1 hr 
Assay 5: 1 step, 3 hr
Results:
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Assay 4+5
0.01
0.1 1 10 
IGFBP-3 (ng/ml)
•3nrNG
Std(1000dHn
BioAb)
IbrNG SU
(1000 diln
BioAb)
■3br Serum
Std(IOOO)
— X — Ib f Serum
SM (1000)
------ * ------ 3hrBG Sa
(2000)
IhrNGStd
(2000)
--- 1--- 3hr Serum
Sid (2000)
■Ihr Serum
SU (2000)
100
Findings: The 3 hour incubation gives an appropriately larger signal while the 1 
hour incubation lends itself to a loading effect due to differing incubation with 
the coating antibody.
Assay 6
Aim: To assess the DSL standards and control solutions VS the serum pool and 
NG IGFBP-3 over one hour incubation.
Method:
COATING ANTIBODY (FPLC- 100pL @ 1.0pG/ML
RBP3/3)
SAMPLES/ STANDARD
50pl @ 20ng/ml n 0.3125ng/ml (2 
fold dilns)
50pl @ 40ng/ml fl 0.625ng/ml (2 
fold dilns)
50pl @ 0.7, 4, 17, 45, 120ng/ml & 
4±1.2, 17±5
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL 
DSL STD 
MAELI’S SERUM
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50pl @ 1/50 & 1/100 diln
BIOTINYLATED ANTIBODY (FPLC- 50pl @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 1 step, Ihr
Results;
Assay 6 (1hr)
1
—  Standard(95/360) 
BP3
-O Serum (high)0.1
*  DSL standards
Maell's serum
0.01
0.1 1 100010 100
IGFBP-3 (ng/ml)
Findings: This assay showed quite clearly that the serum responds differently to 
the NG BP-3 while DSL standards are derived from human serum.
Assay 7
Aim : To assess the effects of a 3 hour incubation on an assay similar to assay 
6 and to determine whether time delay in loading a plate will make a significant 
impact on absorbance readings.
Method:
COATING ANTIBODY (FPLC-RBP3/3) 1 0 0 jliL @  1.0pG/ML
SAMPLES/ STANDARD
50pl @ 20ng/ml □ 0.3125ng/ml (2 fold 
dilns)
NG IGFBP-3 (93/560) (3.5pg/ml) beginning 
and end of plate - 1 5  min
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SERUM POOL 
DSL STD 
MAELI'S SERUM
50pl @ 40ng/ml □ 0.625ng/ml (2 fold 
dilns)
50pl @ 0.7, 4. 17, 45, 120ng/ml & 
4±1.2, 17±5
50pl(g 1/50 & 1/100 diln
BIOTINYLATED ANTIBODY (FPLC- 50pl @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 1 step, 3 hr
Results:
Assay 7 (3hr)
10
♦ —  Standard(95/360) 
BP3 time 1
Semm (high)
Wk - - DSL standards
' A1
Standard(95/360) 
BP3 time 2
High control 
(-17ng/ml)
0.1
0.1 1 10 100 1000
IGFBP-3 (ng/ml)
Findings: Three hours gives a better signal but a plate loading effect is still 
visible.
Assay 8
Aim: To extend the sensitivity of the assay while using the serum pool as the 
standard.
Method:
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COATING ANTIBODY (FPLC-RBP3/3) lOO^L @1.0 piG/ML
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL 
DSL STD 
MAELI’S SERUM
50pl @ 40pg/ml(1/100) □ 1/25600 
0.7, 4, 17, 45, 120ng/ml % 4+1.2, 17 
±5 (X 4)
BIOTINYLATED ANTIBODY (FPLC- lOOpI @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 1 step, 3 hr
Results:
Assay 8
0.01 0.1 1 10 
IGFBP-3 (ng/ml)
10
1
■♦— Serum Standard (high pool)
DSL Standards
0.1
■A—  Low control(4ng/ml)
*  -H igh Control (~17ng/m l)
0.01
100 1000
Findings: This assay appeared to have an effect across the two halves of the 
plate, however these results are not.
Assay 9
Aim: To assess the effects of spiking the serum pool with known standards to 
establish recovery values.
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Method:
COATING ANTIBODY (FPLC- 100pL @ 1.0]^G/ML
RBP3/3)
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5|ag/ml) 
SERUM POOL 
DSL STD
MAELI’S SERUM
50^1 @ 20ng/ml 0.312ng/ml (2 fold 
dilns)
50|xl @ 40ng/ml 0.3125ng/ml (2 fold 
dilns)
Serum + DSL 50^1 @ 
56ng/ml->3.5ng/ml (2 fold)
Serum WDB 50pt @ 
32ng/ml^2.0ng/ml(2 fold)
BIOTINYLATED ANTIBODY (FPLC- 50 1^ @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 1 step, 3 hrs
Results:
Assay 9
 Std BP3 (NG)
•  ■ -Serum (High)
|o.i Serum + DSL
WDB + DSL
0.01
0.1 1 10 100
IGFBP-3 (ng/ml)
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Findings: The spiked dilution's appear to give readings as would be expected. 
These need to be extended.
Assay 10
Aim: To assess the sensitivity of the assay by extending the lower end of the 
standard serum curve. To determine the IGFBP-3 levels in an ‘unknown’ 
serum.
Method:
1 COATING ANTIBODY fPPLC- 100pL @ 1.0pG/ML. .
RBP3/3)
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL
DSL STD 
MAELI'S SERUM
50pl @ 10ng/ml 0.156ng/ml (2 
fold dilns)
50pl @ 10ng/ml -> 0.078ng/ml (2 
fold dilns)
50pl @ 1/500, 1/2500 diln 
50pl @ 1/100, 1/50 diln
BIOTINYLATED ANTIBODY fPPLC- 50pl @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 1 step, 3 hrs
Results:
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Assay 10
std BP3 (NG) 
Serum Std (high) 
Maeii 1/500 
Maeli 1/100 
Serum 1/500 
Serum 1/2500__
Eco
9
(A
<
0.01
1 100.01 0.1
IGFBP-3 (ng/ml)
Findings: Providing enough dilutions are done for the unknown serum the
standard curve appears to give consistent results. Further work needs to be 
done to further test this.
Assay 11 & 12
Aim; To determine whether there is a difference in signal when the biotinylated 
antibody is loaded on to the plate before the serum in order to diminish any 
plate effect obtained through difference in binding times, (see assay 7)
Method:
COATING ANTIBODY (FPLC- lOOuL @ 1.0nG/ML
RBP3/3)
SAMPLES/ STANDARD
50pl @ lOng/ml 
0.15625ng/ml (2 fold dilns)(x2 
on Assay 11 +12)
NG IGFBP-3 (93/560) (3.5ng/ml) 
SERUM POOL
DSL STD 
MAELI’S SERUM
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BIOTINYLATED ANTIBODY fPPLC- Assay 11: 50pl (8) 1/1000 1
RBP3#5Ï before serum
Assay 12: 50pl @ 1/1000
after serum
INCUBATION STEPS 1 step, 3hrs
Results:
Assay 11 & 12
oa>
È
10
1
Bio Ab then Serum pool0.1
* Serum then Bio Ab
0.01
10.1 10
IGFBP-3 (ng/ml)
Findings: The results would suggest that although there is no great difference 
between the curves, the control (NSB) values for assay 12 are significantly 
lower.
Assay 13
Aim: To assess the affects of a two step incubation on the overall sensitivity 
and loading effects of the assay.
Methods:
COATING ANTIBODY (FPLC 
RBP3/3)
100pL @  1 .0p G /M L
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SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL
DSL STD 
MAELI'S SERUM
lOOfil @ 40ng/ml ^  
0,3125ng/ml (2 fold dilns) 
(x4)
BIOTINYLATED ANTIBODY fFPLC- 100pl @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 2 step: 2 hrs then 1 hr
Results:
Assay 1 3 , 2 step
Eco
9
10
1
Series 1
Series2
Series30.1
■Serles4
0.01
0.1 1 10 100
IGFBP-3 (ng/ml)
Findings: Although this assay appears to have remedied the plateau effect, later 
assays would suggest that the concentration of BP-3 may have started at 
20ng/ml rather than 40ng/ml.
Assay 14
Aim: To extend the sensitivity of the two step assay and to assess the signal 
from the non glycosylated and other serum material.
Method:
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COATING ANTIBODY (FPLC- 10Q|iL@ 1.0pG/ML
RBP3/3)
SAMPLES/ STANDARD
100pl @ 100ng/ml 0.195ng/ml (2 
fold dins)
iOOpI @ 80ng/ml -> 0.156ng/ml (2 
fold dilns)
lOOpI @ 1/100, 1/500, 1/2500 dilns 
lOOpI @ 0.7, 4, 17, 45, 120ng/ml 
lOOpI @ 1/20, 1/100, 1/500 dilns
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL
DSL STD 
MAELI’S SERUM
BIOTINYLATED ANTIBODY (FPLC- lOOpI @ 1/4000 diln
RBP3#5)
INCUBATION STEPS 2 step: 2hrs then Ihr
Results:
Assay 14 two step
BP3 Std (NG) 
Serum Std (pool) 
DSL Std
Eco
5
(0
<
Maeli's serum 1/20
— Maeli's serum
   1/100
~ 0 —  Maeli's serum 
. 1/500
— I— Serum Std 1/100
*  Serum std 1/5000,01
Serum std 1/2500100
IGFBP-3 (ng/ml)
Findings: The sensitivity of this assay appears to be repeatable down to a 
concentration of 0.156ng/ml and is highly reproducible.
Assay 15
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Aim: To determine how different concentrations of biotinylated antibody will 
affect the two step assay sensitivity.
Method:
COATING ANTIBODY (FPLC- 100pL@ 1.0NG/ML
RBP3/3)
SAMPLES/ STANDARD
lOOpI @ 100ng/ml 0.195ng/ml (2 
fold dilns)
NG IGFBP-3 (93/560) (3.6pg/ml) 
SERUM POOL 
DSL STD 
MAELI’S SERUM
BIOTINYLATED ANTIBODY (FPLC- lOOpI @ 1/500, 1/1000, 1/2000 dilns
RBP3#5)
INCUBATION STEPS 2 step: 2hrs then 1 hr
Results:
£co
9
0,1 1 10 
IGFBP-3 (ng/ml)
10
Serum with 1/500 
BioAb
Serum with 1/1000 
BioAb
Serum with 1/2000 
BioAb
0.01
100
Findings: The absorbance readings obtained from using the 1/1000 diln of 
biotinylated antibody give an adequate response.
Assay 16
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Aim: To assess the cross reactivity of the antibody with IGF-! and IGF-II.
Method:
COATING ANTIBODY (FPLC.RBP3/3) 100pL@ 1.0^G/ML
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml)
SERUM POOL
IGF-I (87/518) (3.1pg/ml)
IGF-II (96/538) (5pg/ml)
DSL STD 
MAELI’S SERUM
100pl @ 40ng/ml 0.0488ng/ml (2 
fold dilns)
lOOpI @1.0  pg/ml -> 0.0156ng/ml (2 
fold dilns)
lOOpI @ I.Opg/ml 0.0156ng/ml ( 2 
fold dilns)
BIOTINYLATED ANTIBODY (FPLC- lOOpI @ 1/1000 diln
RBP3#5)
INCUBATION STEPS 2 step: 2hrs then 1hr
Results:
Assay 16
10
Ec
I
Ê
< 0.1
0.01
0.01
Serum pool
0.1 1 10 
IGF-BP3 (ng/ml)
100
Findings: IGF-I and II did not give a significant signal at any concentration and 
do not therefore appear to be binding to the antibody.
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Assay 17
Aim: To assess possible competitive binding of IGF-I and II with BP-3 by spiking 
the serum with known amounts of the growth factors.
Method:
COATING ANTIBODY (FPLC-RBP3/3) 1 0 0 p L @  1.0 pG /M L
SAMPLES/ STANDARD
NG IGFBP-3 (93/560) (3.5pg/ml) 
SERUM POOL 
SERUM WITH WDB 
SERUM WITH IGF-I 
SERUM WITH IGF-II
lOOpI @ 80ng/ml -> 1.25ng/ml (2 
fold dilns)
lOOf^ L @ 20ng/ml 0.625ng/ml (2 
fold dilns)
lOOpI @ 40ng/ml 0.625ng/ml (2 
fold dilns)
lOOpI @ 40ng/ml 0.625 ng/ml (2 
fold dilns)
BIOTINYLATED ANTIBODY fFPLC 
RBP3#5)
100pl@ 1/1000 diln
INCUBATION STEPS 2 step: 2hrs then Ihr
Results:
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Assay 17
Ec
I
I
10
Serum Pool
- ■ O  - "Serum + WDB(200mcL)
— Serum + IGF-1{200mcL 
@1mcg/ml)
— Serum + IGF-2 (200mcL 
@  1mcg/ml)______1
0.1
0.1 101 100
IGFBP-3 (ng/ml)
Findings: IGF-1 and II appear to be competing with the antibody in binding to 
BP-3 however there does not appear to be a significant effect on absorbance 
levels and binding appears to be constant.
2.3.4 Discussion
Optimal conditions were found to be with the two-step incubation, whereby the 
samples were allowed to bind to the walls of the plate for 2 hours before the 
Biotinylated Antibody was added, this appeared to remedy the hook affect seen 
with a one step incubation of 3 hours. The standard curve established was 
found to be highly reproducible. However as serum must be screened before 
use at NIBSC facility we were unable to assess the assay on more than one 
individual serum sample.
In order to validate this assay for future use of the clinical assessment of 
patients, many serum samples would need to be tested and the assay would 
need to be compared with commercial ELISAs that use human serum for 
production of standard curves. Although initial results were encouraging this 
ELISA was left at the experimental stage as there would need to be 
considerable testing before it could be published as a standard ELISA for 
IGFBP3 and used for the analysis of samples in subsequent studies.
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It was not therefore used for the analysis of IGFBP-3 in this thesis, and 
represents early stage assay development.
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2.4 Cell Culture
MCF-7 and MDA MB -231 cells (kindly donated by Ludwig cancer research 
group) were maintained in Phenol Red IMEM (GIBCO) supplemented with 5% 
PCS (GIBCO), 1% L-Glutamine (sigma) and 1% Fungizone (GIBCO) in 5% CO2 
at 37°C. Conditions involved growing cells in phenol red free IMEM 
supplemented with 5%FCS for 72 hours prior to plating. Cells were then seeded 
in 96 well plates (NUNC) at1x10^ cells per well in 5% DCC-FCS (Dextran 
charcoal coated foetal calf serum) phenol red free IMEM and incubated for 24 
hours. Medium was changed to serum free IMEM for another 24 hours before 
the compounds were added. Stock solutions of tamoxifen, Genistein (4,5,7- 
trihydroxyisoflavone), Daidzein (4,7-dihydroxyisoflavone), Equol and 17p- 
estradiol (Sigma) in ethanol, were used to produce the required concentrations 
of compounds in culture medium. Control conditions also contained the 
appropriate amount of ethanol (0.1%).
2.5 BrdU assay
The principle of the assay was to determine cell proliferation by measuring 5- 
bromo-2-deoxyuridine (BrdU) incorporation during DNA synthesis in 
proliferating cells. This assay indicates growth rate as opposed to cumulative 
cell growth. Conventional methods use thymidine, however this technique is 
based on the incorporation of the pyrimidine analogue 5-bromo-2'-deoxyuridine 
(BrdU). The BrdU assay was performed using a colorimetric ELISA kit (Biotrak 
version 2 from Amersham Pharmacia Biotech).
The assay involved culturing cells in the presence of the respective test 
substances in a 96-well microtitre plate at 37°C for 1 to 5 days. BrdU was added
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to the cells and reincubated (usually 2-24h). During this labelling period, the 
pyrimidine analogue BrdU wass incorporated in place of thymidine into the DNA 
of proliferating cells. After removing the culture medium, the cells were fixed 
and the DNA denatured by addition of fixative (the dénaturation of the DNA was 
necessary to improve the accessibility of the incorporated BrdU for detection by 
the antibody). The peroxidase-labelled anti-BrdU bound to the BrdU 
incorporated in newly synthesised, cellular DNA. The immune complexes were 
detected by the subsequent substrate reaction, and the resultant colour read at 
450nm in a microtitre plate spectrophotometer. The absorbance values 
correlated directly to the amount of DNA and thereby to the number of 
proliferating cells in culture (Amersham-Pharmacia-Biotech, 1998).
2.5.1 BrdU incorporation
After 24 hours of treatment with test compounds, 5-bromo-2-deoxyuridine 
(BrdU) was added to 200pl of medium to give a final concentration of 10pM per 
well. Incorporation was allowed to proceed for a further 24 hours at 37°C 
before the medium was collected and cells were fixed with an ethanol- 
containing fixative. Cells were blocked then incubated for 30 min at room 
temperature on a plate shaker with a peroxidase conjugated mouse monoclonal 
antibody (1:100). After washing, peroxidase substrate (tetramethylbenzidine) 
was added and the reaction stopped after 10 min with 1 M H2SO4. Absorbance 
was read within 5 min at 450nm using a 96-well plate reader. Results were from 
five replicate wells with experiments performed two to three times.
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2.5.2 Optimal conditions
To develop conditions whereby assay blank and non specific binding control 
absorbance readings were low and the difference between controls and 
stimulated cells were optimal, the following parameters were manipulated:
1. Different cell types were used to establish which growth patterns were 
more suited to the assay. These included T47D and ZR75 breast cancer 
cell lines which were both unsuitable due to slow and for ZR75 non­
monolayered growth which made denaturing and fixing cells more 
difficult.
2. Seeding density was altered between 1x10^ cells/well and 5X10^  
cells/well with 1 x 10"^  cells/well giving optimal results.
3. Percentage of DCC-FCS used for seeding the cells was varied between 
1%, 2.5% and 5% with optimal results seen with 5% DCC-FCS.
4. Length of time cells were starved in 0% DCC-FCS was varied between 0, 
24 and 48 hours with 24 hours giving optimal results.
5. Percentage of DCC-FCS used after starvation was varied between 0%, 
1%, 2.5% and 5% with compounds added to 0% starvation medium 
giving optimal results.
6. Test compounds were added for 3, 6 24 and 48 hours before BrdU was 
incorporated, with 24 hour incubations giving optimal results.
7. BrdU incubation was varied to 3, 6 and 24 hours with optimal results 
seen after 24 hours.
8. Cells were fixed for 30 and 60 minutes with 30 minutes giving optimal 
results.
9. Incubation with the blocking buffer was varied between 30 and 60 
minutes with 30 minutes giving optimal results.
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10. Incubation time with the Peroxidase labelled antibody was varied 
between 30 and 90 minutes with 30 minutes giving optimal results.
11. Incubation with the substrate TMB was varied between 5 and 30 minutes 
with optimal results seen after 10 minutes.
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CHAPTER THREE -  THE EFFECT OF TAMOXIFEN ON IGF 
STATUS IN BREAST CANCER PATIENTS -  A CASE CONTROL 
STUDY
3.1 Introduction
Breast cancer is the most prevalent cancer in women in Western populations. 
The risk of breast cancer increases greatly with age, and other established 
hormone related risk factors include early menarche, late age at menopause, 
and delayed age at first pregnancy (Bernstein & Ross, 1993). Family history is 
also important, although established genetic factors only account for about 5% 
of breast cancers in Western populations (McPherson et al., 2000).
Insulin-like growth factor-1 is a potent mitogen for breast cancer cell lines 
(Karey & Sirbasku, 1988). Increased concentrations of IGF-1 have been found 
in patients with breast cancer when compared with healthy controls (Bruning et 
al., 1995). In addition, healthy subjects with high IGF-1 concentrations, when 
controlled for binding proteins, have been shown to have an increased risk of 
breast cancer (RR 7.28, highest vs. lowest quintile) (Hankinson et al., 1998), 
and this has been confirmed by meta-analysis (Renehan et al., 2004). It is 
therefore now largely accepted that high circulating levels of IGF-1 and possibly 
BP-3 are a risk factor for pre menopausal breast cancer (Del Giudice et al., 
1998; Johansson et al., 2004; Krajcik et al., 2002; Li et al., 2001; Renehan et 
al., 2006; Renehan et al., 2004; Shi et al., 2004; Toniolo et al., 2000; Yu et al., 
2002).
Tamoxifen, an anti-oestrogen in use for over 20 years or more, is the most 
commonly used agent in the treatment of hormone responsive breast cancer
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(Katzenellenbogen et al., 1997). Clinical trials have confirmed the benefit of 
tamoxifen in preventing breast cancer recurrence and improving disease-free 
survival (1988; Baum, 1998). Tamoxifen has been tested as a preventative 
agent in healthy women and appears to significantly reduce both invasive and 
non-invasive breast cancer in those at increased risk of the disease (Fisher et 
a!., 1998; Powles et al., 1998).
Apart from its main action via oestrogen receptors, tamoxifen has been found to 
possess numerous other plausible mechanisms in controlling tumour growth, 
such as binding to protein kinase C (O'Brian et al., 1985), inhibiting ornithine 
decarboxylase activity (Thomas et al., 1989) and inhibiting angiogenesis 
(Gagliardi & Collins, 1993). Tamoxifen can also act as an antioxidant (Wei et al., 
1998), and can suppress the production of TGFa and stimulate the production 
of TGFp (Carmichael et al., 2000; Winston et al., 1994).
In addition, tamoxifen initially seems to reduce IGF-1 concentrations in breast 
cancer patients (Poliak et al., 1990) and increase concentrations of its binding 
proteins, but studies with longitudinal sampling and long-term follow-up have yet 
to be carried out.
The aim of the study was to compare concentrations of IGF-1 and its binding 
proteins in patients with breast cancer (n=14) with those found in age and sex 
matched control subjects (n=23). A further aim was to assess the longitudinal 
effect of tamoxifen on IGF status in patients with breast cancer.
Study published in (Campbell et al., 2001).
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3.2 Materials and methods
Non-fasting serum samples were collected before surgery from patients with 
stage I II! invasive breast cancer, both pre-menopausal and post-menopausal. 
Serum samples were collected, again non-fasting, after <9, <18 and <27 
months of tamoxifen treatment at routine surgical outpatients appointments. 
These 14 patients were part of a larger prospective study looking at the role of 
diet and lifestyle in survival after breast cancer. They formed a subset of women 
where blood samples had been collected prior to surgery, before tamoxifen 
treatment had begun. The baseline concentrations were compared with age- 
and sex-matched control subjects (n=23) taken from the general population. In 
the patients with breast cancer, no patient showed evidence of metastatic 
disease during the treatment period. None of the patients suffered from any 
other endocrine or malignant disorder during the treatment period. All patients 
had been prescribed 20mg of tamoxifen daily and gave written informed 
consent to participate. The study was approved by the Ethical Committee of the 
Royal Free and University College London Medical School.
3.2.1 Laboratory methods
Serum was stored at -80°C until analysis. Concentrations of IGF-1, IGF 
binding protein (IGFBP-1), and IGFBP-3 were measured in serum by means of 
enzyme linked immuno-sorbent assay kits (ELISA) kits purchased from 
Diagnostics Systems Laboratories (London, UK).
See Chapter two for further detail of Laboratory Methods.
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3.2.2 Statistical methods
Owing to the small numbers of subjects involved, non-parametric tests were 
used throughout. The IGF status of patients with breast cancer compared with 
healthy controls was analysed using a Mann Whitney-U test. Analysis of the 
change in IGF status at particular time points compared with baseline values 
was carried out using Wilcoxon signed rank tests. Test results were considered 
to be significant when p<0.05.
3.3 Results
The mean (SE) patient age was 51.0 (2.7) years (range, 38-70). Five of the 14 
pateints were over 50 y.
Concentrations of IGF-1, IGFBP-1 and IGFBP-3 at baseline did not differ 
between cases and controls (Table 3.3.1). Patient concentrations at baseline 
and during tamoxifen treatment can be seen in (Table 3.3.2).
The concentrations of the three variables measured were within the expected 
range reported in the literature. IGF-BP1 was increased significantly after 18 
and 27 months of tamoxifen treatment (fig 3.3.1). IGFBP-3 was significantly 
increased from baseline at nine, 18 and 27 months (fig 3.3.2). IGF-1 was not 
decreased significantly (fig 3.3.3), but the IGF-1 to IGFBP-3 ratio, a commonly 
used measure of bioavailable IGF-1 (Hankinson et al., 1998), was significantly 
decreased both at nine and 18 months (fig 3.3.4). The IGF-1 to IGFBP-3 ratio 
was not significantly different from baseline at 27 months.
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Table 3.3.1: Baseline concentrations of insulin-like growth factor 1 (IGF-1), IGF
binding protein 1 ( GFBP-1), and IGFBP-3 in patients and controls
Patients
(n=14)
Controls
(n=23)
P value
IGF-1 (ng/ml) 166.6(42.0) 194.2 (63.4) NS
IGFBP-1 (ng/ml) 13.9 (2.9) 17.8 (3.9) NS
IGFBP-3(ng/ml) 3119(507) 3211 (598) NS
NS, not significant. Mann Whitney- Ü test
Table 3.3.2: Patient concentrations of insulin-like growth factor 1 (IGF-1), IGF 
binding protein 1 (IGFBP-1), and IGFBP-3 at baseline and during tamoxifen 
treatment
Pre-Tamoxifen
baseline
(n=14)
<9 months 
Tamoxifen 
(n=11)
<18 months
Tamoxifen
(n=12)
<27 months
Tamoxifen
(n=5)
IGF-1 (ng/ml) 166.6 (42) 144.3 (35.8) 149.4 (44.7) 181 (26.9)
IGFBP-1
(ng/ml)
21.6(16.6) 38.9 (23.4) 52.0 (41.8)' 40.7 (24.9)'
IGFBP-3
(ng/ml)
3119(507) 3673 (476)" 3445 (634)' 3409 (501)'
* P<0.05, **P<0.01 using Wilcoxon signed rank test compared with pre- 
tamoxifen baseline concentrations
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Figure 3.3.1: Effect of tamoxifen supplementation on insulin-like growth factor 
binding protein 1 (IGFBP-1).
Values are median (black line) with interquartile ranges (boxed area) and 
minimum-maximum values (bars). *p <0.05 for differences from baseline; 
Wilcoxon signed rank test.
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Figure 3.3.2. Effect of tamoxifen supplementation on insulin-like growth factor 
binding protein 3 (IGFBP-3).
Values are median (black line) with interquartile ranges (boxed area) and 
minimum-maximum values (bars). *p<0.05 for differences from baseline; 
Wilcoxon signed rank test.
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Figure 3.3.3: Effect of tamoxifen supplementation on insulin-like growth factor 1 
(IGF-1).
Values are median (black line) with interquartile ranges (boxed area) and 
minimum-maximum values (bars). *p<0.05 for differences from baseline; 
Wilcoxon signed rank test.
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Figure 3.3.4: Effect of tamoxifen supplementation on insulin-like growth factor 1 
(IGF-1) to IGF binding protein 3 (IGFBP-3) ratio.
Values are median (black line) with interquartile ranges (boxed area) and 
minimum-maximum values (bars). *p<0.05 for differences from baseline; 
Wilcoxon signed rank test.
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3.4 Discussion
We found that tamoxifen has the ability to lower bioavailable IGF-1 (calculated 
as the IGF-1 to IGFBP-3 ratio) for at least 18 months. Although concentrations 
of IGF-1 were not reduced significantly, concentrations of its major binding 
protein IGFBP-3 increased significantly, thereby reducing the amount of IGF-1 
available. However, this ratio of IGF-1 to IGFBP-3 was not significantly reduced 
from baseline at 27 months, so that the effect of longer treatment remains to be 
elucidated. Tamoxifen also significantly increased concentrations of IGFBP-1 
from baseline after 18 months of treatment. This increase has also been seen in 
other studies (Helle et al., 1996; Lahti et al., 1994).
Our finding of a lack of effect on IGF-1 concentrations is surprising because 
other studies have shown a reduction in IGF-1 by tamoxifen (Helle et al., 1996; 
Poliak et al., 1990). This might be the result of the small numbers of patients in 
our study group or population selection. However, another study (Lahti et al., 
1994) also failed to show an effect on IGF-1 at a median follow up of 29 
months. These investigators had seen a significant decrease in IGF-1 values 
after six months of tamoxifen treatment and their data point to a limited effect 
after long term treatment. Our data also indicate an initial (although non­
significant) reduction in IGF-1, which is lost as follow up time increases. This 
indicates a potentially important effect of duration of treatment on outcome and 
highlights the need for further longitudinal studies with strictly timed follow up 
periods.
We also found no differences between cases and controls in terms of IGF-1, 
IGFBP-1, and IGFBP-3 concentrations. Again, this is surprising because earlier 
studies have revealed differences in similar groups. A lack of such a finding 
may again simply reflect a lack of numbers. We were unable to divide our
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subjects into pre-menopausal and post menopausal groups, again owing to the 
small sample size, and this may have been reflected in our results because 
IGF-1 values have been shown to be a stronger predictor of breast cancer risk 
in pre-menopausal than in postmenopausal women (Hankinson et al., 1998).
Our study was not placebo-controlled, and therefore subjects were not 
randomised to a treatment regimen; a placebo-controlled study would have 
distinct design advantages over the one described here. However, placebo- 
controlled trials of tamoxifen would now be considered ethically unsound (Fisher 
et al., 2000). An earlier placebo controlled, long term study showed a 
significant reduction in IGF-1 after a mean follow up of 27 months (minimum 
follow up three months) but longitudinal samples were not taken (Poliak et al., 
1990). The samples used in our study were non-fasting and this may be 
important because IGF values may fluctuate according to nutrient intake 
(Clemmons & Underwood, 1991).
Changes in serum concentrations of IGF-1 have been shown to correlate 
positively with serum oestradiol concentrations in menstruating women (Massa 
et al., 1993). This agrees with findings that IGF-1 can vary over the menstrual 
cycle, with significantly lower values being found during the menstrual phase 
than the follicular and luteal phases (Helle et al., 1998). Although other studies 
found that IGF-1 concentrations were dependent on the menstrual cycle phase 
they considered this to be a fairly minor variation (Juul et al., 1997). Our study 
did not take into account the effect of the menstrual cycle and it may be 
important to control for this in future work.
The mechanism by which tamoxifen alters IGF status has not been fully 
elucidated. However, tamoxifen is thought to alter IGF-1 values by reducing the 
production of growth hormone from the pituitary, thereby lowering the amount of
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IGF-1 that is produced by the liver and released into the circulation. Tamoxifen 
also has direct action as an antioestrogen on breast cancer cells and appears to 
alter the amount of IGF-1 and binding proteins released by the cells themselves 
(Poliak et al., 1990; Winston et al., 1994).
Since this work was published, there have been significant developments in the 
field, both in the use of SERMS and other treatments for breast cancer, and in 
how these treatments affect IGF concentrations. These will now be 
summarised. Tamoxifen has been shown to reduce breast cancer incidence by 
30-40% in high risk subjects, in large phase III Trials (Cuzick et al., 2002; Fisher 
et al., 1998; Gasco et al., 2005; Veronesi et al., 2003). However, with the 
increased risk of endometrial cancer and venous thrombolitic events attributed 
to tamoxifen other compounds including lower dose tamoxifen, other SERMS, 
aromatase inhibitors, and retinoids are now being assessed. Some of these 
trials have included analysis of IGF-1 and its binding proteins as cancer risk 
biomarkers.
Low dose tamoxifen studies have shown that 10mg/day gives comparable 
reductions in IGF-1 levels to standard 20mg/day doses (Bonanni et al., 2001; 
Decensi et al., 1998; Decensi et al., 1999; Decensi et al., 2003) with possible 
dose-resposnse relationships seein in IGF-1/BP-3 rations (Bonanni et al.,
2001). A recent study by (Guerrieri-Gonzaga et al., 2006) has shown a 13% 
reduction in IGF-1 levels after 40 months of 5mg/day tamoxifen in 235 pre­
menopausal women at risk of breast cancer, while the use of low does 
tamoxifen for combination hormone replacement therapy users has shown a 
significant reduction in IGF-1 and increase in BP-3 for those who received 
5mg/day tamoxifen over 12 months (Decensi et al., 2007).
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other SERMS including Raloxifene have been trialed in large studies and show 
76% reduced risk of breast cancer with no increase risk in endometrial cancer 
(Cauley et ai., 2001; Martino et al., 2004) with the National Surgical Adjuvant 
Breast and Bowel Project Study of tamoxifen and Raloxifene trial (STAR) 
showing that Raloxifene is as effective as tamoxifen in reducing the risk of 
invasive breast cancer and has a lower risk of thromboembolic events and 
cataracts but a nonstatistically significant higher risk of non-invasive breast 
cancer(Vogel et al., 2006). Raloxifene has also been shown to reduce IGF-1 
and increase BP-3 when compared with placebo after 3 months (Andersson et 
al., 2002; Eng-Wong et al., 2003) and 2 years in post-menopausal type II 
diabetes patients (Duschek et al., 2004).
Recent trials have also shown improved efficacy and decreased side effects of 
aromatase inhibitors such as anastrazole and letrazole compared to tamoxifen 
(Baum et al., 2002; Ellis et al., 2001 ; Howell et al., 2005; Mouridsen et al., 2001 ; 
Nabhoitz et al., 2000). However, the effects of Vorozole on IGF-1 levels 
(Harper-Wynne et al., 2002) showed a non significant increase in IGF-1 and are 
in line with earlier studies showing increases in IGF-1 levels with other 
aromatase inhibitors (Bajetta et al., 1997) (Frost et al., 1996).
A case control study found that one year of the retinoid fenretinide reduced IGF- 
1 by 13% in women aged <50 and by 3% in women over 50 with changes 
maintained for up to 5 years (Decensi et al., 2001). However, other trials 
comparing the retinoid fenretinide with tamoxifen found only 2% lowering in 
IGF-1 with Fenretinide vs 15% in tamoxifen and no synergistic effects between 
the two treatments were seen (Guerrieri-Gonzaga et al., 2006).
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3.5 Conclusion
Patients with breast cancer had similar concentrations of IGF-1, IGFBP-1, and 
IGFBP-3 to those seen in healthy control subjects in this pilot study. Tamoxifen 
can increase IGFBP-1, IGFBP-3, and reduce the IGF-1 to IGFBP-3 ratio, and 
these alterations may contribute to the therapeutic benefits of tamoxifen. The 
long term effects of tamoxifen use on IGF status remain to be established. 
Longer follow up with larger numbers of patients would determine when, and for 
how long, tamoxifen can reduce circulating IGF-1. The effect of other 
treatments for breast cancer, including lower dose tamoxifen and other SERMS 
is now being tested. Given the increase in risk of breast cancer associated with 
higher levels of IGF-1 in pre-menopausal women and the ability of 
phytoestrogens to act as SERMS, the potential of these dietary compounds to 
alter IGF status like tamoxifen and other SERMs is investigated in the following 
chapters.
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CHAPTER FOUR -  SHORT-TERM PHYTOESTROGEN 
SUPPLEMENTATION IN HEALTHY FEMALE VOLUNTEERS -  
PILOT STUDY
4.1 Introduction
Phytoestrogens have been proposed to protect against many diseases 
including hormone-dependent cancers and coronary heart disease. Found in 
many plant products, but particularly soy, legumes, and vegetables, they have a 
wide variety of proposed biochemical effects including estrogenic and 
antioxidant effects (Bingham et al., 1998).
Many studies have examined the effect of phytoestrogen supplementation in 
vitro, but fewer have looked at their physiological effects in vivo. A summary of 
human intervention studies examining effects of phytoestogen supplementation 
on IGF-1 levels can be found in tablel.3.5.1. As a preliminary pilot in vivo study, 
we have examined the effects of a single intake of phytoestrogens and a week- 
long intervention. We have assessed a variety of biochemical endpoints, 
including phytoestrogen metabolites in urine, antioxidant status and lipid status. 
These are all potentially altered by phytoestrogen consumption (Bingham et al., 
1998). We have also examined the effects of phytoestrogen supplementation on 
insulin-like growth factor (IGF) profile as there is increasing evidence that high 
circulating levels of IGF-1 and possibly BP3 are a risk factor for pre-menopausal 
breast cancer (Del Giudice et al., 1998; Hankinson et al., 1998; Johansson et 
al., 2004; Krajcik et al., 2002; Li et al., 2001; Renehan et al., 2006; Renehan et 
al., 2004; Shi et al., 2004; Toniolo et al., 2000; Yu et al., 2002). As shown in the 
previous chapter, levels of IGF-1 and its related binding proteins are altered by
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tamoxifen (Campbell et al., 2001), and phytoestrogens have a similar structure 
to tamoxifen (Bingham et al., 1998).
We have also examined the effects of phytoestrogens on DNA damage, as 
assessed by the COMET assay. Phytoestrogens have antioxidant properties 
(Bingham et al., 1998) and may therefore protect against oxidative DNA 
damage.
The aim of this pilot feeding study was therefore to compare the effects of acute 
(single 80 mg load) versus chronic (80 mg/day for 7 days) administration of 
phytoestrogens on a number of physiological endpoints including urinary 
phytoestrogen metabolites, lipids, antioxidant status, DNA damage and IGF-1, 
IGFBP-1 and IGFBP-3, in healthy female volunteers (n=10).
This was a feasibility study used to establish the assays for analyses of serum 
IGF-1, BP1 and BP3 concentrations and GC-MS analysis of phytoestrogens in 
urine and to determine the practicalities of use of the phytoestrogen-rich 
‘energiser bar’ for future feeding studies.
Study published in (Woodside et a!., 2006)
4.2 Materials and methods
4.2.1 Study Design
Subjects were healthy female volunteers (n=10), employed within University 
College London. The study was fully explained to the subjects, and written 
informed consent obtained. This study received ethical approval from the Royal 
Free and University College London Medical School Research Ethics 
Committee.
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The supplement used was a soy and linseed bar, each bar containing a total of 
20mg of isoflavones and lignans. The nutritional information is shown in Table 
4.2.1.1.
The ingredients list was as follows: Dehulled Split Soya Beans, Glucose Syrup, 
Sugar, Golden Linseeds, Rye Flour, Crisped Rice, Dried Apple, Rolled Oats, 
Fructose, Corn Syrup Solids, Water, Flavourings and Pectin.
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Table 4.2.1.1: Estimated nutritional content of phytoestrogen supplement
per 10Og per bar Per day
Energy (kJ) 1656 497 1988
Energy (Kcal) 395 119 476
Protein (g) 15.1 4.5 18
Carbohydrate (g) 56.7 17.0 68.0
of which sugars (g) 29.2 8.8 35.2
Fat(g) 12.0 3.6 14.4
of which saturates (g) 1.9 0.6 2.4
Fibre (g) 4.2 1.3 5.2
Sodium (g) 0.1 Trace 0.03
The study was divided into two phases with a wash-out period of 6 days 
between phases. Subjects were instructed to follow a soy-free diet for 1 week 
before the study began.
4.2.2 Phase 1
Subjects were asked to provide a 24-h urine collection prior to the study. After 
an overnight fast, subjects gave a baseline blood sample. They were then given 
a breakfast containing 80 mg of phytoestrogens (4x supplement bars). Blood 
samples were taken at 8 and 24 h (fasting) after the meal with spot urine 
samples collected during the hours 1-2, 2-4, 4-6, 6-8 and 24 h. Meals or snacks, 
excluding soy products, were permitted throughout the 8 h post meal period, but 
only liquids were consumed until 2 h after the meal.
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4.2.3 Phase 2
Six days later, subjects collected a further 24-h urine sample and had a further 
fasting baseline blood sample prior to the study. They were then asked to take 
80 mg Phytoestrogen (4x supplement bars) daily for a period of 7 days, after 
which they collected a final 24-h urine sample and had a final fasting blood 
sample taken.
4.2.4 Collection and preparation of biological samples
Urine samples (24 h) were stabilised with 1-2 g/l ascorbic acid and sodium 
azide (0.1 g/L) and stored at -80°C until analysis. Spot urine samples were not 
stabilised but immediately frozen after collection. Blood samples either kept at 
4°C for a maximum of 30 min (plasma) or were allowed to clot for 30 minutes in 
the dark (serum) and then centrifuged at 3000 rpm for 10 min. Serum or plasma 
was aliquoted and stored at -80°C until analysis. Lymphocytes were collected 
into a Vacutainer Cell Preparation Tube (Becton Dickinson, New Jersey), 
extracted and washed according to manufacturer’s instructions and stored at - 
80°C.
4.2.5 Endpoint measurements
Urine samples were analysed for the isoflavonoids genistein and daidzein, the 
isoflavan equol and the lignans enterolactone and enterodiol levels, using gas 
chromatography-mass spectrometry following enzyme hydrolysis, extraction 
into ether and silylation according to Morton et al. (Morton et al., 1994).
Ascorbic acid concentrations were determined in EDTA plasma as described by 
Vuillemier & Keck (Vuillemier & Keck, 1989). Concentrations of lipid-soluble 
antioxidants were measured by HPLC in serum according to the method of
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Thurnham et al. (Thurnham et al., 1988). Levels of aqueous phase lipid 
hydroperoxides were assessed in plasma by the FOX 1 (ferrous oxidation in 
xylenol orange) assay according to Wolff (Wolff, 1994). Susceptibility of LDL to 
oxidation was assessed in Phase 2 according to McDowell et al. (McDowell et 
al., 1995). DMA damage was analysed by the COMET assay in both 
lymphocytes according to Spanswick et al. (Spanswick et al., 1999).
Serum total cholesterol was estimated using an enzymatic CHOD-PAP kit, while 
serum triglycerides were measured using the Peridochrom GPO-PAP kit (both 
Boehringer Mannheim). Precipitation for HDL-cholesterol estimation employs 
phosphotungstic Mg^  ^ reagents.
Serum samples were analysed for IGF-1 and IGFBP-1 and IGFBP-3 using 
ELISA kits from Diagnostic System Laboratories (London, UK). For all 
laboratory methods, daily quality controls were utilised to ensure both within- 
and between-assay reproducibility.
See Chapter two for further detail on Methods.
4.2.6 Statistical methods
Comparisons between subjects pre- and post-intervention were carried out 
using a non-parametric Wilcoxon signed rank test due to the small numbers of 
subjects and the non-normal distribution of the data. Associations between 
continuous variables were tested using Spearman correlation coefficients. All 
analyses were carried out using SPSS.
4.3 Results
Subjects had a mean age of 33.1 years ranging from 23 to 50. Eight were pre­
menopausal, of whom three were on the oral contraceptive pill. One of the
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subjects was post-menopausal and was also on hormone replacement therapy. 
All subjects were non-smokers.
Concentrations of genistein, daidzein, equol, enterolactone and enterodiol were 
elevated, both after a single 80 mg dose (Table 4.3.1) and after 1 week of 
supplementation (Table 4.3.2).
The effect of phytoestrogen supplementation on lipid and antioxidant-related 
endpoints is shown in Table 4.3.3. Neither acute nor chronic phytoestrogen 
supplementation had any effect on any of the lipid or antioxidant-related 
endpoints assessed.
All IGF-1 and IGFBP-3 levels fell within the range of expected values given for 
healthy females in this age group. As fasting samples are required for these 
assays, measures of IGF-1 and IGFBP-3 status were limited to baseline and 
24-hour post supplement in the first phase of the study.
Levels of IGF-1 were unchanged following the single 80 mg load. However, in 
Phase 2, IGF-1 and IGFBP-3 concentrations were significantly elevated after a 
week of supplementation. Levels of IGFBP-1 were not altered by 
phytoestrogens in either phase of the study (Table 4.3.4).
The change in IGF-1 in Phase 2 was significantly associated with the change in 
IGFBP-3 (r=0.721, P<0.05; Spearman correlation coefficient) (Figure 4.3.1) 
However, if the ratio of IGF-1/IGFBP-3 was compared pre- and post­
supplementation, the ratio was also significantly increased post­
supplementation, suggesting that IGF-1 has increased independently of the 
increase seen in IGFBP-3 (Table 4.3.4).
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Table 4.3.1 : Effect of one phytoestrogen meal on urinary phytoestrogen 
excretion- Phase 1
Baseline 1-2 h 2 -4  h 4 -6 h 6 -8 h 24 h
[median (IQ range)]
[median
(IQ
range)]
[median
(IQ
range)]
[median
(IQ
range)]
[median
(IQ
range)]
[median
(IQ
range)]
Genistein
(ng/ml)
196
(146,
308)
217(169,
377)
313(201,
416)*
392 (344, 
558)*
1257
(1013,
2711)*
289(139,
417)
Daidzein
(ng/ml)
428
(236,
593)
484 (388, 
714)*
642 (375, 
854)*
952 (681, 
1837)*
3283
(2463,
4365)*
408 (252, 
634)
Equol (ng/ml) 91 (48, 192)
104(31,
268)
191 (25, 
328)
356 (36. 
523)*
757 (207, 
915)*
136 (42, 
264)
Enterolactone
(ng/ml)
284
(105,
334)
280 (149, 
307)
226(153,
308)
242 (146, 
305)
301 (206, 
335)
284(169,
461)
Enterodiol
(ng/ml)
69 (22, 
101)
66 (42, 
88)
79 (47, 
88)
77 (40, 
95)
75 (48, 
95)
77 (46, 
145)
* P<.05 when compared to baseline, Wilcoxon 
signed rank test.
Table 4.3.2: Effect of 1 week of phytoestrogen supplementation on urinary 
phytoestrogen excretion -  Phase 2
Baseline Postweek
[median (IQ range)] [median (IQ range)]
Genistein (ng/ml) 
Daidzein (ng/ml) 
Equol (ng/ml) 
Enterolactone(ng/ml) 
Enterodiol (ng/ml)
206 (88, 306) 
385 (195, 599) 
96 (53, 131) 
224 (95, 403) 
46(19, 81)
2775 (1818, 3101)* 
4571 (3934. 5803)* 
899 (501, 1540)* 
392(181,565)* 
83 (58, 114)*
*P<.05 when compared to baseline 2, Wilcoxon signed rank 
test.
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Table 4.3.3: Effect of phytoestrogen supplementation on lipids and antioxidant 
status
Phase 1 [median (IQ range)] Phase 2 [median (IQ  range)]
Baseline 8 h 24 h ^ Baseline postweek
Total cholesterol 
(mmol/L)
4.59 (4.07, 
5.31)
4.47
(4.05,
4.82)
4.19
(3.89,
4.79)
4.63 (4.16, 
5.54)
5.00 (4.32, 
5.27)
HDL cholesterol 
(mmol/L)
1.49 (0.91, 
1.68)
1.43
(0.96,
1.62)
1.43
(0.93,
1.87)
1 .48(1 .16,
1.58)
1.57 (1.10, 
1.73)
Triacylglycerol
(mmol/L)
1.00 (0.83, 
1.58)
1.44
(1.31,
2.39)
0.92
(0.66,
1.20)
1 .19(0 .84,
1.78)
1 .19(0 .86,
1.45)
LDL cholesterol 
(mmol/L)
2.59 (2.24, 
3.39)
2.27
(2.13,
2.86)
2.36
(2.16,
2.51)
2.86 (2.29, 
3.41)
2.96 (2.70, 
3.31)
F0X1 (pmol/L) 1.65(1 .15,
2.57)
1.42
(1.37,
1.64)
1.20
(1-10,
1.37)
1.35 (1.19, 
1.45)
1 .34(1 .29,
1.46)
Retinol (pmol/L) 1.00 (0.74, 
1.49)
0.79
(0.48,
1.47)
1.01
(0.69,
1.30)
0.99 (0.61, 
1.10)
0.91 (0.52, 
1.19)
a-Tocopherol
(pmol/L) 20.9 (17.6 ,23.9)
19.1
(14.8,
22.8)
21.4
(16.3,
24.8)
18.9 (15.5, 
24.2)
21.0 (12.6, 
23.3)
Lycopene (pmol/L) 0.09 (0.04, 
0.16)
0.09
(0.06,
0.11)
0.09
(0.06,
0.11)
0.06 (0.04, 
0.09)
0.07 (0.03, 
0.16)
a-Carotene (pmol/L) 0 .14(0 .06 ,
0.29)
0.12
(0.06,
0.21)
0.15
(0.09,
0.27)
0.08 (0.04, 
0.11)
0.07 (0.05, 
0.41)
P-Carotene (pmol/L) 0.14 (0.09, 
0.20)
0.13
(0.09,
0.18)
0.16
(0.08,
0.19)
0.12 (0.09, 
0.16)
0 .10 (0 .07 ,
0.17)
DNA damage (olive 
tail moment) - - -
4.21 (1.50, 
5.07)
2.11 (1.31, 
2.74)
Lag time (min) - - - 44.2 (37.4, 53.6)
44.5 (38.8, 
48.4)
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Table 4.3.4: Effect of phytoestrogen supplementation on insulin-like growth
factor and binding protein concentrations
Phase 1 [median (IQ range)] Phase 2 [median (IQ range)]
Baseline 24 h Baseline 2 Postweek
IGF-1 (ng/ml) 2 1 8 (1 5 1 ,2 9 3 ) 250(179 ,310) 155(123, 258) 265 (228, 360)*
IGFBP-1 (ng/ml) 22 .6 (19 .0 ,36.8)
17.4 (15.8, 
34.6)
24.8 (14.6 ,
57.7)
14.7(10.0 ,
36.0)
IGFBP-3 (ng/ml) 4564 (3954, 5306)
4110(3887,
4533)
3735 (3631, 
4196)
4420 (4192, 
4935)*
IGF-1/IGFBP-3
ratio
0.05 (0.04, 
0.06)
0.06 (0.04, 
0.07)
0.04 (0.03, 
0.06)
0.06 (0.05, 
0.07)*
'P<.05 when compared to baseline, Wilcoxon rank signed test.
1 6 0 0 -,
I 1400 
S
S 1200 
» 1000 
*  800
r=0.721, p<0.05,
Pearson correlation coefficient
à 600
400
2 0 0 -
600 20 40 80 100 120 140 160 180
C h an g e  in IG F-1 over 1 w eak supplem entation
Figure 4.3.1: Association between change in IGF-1 and IGFBP-3 over 1 week of 
supplementation (r=0.721, P<0.05; Spearman correlation coefficient).
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4.4 Discussion
This study has assessed the effect of phytoestrogen supplementation, in the 
form of a soy, rye and linseed bar, on a variety of biochemical endpoints. 
Concentrations of phytoestrogen metabolites in urine reached their highest 
levels 6-8 h after supplementation for isoflavones, and 24 h for lignans in phase 
1. This is generally in agreement with other studies examining the effect of 
supplementation on urinary excretion of phytoestrogens (King & Bursill, 1998); 
(Rowland et al., 2003; Setchell et al., 2003). This study, however, was not 
designed to be a rigorous study of phytoestrogen pharmacokinetics. 
Phytoestrogens can act as antioxidants (Bingham et al., 1998) and may inhibit 
the oxidation of LDL (Lissin & Cooke, 2000) although the data from this study 
has not confirmed this in terms of lag time to oxidation. A protective/antioxidant 
effect has been shown by phytoestrogen supplementation on the susceptibility 
of LDL to oxidation in another study (Tikkanen et al., 1998). Another study, 
however, in common with this one, has failed to show an inhibition of lipid 
peroxidation after 8 weeks of isoflavonoid supplementation in subjects with 
high-normal blood pressure (Hodgson et al., 1999), measuring urinary F-2- 
isoprostanes a reliable indicator of oxidative stress. The study measuring F-2- 
isoprostanes was randomised, double-blind and placebo-controlled, in contrast 
to the present study and was carried out in relatively large numbers (n=59). Our 
subjects were healthy and therefore had normal antioxidant status. Therefore 
the lag times of these subjects may not have been easily affected by this 
supplement.
We have also observed an apparent reduction in DNA damage in lymphocytes 
(Olive tail moment from 4.21 to 2.11) after 1 week of phytoestrogen 
supplementation, although this was not significant. We have previously shown
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that genistein and equol within physiological range can reduce oxidative DNA 
damage in vitro in lymphocytes (Sierens et al., 2001), Mitchell & Collins 
(Mitchell & Collins, 1999) carried out a 4 week feeding study in healthy men to 
assess the effects of a phytoestrogen supplement in the form of soy milk on 
levels of DNA damage. There was no significant effect on H202-induced DNA 
damage in lymphocytes in those receiving the soy milk supplement as assessed 
by the comet assay. However, the levels of oxidised pyrimidine base damage 
over the 4-week period progressively decreased. A recent study found no effect 
of rye crispbread (rich in lignans secoisolariciresinol and matairesinol) over 2 
weeks on oxidative DNA damage (Pool-Zobel et al., 2000). We have only 
evaluated endogenous DNA damage in this study, where the damage may or 
may not have been oxidative in origin, and our intervention period was shorter 
than that which previously showed an effect. The antioxidant potential of these 
foods and compounds in vivo clearly requires further investigation.
This study found no effect of either a single dose or week’s supplementation 
with 80 mg phytoestrogens daily on serum lipids. This is in contrast to a meta- 
analysis of studies published in 1995 (Anderson et al., 1995). Of the 38 studies 
reviewed, 89% reported a net decrease in plasma cholesterol that averaged 
around 9% for an intake of around 47 g soy protein daily. However, it is notable 
that 77% of the studies included in the meta-analysis had 95% confidence 
intervals that included zero.
Since the meta-analysis, several well-controlled studies have been carried out, 
and the results of these have been variable (Lichtenstein, 2001). There are 
several potential explanations for this variability. Merz-Demlow et al. (Merz- 
Demlow et al., 2000) suggest that the effect of isoflavones on lipids may be 
related to menstrual cycle phase. The food matrix may also be important, as
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Lichtenstein (Lichtenstein, 2001) suggests that the effect of isoflavones appears 
to be somewhat dependent on whether the isoflavones are ingested in isolation 
or as an enriched preparation of those endogenously present in soy.
A recent study observed a reduction in LDL cholesterol in 156 men and women 
by an average of 6%. This was due entirely, however, to a mean reduction of 
9% among those with a raised baseline LDL cholesterol (>4.29 mmol/1) and was 
only observed in men and post-menopausal women (Crouse et al., 1999). The 
original meta-analysis also found a greater lowering effect in those with initially 
raised total cholesterol levels (Anderson et al., 1995). It may be that we 
observed no difference in our largely pre-menopausal sample set because they 
had low-normal lipid status initially, but it is more likely that one week of 
supplementation was too short to demonstrate an effect.
This study has shown that 1 week of phytoestrogen supplementation can alter 
IGF status, producing a significant increase in both IGF-1 and IGFBP-3 levels. 
The vast majority of IGF-1 is carried through the circulation bound to a complex 
containing IGFBP-3 and, until released by proteolysis, is relatively un reactive 
(Rajaram et al., 1997). Thus the strong correlation between increasing levels of 
IGF-1 and IGFBP-3 was as expected. However, when the ratio of IGF-1 to BP- 
3 was considered, this ratio was significantly increased post-supplement, and 
this finding requires further elucidation. Tamoxifen, a selective estrogen 
receptor modulator (SERM) has been shown to lower IGF-1 and increase 
IGFBP-3 concentrations (Campbell et al., 2001; Helle et al., 1996); therefore the 
phytoestrogen supplement appears to be behaving differently to tamoxifen.
Oral estrogen treatment for menopausal women has also been shown to reduce 
IGF-1 (Kelly et al., 1993) through inhibition of hepatic IGF-1 synthesis. The 
mechanism by which this supplement has increased IGF-1 requires further
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study. Since conducting this study in 1998, other intervention studies have also 
published their findings on the effects of soy supplementation on IGF status 
(Table 1.3.5.1).
Of the twelve studies published to date, half have seen a significant increase in 
serum IGF-1 concentrations while the others have seen no effect (Table 
1.3.5.1).
Two studies were conducted using soy protein with a milk protein control. In 
men, serum IGF-1 was higher in those supplemented with soy protein than 
those consuming milk protein (Khalil et al., 2002). The same supplements given 
to post-menopausal women (Arjmandi et al., 2003) resulted in significant 
increases in IGF-1 on both soy protein (p<0.0001) and the milk protein control 
(p=0.0045). However like the men, the greatest increases in IGF-1 (97%) was 
seen in women on the soy protein especially those who were not on HRT.
These two studies would suggest that protein itself does increase IGF-1 but that 
soy protein had an effect on IGF-1 independent of its protein content. Calcium 
content did not explain the findings as both supplements had similar calcium 
content.
By contrast, in a three month study looking at markers of bone turnover 
(Wangen et al., 2000) in pre menopausal women, IGF-1 and IGF-BP3 were 
increased by a low isoflavone diet, while in post-menopausal women, there 
were trends towards decreased IGF-1 and IGF-BP3 concentrations with 
increasing isoflavone concentration. The authors concluded that, although soy 
isoflavones do affect markers of bone turnover, the changes observed were of 
small magnitude and were not likely to be clinically relevant. In a study looking 
at soy protein supplementation with or with out 83 mg isoflavones (Adams et al., 
2003), it was found that changes in serum IGF-1 and BP3 were similar in both
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groups and there appeared to be no effect of soy isoflavones on IGF-1 when 
compared to the protein supplement alone. Similarly, a one year soy protein 
supplementation in post-menopausal women (n=62) (Arjmandi et al., 2005), 
found that both soy and dietary protein supplements significantly increased 
serum IGF-1, however only those consuming soy protein had a significant 
increase in 1GF-BP3.
In a 2 year soya intervention (~30mg isoflavones) in pre-menopausal women 
(Maskarinec et al., 2005b), there was no significant change in serum IGF-1 or 
BP3 throughout. They did see a positive correlation between total isoflavone 
excretion and IGF-1 (p=0.004). The author concluded that adding soya foods to 
the diet of pre-menopausal women does not appear to lower serum levels of 
IGF-1 and BP-3, if anything the greater protein intake from soy may lead to a 
small increase in IGF-1 serum levels.
In all of the studies mentioned above it is difficult to disentangle the effects of 
isoflavones from soy protein (Voskuil et al., 2005) especially in those studies 
which have looked at soy supplementation as part of an overall healthy dietary 
intervention (Gann et al., 2005; Kaaks et al., 2003; Spentzos et al., 2003).
Only our study (discussed in chapter four) (Campbell et al., 2004) and, to our 
knowledge, one subsequent study published recently (Vrieling et al., 2007), has 
looked at the effects of isoflavone supplementation on its own.
The results from this study and the intervention studies above are inconclusive 
but possibly show opposing effects of isoflavones and soy protein, with IGF-1 
decreased by isoflavones but increased by soy protein and possibly protein in 
general. Certainly feeding studies (Clemmons et al., 1985; Smith et al., 1995) 
have shown that a diet restricted of certain essential amino acids reduces IGF-1 
levels possibly by decreasing production of GH which in turn reduces hepatic
111
production of IGF-1 (Ketelslegers et al., 1995) and increases BP-1 (Jousse et 
al., 1998). It has been observed previously that IGF is closely linked to 
nutritional status (Clemmons & Underwood, 1991). Our observation of an 
increase in both IGF-1 and IGF-BP3 could well be attributed to the increase in 
kilocalories and protein consumed in the phytoestrogen bar (476 Kcal daily; 18 
g protein daily; Table 1), as IGF-1 appears to be closely related to protein and 
energy metabolism (Clemmons & Underwood, 1991). No dietary intake data 
were collected in the present study so it is unclear whether total protein and 
energy intake increased or whether subjects unconsciously decreased their 
intake to compensate for the extra calories over the week. Intervention studies 
using a phytoestrogen extract or, as a control, a food supplement from which 
phytoestrogens have been removed, should be used in future to exclude the 
possibility that an increase in protein and/or energy intake produced the 
observed alteration in IGF-1 and IGF-BP3.
The status of endogenous oestrogen concentrations may also contribute to the 
differences seen with IGF-1 -  this was a heterogeneous study population 
including pre and post-menopausal women, HRT vs none, those on the oral 
contraceptive pill, etc. Thus it may also be important to take into account the 
effects of the menstrual cycle in future studies as it has been shown that IGF-1 
can vary throughout the menstrual cycle (Gaufriez et al., 1986; Helle et al., 
1998; Juul et al., 1997; Lavigne et al., 2004).
Oestrogenic, and therefore confounding, effects of oral contraceptives and 
hormone replacement therapy should also be considered as numbers were not 
large enough in this study to examine their effect.
The supplement bar we used contained two classes of phytoestrogen -  
isoflavones (found predominantly in soy) and lignans (found predominantly in
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linseed)(Bingham et al., 1998). The biological effects of these two classes may 
be different, and research has, to date, concentrated on the isoflavones. 
However, some recent studies have assessed lignan intake and would appear 
to show a protective effect on breast cancer risk (Keinan-Boker et al., 2004; 
Thanos et al., 2006; Touillaud et al., 2007). From this study, we cannot 
distinguish the effect of the two different classes, or indeed, conclusively 
attribute the biological effects we have observed to the phytoestrogens 
independent of any other supplement constituent.
Nevertheless these findings may have future implications for health and 
disease. Phytoestrogens have been proposed to protect against breast cancer, 
as Japanese women, who consume their traditional diet with a high intake of 
phytoestrogens, have a very low incidence of breast cancer (Woodside & 
Campbell, 2001 ). IGF-1 has been shown to be a risk factor for breast cancer in 
pre-menopausal women (Del Giudice et al., 1998; Hankinson et al., 1998; 
Johansson et al., 2004; Krajcik et al., 2002; Li et al., 2001; Renehan et al.,
2006; Renehan et al., 2004; Shi et al., 2004; Tonlolo et al., 2000; Yu et al.,
2002) and, if it can be confirmed that phytoestrogens increase circulating IGF-1 
concentrations, then this would actually indicate an increased risk of breast 
cancer in those consuming high-phytoestrogen diets. Obviously further work 
would be required before such conclusions can be drawn, but the data 
presented here do highlight the need for further, well-designed trials. Some of 
the issues raised above have been taken into consideration in the study design 
described and tested in chapter 5.
In conclusion, this small study suggests that one week of supplementation with 
a phytoestrogen-rich bar alters concentrations of IGF-1 and IGF-BP3. The 
supplement also seemed to protect DNA against damage in lymphocytes, but
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had no effect on other antioxidant parameters or lipid status in healthy female 
subjects. Further larger and long-term intervention studies using isolated 
isoflavone supplementation, which therefore allow the inclusion of a placebo 
control, should determine whether the isoflavone content of soy has an effect on 
IGF status.
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CHAPTER FIVE -  THE EFFECT OF ISOFLAVONE 
SUPPLEMENTATION ON INSULIN-LIKE GROWTH FACTOR. 
LIPID AND ANTIOXIDANT STATUS IN HEALTHY FEMALE 
VOLUNTEERS
5.1 Introduction
High concentrations of IGF-1 in serum have been associated with an increased 
risk of breast cancer, in case control studies (Bohlke et al., 1998; Bruning et al., 
1995; Del Giudice et al., 1998; Johansson et al., 2004; Li et al., 2001; Peyrat et 
al., 1993; Yu et al., 2002) and more recently in prospective studies (Hankinson 
et al., 1998; Krajcik et al., 2002; Muti et al., 2002; Rinaldi et al., 2006; Toniolo et 
al., 2000). Most reviews agree that this relationship is more prominent in pre­
menopausal women (Fletcher et al., 2005; Renehan et al., 2004;
Schernhammer et al., 2005; Shi et al., 2004; Sugumar et al., 2004) but not all 
studies comply (Kaaks et al., 2002; Rinaldi et al., 2006; Rinaldi et al., 2005b), 
although a recent prospective analysis of the Nurses Health study II cohort 
study found no associations in either pre or post-menopausal women 
(Schernhammer et al., 2006).
Tamoxifen has been shown to lower circulating IGF-1 levels by approximately 
30% in breast cancer patients (Campbell et al., 2001; Poliak et al., 1990), 
(Colletti et al., 1989; Helle et al., 1996; Lonning et al., 1992) and in healthy 
women (Bonanni et al., 2001; Decensi et al., 1998; Decensi et al., 2003). 
Isoflavones are a class of phytoestrogens which may have a variety of potential 
health benefits in endocrine-responsive cancers (Adlercreutz, 2002b), 
(Adlercreutz, 2002a) and CVD (Cassidy & Hooper, 2006), (Bingham et al.,
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1998); (This et al., 2001). They are obtained in the diet predominantly from soy 
products (Bingham et al., 1998). Isoflavones are structurally similar to tamoxifen 
and, like tamoxifen, can act as selective oestrogen receptor modulators 
(Brzezinski & Debi, 1999). They may therefore be able to alter concentrations of 
IGF-1 and its binding proteins.
The aim of this study was to determine whether one month of isoflavone 
supplementation could alter serum concentrations of IGF-1 and its related 
binding proteins. In light of the results in the previous chapter, where a 
phytoestrogen-rich bar providing 80 mg phytoestrogens/day over 7 days 
produced an increase in IGF-1 and IGFBP-3, this study used a phytoestrogen 
extract, which allowed the use of a placebo control. The effect of the menstrual 
cycle on insulin-like growth factor profile was accounted for in the study design. 
We also assessed whether the isoflavone supplement produced an alteration in 
hormone, lipid or antioxidant status as effects on these parameters have been 
demonstrated in some studies (Merz-Demlow et al., 2000; Takatsuka et al., 
2000), but not in others (Howes et al., 2000; Jenkins et al., 2000; Nestel et al., 
1999; Simons et al., 2000). The inclusion of a food frequency questionnaire and 
a 7-day food diary completed in each phase allowed the assessment of 
nutritional intake.
Study published in (Campbell et al., 2004).
5.2 Materials and methods
5.2.1 study design
The study was based on a randomised, double-blind, placebo-controlled cross­
over design (Figure 4.2.1). Pre- and post menopausal subjects were 
randomised to receive either two placebo or two supplement tablets containing
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a total of 80 mg isoflavones daily. Each phase was followed by a minimum 2- 
month washout period and the alternative intervention.
Supplement
Placebo
I
Day of
menstrual
cycle
WASHOUT
Supplement 
 ►
Placebo
\
\
%
X
V
N*
V
; 1 Î
1-3 6-8 12-15 21-23 26-28
Fasting blood Fasting Fasting Fasting Fasting blood
24 h urine blood blood blood 24 h urine
Figure 5.2.1 Study design -  for pre-menopausal women blood samples were taken 
throughout the menstrual cycle as shown. For post-menopausal women, fasting blood 
and urine were only collected at the start and end of the 28 day intervention period.
5.2.2 Eligibility Criteria
Pre-menopausal - not on oral contraceptives, no antibiotics within previous 4 
months, regular menstrual cycle of approximately 28 days.
Post-menopausal - not on hormone replacement therapy, no antibiotics within 
previous 4 months, had an oophorectomy or amenorrhoea for at least 12 
months.
5.2.3 Sample Collection
Fasting blood samples were obtained from post-menopausal subjects at 
baseline and at 28 days in each phase of the study. Fasting blood samples
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were collected at baseline, day 1-3, day 6-8, day 12-15, day 21-23 and day 26- 
28 from pre-menopausal subjects to assess the effects of the menstrual cycle 
on the endpoints measured. For all subjects, a 24-h urine sample was collected 
at baseline and 28 days for each phase. In addition, a fully validated food 
frequency questionnaire was filled in at the baseline stage of each phase and a 
food diary completed over the last seven days of each phase. All biological 
samples were stored at -80°C until analysis. The study was approved by the 
Royal Free and University College London Ethical Committee.
5.2.4 Endpoint measurements
A variety of endpoint measures were assessed. Levels of IGF-1, IGF-BP1, IGF- 
BP3 were measured in serum using ELISA methods (Diagnostic Systems 
Laboratories). Oestradiol, progesterone, LH, FSH, SHBG were measured in 
serum using routine IRMA/RIA methods. Isoflavones were assessed in urine at 
the start and end of each supplementation period by GC-MS according to 
(Morton et al., 1994). Serum lipids were assessed, again at the start and end of 
each supplementation phase, using standard spectrophotometric assays. 
Antioxidant status was assessed by the measurement of vitamins A and E and 
carotenoids (Craft, 1992), malondialdehyde (Young & Trimble, 1991), vitamin C 
(Vuillemier & Keck, 1989), and aqueous phase lipid hydroperoxides (Wolff, 
1994).
Fully validated EPIC food frequency questionnaires (FFQ) and 7-day food 
diaries (FD) (McKeown et al., 2001) were analysed using DietPlan 5 for 
Windows 98.
See Chapter two for further detail on Methods.
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5.2.5 Supplement
The supplement used was a proprietary product called Promensil donated by 
Novogen. Each 500 mg supplement tablet contained 215 mg of an extract of 
Trifolium pratense (red clover) leaf. This extract contained 40 mg/tablet of total 
isoflavones present as hydrolysed aglycones. Each tablet contained 4.0 mg 
genistein (4’,5,7-trihydroxyisoflavone), 3.5 mg daidzein (4 ,7- 
dihydroxyisoflavone), and their methylated precursors 24.5 mg biochanin A (4- 
methoxy-5,7-dihydroxyisoflavone) and 8.0mg formononetin (4’-methoxy-7- 
hydroxyisoflavone). The residual material in each tablet was predominantly 
flavonoids, principally chlorophylls a and b. Other ingredients were as follows: 
Calcium hydrogen phosphate, Cellulose-microcrystalline, Soy polysaccharide. 
Natural vitamin E, Magnesium stearate. Silica, hydroxyl propyl mehyl cellulose, 
Rosemary extract and iron oxide. The placebo had the same physical 
properties (appearance and taste) and excipient ingredients but did not contain 
the isoflavone extracts.
5.2.6 Statistical analyses
The intervention was double-blinded and was not un-blinded until all analyses, 
including statistical analyses had been completed.
Pre- and post-menopausal women were considered separately in the analyses. 
Changes from baseline were compared between treatment groups using a 
paired samples t-test (for two time-point comparisons) or repeated measures 
AN OVA (for multiple time-point comparisons). The association of continuous 
variables was assessed using Pearson correlation coefficients. For the pre­
menopausal subjects, at the 5% level of significance, the study had 80% power
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to detect as statistically significant a 35% difference in change in IGF-1 between 
the treatment groups over the supplementation period.
5.3 Results
A total of 16 pre- and 7 post-menopausal subjects completed both phases of 
the study. The baseline characteristics of the subjects are shown in Table 
5.3.1. Among pre-menopausal subjects, three out of 16 were parous and 
among post-menopausal subjects, five out of six were parous. The mean 
(range) number of wash-out days was 95 (56, 206) in pre-menopausal subjects 
and 70 (62, 91 ) in post-menopausal subjects.
Table 5.3.1 Baseline characteristics of study subjects
Pre-menopausal
(n=16)
Post-menopausal
(n=7)
Age 34 (9) 57 (6)
BMI 23.3 (4.3) 24.4 (5.0)
Waist to hip ratio 0.75 (0.04) 0.77 (0.05)
Protein (E%) 14.1 (2.5) 14.3(1.6)
Carbohydrate (E%) 41.8 (6.8) 47.0 (7.6)
Fat (E%) 38.8 (4.9) 35.8 (3.8)
Alcohol (E%) 5.3 (5.1) 3.0 (3.9)
Data presented as mean (SD). E% = percentage of total calories
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5.3.1 Isoflavones
The change in concentration of genistein, daidzein and equol over the 
supplementation period was significantly larger during the supplement phase 
compared to placebo in both pre- and post-me no pa usa I women (Table 5.3.1.1) 
Concentrations excreted on the placebo were comparable to normal ranges in 
other studies (Cassidy, 2006). Concentrations of genistein, daidzein and equol 
excreted in urine, in pre-menopausal subjects, did not change during the 
placebo phase, but increased significantly during the supplement phase (Fig
5.3.1.1). This was also the case in post-menopausal subjects (Fig 5.3.1.2). 
However, the concentrations of genistein in postmenopausal subjects (Table
5.3.1.2) increased both on placebo (Mean±SD placebo (baseline 258.6+174.6 
versus 28 days 659.2+388.5 ng/ml; p<0.05)) and on supplement (Mean+SD 
supplement baseline 749,9+374.7 ng/ml versus 28 days 3959.5+2194.4; 
p<0.01 )). However, the magnitude of increase in genistein was much higher on 
the supplement (5.3-fold) than when on placebo (2.5-fold) and would appear to 
be because of a very low baseline level for genistein during the placebo phase, 
compared to the baseline level at the start of the supplement phase.
The placebo increase seen in post-menopausal women may have been caused 
by a carry over effect. Subjects who completed the supplement phase first did 
show higher genistein concentrations in the placebo phase nevertheless there 
was no statistical difference between the two groups when compared with the 
Mann Whitney U test (Mean+SD placebo first (placebo baseline 170.93+ 65.05) 
and on supplement first (placebo baseline 375.6+ 221.92)).
Concentrations of the two lignans, enterolactone and enterodiol, did not change 
during either phase, which is to be expected as neither of these compounds 
were present in the supplement.
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The metabolite equol, was significantly elevated on the supplement though the 
increase varied greatly between individuals ranging from 0.0 - 4172 ng/ml. A 
comparison of mean urine isoflavone concentrations post-supplement with other 
studies, shows that equol excretion varies considerably more than the other 
isoflavones (between 8 and 93 fold difference) (Table 5.3.1.3).
Subjects with urinary equol concentrations post-isoflavone supplement of 
>1pg/ml were defined as equol excretors. As defined above, 23% (3/14) pre­
menopausal subjects were equol excreters compared to 20% (1/5) of post­
menopausal subjects. Post-supplementation, Equol excretion ranged from 0- 
946 ng/ml in the non-excreters to 1197-4172 ng/ml in the excreters. When the 
four excreters were compared to the 15 non-excreters using an independent 
samples t test, levels of MDA, triglycerides, y-tocopherol and a-tocopherol (at 
baseline) were significantly higher in the excreters. There were no significant 
differences seen in the FFQ or the food diaries of these subjects. There were 
also no significant differences in alterations of IGF-1 and BP-3 or BP-1 
concentrations in these two groups when comparing mean changes on placebo 
or supplement (Table 5.3.1.4).
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Table 5.3.1.1. Effect of supplementation on urinary excretion of isoflavone
Placebo Supplement
Day 1-3 Day 26-28 Day 1-3 Day 26-28
Genistein ng/ml 254.8(212.8) 487.9(386.6) 567.2(458.2) 2756.1(2248)*
ng/day 436.5(375.3) 967.3(1064.7) 1097.4(999.5) 4641.9(3599.7)*
ng/|amol creatinine 41.6(38.2) 86.4(81.4) 106.2(93.7) 445.4(282.2)**
^mol/mol creatinine 
median (interquartile
127.2 186.0 319.1 15323.1(793.7,
range) (45.4,266.9) (137.4, 476.5) (39.5,731.5) 2254.5)**
Daidzein ng/ml 411.5(410.6) 228.5(187.5) 216.6(147.0) 3582.5(2107)**
MQ/day 740.7(1032.8) 384.8(280.8) 416.9(453.5) 6362.6(5273)**
ng/|imol creatinine 64.6(79.2) 40.3(37.2) 34.9(25.2) 607.3(455.6)**
|imol/mol creatinine 
median (interquartile
147.8 (48.0, 102.5 (63.7, 94.0 (66.9, 1785.7 (925.1,
range) 308.7) 194.2) 231.4) 3416.1)**
Equol ng/ml 94.9(108.9) 68.0(52.4) 162.2(404.6) 911.9(1133.2)
ixg/day 118.4(134.1) 121.1(110.4) 167.5(286.4) 1363.4(1726)*
ng/j^mol creatinine 9.22(8.8) 12.5(13.0) 16.27(28.9) 132.7(131.3)*
pmol/mol creatinine 
median (interquartile 
range)
20.8(13.3, 56.9) 49.9 (17.8, 57.5) 32.2 (2.6, 82.8) 443.3
(152.2, 760.9)*
Enterolactoneng/ml 336.8(888.5) 198.1(274.5) 203.0(185.7) 188.3(377.8)
l^g/day 542.0(1286) 332.8(474.9) 337.7(312.3) 289.0(597.7)
ng/^mol creatinine 65.1(180.7) 39.7(76.8) 32.3(30.4) 28.4(60.1)
^mol/mol creatinine 
median (interquartile
32.7 (14.4, 66.0 (31.4, 85.8 (24.1, 34.9(15.9, 86.5)
range) 131.9) 110.7) 168.9)
Enterodiol ng/ml 26.9(30.9) 18.4(18.3) 40.9(62.0) 18.1(18.6)
i^g/day 36.7(50.4) 29.6(32.5) 74.6(137.3) 28.0(26.8)
ng/|imol creatinine 3.49(5.7) 3.14(3.54) 6.45(10.8) 2.72(2.33)
|nmol/mol creatinine 
median (interquartile 
range)
5.8 (4.04, 8.87) 3.6(1.66, 22.9) 6.17(3.14, 19.4) 5.31 (4.25, 12.0)
Mean (SD) *p<0.05, **p<0.01 when baseline is compared with post
placebo/supplement (paired t test)
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Table 5.3.1.2. Effect of supplementation on urinary excretion of isoflavone
Placebo Supplement
Baseline Day 28 Baseline Day 28
Genistein ng/ml 258.6(174.6) 659.2(388.5)* 749.9(374.7) 3959.5(2194)**
ng/day 581.0(376.4) 1362.8(886.3)* 1361.3(579.3) 8696.8(5096)**
ng/|imol creatinine 66.2(56.8) 141.0(89.4)* 131.0(76.8) 1455.5(1610)
pmol/mol creatinine 
median (Interquartile
155.3 (104.0, 617.0(141.8, 411.0 (336.9, 3538.2(1461.1,6
range) 333.8) 785.9)* 517.9) 756.3)*
Daidzein ng/ml 343.7(196.6) 353.4(255.8) 525.5(345.4) 4964.0(3733)*
pg/day 765.4(396.8) 758.5(660.3) 1013.6(801.8) 11083(9432)*
ng/^mol creatinine 85.8(58.7) 77.8(64.6) 102.1(88.4) 1335.6(783.2)**
jimol/mol creatinine 
median (interquartile
259.4(187.4. 195.0(122.2, 301.9(100.5, 5717.0(2464.9,5
range) 496.6) 562.3) 794.2) 932.5)*
Equol ng/ml 63.0(26.7) 78.4(56.4) 86.5(39.4) 705.0(344)*
ng/day 141.6(69.6) 172.5(143.6) 163.2(72.5) 1536.9(823)*
ng/|imol creatinine 13.7(5.47) 17.7(14.2) 12.9(3.08) 256.9(267)
^mol/mol creatinine 
median (interquartile
67.2 (34.5, 58.0 (25.5, 50.5 (45.3, 704.8 (282.3,
range) 73.5) 127.9) 63.2) 2019.6)
Enterolactoneng/ml 166.7(161.3) 142.9(74.8) 169.7(154.2) 167.0(166.5)
ng/day 364.9(334.2) 269.2(128.4) 353.3(361.5) 396.9(410.5)
ng/pmol creatinine 38.14(32.7) 27.9(13.3) 32.8(38.5) 73.7(94.0)
|imol/mol creatinine 
median (interquartile
82.2(38.2, 108.8(74.9, 59.5(17.2, 119.0(21.7,
range) 187.9) 120.6) 216.5) 560.5)
Enterodiol ng/ml 9.95(9.08) 10.0(12.7) 8.94(5.94) 9.19(6.82)
ng/day 22.12(20.9) 22.64(31.2) 17.2(13.8) 20.2(15.4)
ng/|umol creatinine 2.51(2.54) 2.32(3.11) 1.65(1.47) 2.85(2.21)
nmol/mol creatinine 
median (interquartile 
range)
7.65(2.56,
9.01)
4.0(22, 11.8) 3.90(2.7, 6.25) 6.85(3.05, 18.3)
Mean (SD) *p<0.05, **p<0.01 when baseline is compared with pos
placebo/supplement (paired t test)
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Figure 5.3.1.1 Effect of supplementation on urinary excretion of isoflavone 
metabolites in pre-menopausal subjects.
Mean ± SE; *p<0.05, **p<0.01 when baseline is compared with post­
supplement (paired t test)
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Figure 5.3.1.2. Effect of supplement on urinary excretion of isoflavone 
metabolites in post-menopausal subjects.
Mean ± SE *p<0.05, **p<0.01 when baseline is compared with post­
supplement. (paired t test)
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Table 5.3.1.3. Comparison of Isoflavone excretion with other studies
Author Baseline Post­
supplement
Fold
increase
Albertazzi 
(60g soy powder, 
3 months)
Genistein ng/ml 114 2818 25
Daidzein ng/ml 224 2956 13
Equol ng/ml 42 989 23
Campbell
{80mg
1 Sofiavones, 28 
days)
Genistein nmol/d 1478 20561 14
Daidzein nmol/d 2543 26044 10
Equol nmol/d 651 5268 8
Karr
(23mg Gen,
13mg Daid in soy 
protein, 9 days)
Genistein nmol/d 225 5139 23
Daidzein nmol/d 561 9303 17
Equol nmol/d 449 5900 13
Petrakis
{38mg Genistein 
in soy protein, 5 
months)
Genistein ug/d 197 3121 16
Daidzein pg/d 114 6007 53
Rowland
(35mg Gen,
21 mg Daid in soy 
protein, 17days)
Genistein nmol/d 384 10326 27
Daidzein nmol/d 1060 17969 17
Equol nmol/d 43 3995 93
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Table 5.3.1.4: Comparison of serum lipids, tocopherols and IGF-1, BP-3 and
Nutrients Non-excreters
(n=15)
Excreters (n=4) P
MDA placebo 1.85 4.13 0.000
baseline (0.57) (1.77)
Triglycerides 0.665 2.23 0.014
placebo baseline (0.535) (2.13)
y-tocopherol 4.00 5.72 0.009
placebo baseline (0.43) (2.30)
a-tocopherol 21.60 31.44 0.024
placebo baseline (4.99) (12.80)
IGF-1 Placebo 
(day 1- day 28)
-27.87 (37.93) 7.32 (19.5) 0.095
IGF-1 Supplement 
(day 1 -  day 28)
-2.95 (49.47) 4.47(45.51) 0.790
IGFBP-3 Placebo 
(day 1- day28)
-228.4(344) -418.6(225.8) 0.315
BP-3 Supplement 
(day 1-day 28)
-111.0 (334.2) -408.2 (257.6) 0.120
IGFBP-1 Placebo 
(day 1-day 28)
-14.21(30.4) -5.53 (25.3) 0.609
BP-1 Supplement 
(day 1-day 28)
-5.64(26.77) -9.59 (31.02) 0.802
Mean (SD) Independent samples t test
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5.3.2 Hormones
Oestradiol, progesterone, LH, FSH and SHBG ail followed normal menstrual 
cycle patterns in pre-menopausal subjects on placebo (Figures 5.3.2.1- 
5.3.2.S), and levels were not significantly different on the isoflavone supplement 
(Table 5.3.2.1) when compared using repeated measures ANOVA. Similarly, 
there was no significant difference seen between placebo and supplement 
hormone levels measured in post-menopausal subjects (Table 5.3.2.2).
However when hormone concentrations where compared using a paried t test 
there was a significant increase in SHBG concentrations on day 21-23 in 
supplement phase vs placebo of pre-menopausal subjects (P=0.003).
When hormone levels were compared between groups, pre-menopausal 
women had higher levels of oestradiol (P=0.019) and Progesterone (P=0.016) 
and post-menopausal women had significantly higher levels of LH (P= 0.000) 
and FSH (P= 0.001). No significant difference was seen with SHBG levels in 
these groups (Table 5.3.2 3.).
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Figure 5.3.2.1: Effect of supplementation on LH levels in pre-menopausal 
women. Mean (SE)
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Figure 5.3.2.2: Effect of supplementation on FSH levels in pre-menopausal 
women. Mean (SE)
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Figure 5.3.2.3: Effect of supplementation on Oestradiol levels in pre­
menopausal women. Mean (SB)
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Figure 5.3.2.4: Effect of supplementation on Progesterone levels in pre­
menopausal women. Mean (SE)
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Figure 5.3.2.5: Effect of supplementation on SHBG levels in pre-menopausal 
women. Mean (SE). *P=0.003 paried t test supplement vs placebo (Day 21-23).
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Table 5.3.2.1: Effect of isoflavone supplementation on circulating hormone
levels in pre-menopausal women. Mean ± (SD).
Baseline Day 6-8 Day 12- 
14
Day 21 - 
23
Day 26- 
28
LH (U/L) Placebo 2.5 (1.0) 2.7 (1.6) 6.6 (4.6) 3.1 (3.0) 2.2 (1.9)
Supplement 2.5 (1.4) 2.5 (0.8) 9.1 (8.8) 2.5 (2.3) 1.6 (1.0)
FSH (U/L) Placebo 6.5 (2.6) 6.9 (1.8) 6.6 (1.9) 4.8 (2.2) 4.8 (3.2)
Supplement 7.0 (2.5) 7.4 (2.4) 8.2 (3.2) 4.4 (1.7) 4.5 (2.6)
Oestradiol
(pmol/L)
Placebo 170.7
(167.4)
271.4
(345.2)
801.7
(967.3)
463.9
(334.9)
217.1
(165.7)
Supplement 105.5
(60.8)
396.5
(669.6)
711.9
(487.4)
425.1
(308.6)
269.1
(183.0)
Progestero 
ne (nmol/L)
Placebo 3.2 (3.1) 1.0 (0.8) 4.3 (8.6) 17.1
(11.5)
11.6
(13.4)
Supplement 2.3 (2.1) 1.3 (0.9) 1.9 (1.3) 22.5
(13.3)
11.0 (6.7)
SHBG
(nmol/L)
Placebo 52.5
(28.2)
52.5 
X31J) _
49.1
i23-7)
47.9
_(28.9)
53.3
(31.7)
Supplement 56.9
(35.3)
50.3
(30.1)
51.0
(28.3)
57.4*
(36.6)
57.9
(33.0)
'P=0.003 paried t test supplement vs placebo (SH BG Day 21-23).
Table 5.3 2.2: Effect of isoflavone supplementation on circulating hormone 
levels in post-menopausal women. Mean ± (SD).
Baseline Day 28
LH (U/L) Placebo 17.3 (4.0) 18.5 (6.5)
Supplement 16.3(4.3) 17.7 (6.0)
FSH (U/L) Placebo 90.9 (39.3) 106.7(58.6)
Supplement 86.7 (32.8) 97.6 (48.5)
Oestradiol (pmol/L) Placebo 49.1 (43.4) 40.1 (13.4)
Supplement 42.1 (17.6) 47.6 (25.5)
Progesterone (nmol/L) Placebo 1.05 (0.41) 1.09 (0.62)
Supplement 0.91 (0.73) 0.99 (0.47)
SHBG (nmol/L) Placebo 62.8 (35.9) 61.8 (28.4)
Supplement 61.9 (24.5) 63.0 (24.0)
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Table 5.3.2.3: Comparison of IGFs and hormone levels measured by 
menopausal status.
Premenopaus 
al (n=16) 
Mean (SD)
Postmenopaus 
al (n=7) 
Mean (SD)
Mean
Difference
(95%CI)
Sig. (2-tailed)
Age (y) 33.9(8.5) 57.4 (5.7) -23.49 
( -29.87, - 
17.11)
0.000
IGF-1
(ng/ml)
169.6 (51.4) 125.9 (43.5) 43.68
(-1.24,88.6)
0.056
IGFBP-1
(ng/ml)
53.4 (39.9) 47.9(16.6) 5.51
(-19.0, 30.0)
NS
IGFBP-3
(ng/ml)
3116(395) 2874 (418) 241.7
(-168.6,
652.0)
NS
Oestradiol
(pmol/l)
170.7(167.4) 49.1 (43.4) 113.5
(20.7, 206.4)
0.019
Progestero 
ne (nmol/l)
3.16 (3.10) 1.05 (0.41) 2.07
(0.45, 3.70)
0.016
LH (U/l) 2.5 (1.0) 17.3(4.0) -14.5
(-18.2,-10.8)
0.000
FSH (U/l) 6.5 (2.6) 90.9 (39.3) -84.1
(-120.5,-
47.7)
0.001
SHBG
(nmol/l)
52.5(28.2) 62.8 (35.9) -11.0 (-45.2, 
23.3)
NS
Data taken from placebo baseline levels. Comparisons done with 
test and equal variances not assumed.
two sample t
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5.3.3 Insulin-like Growth Factors
Baseline concentrations of IGF-1, BP1 and BPS fell within the expected ranges 
given by the manufacturers of the ELISA kits used (Diagnostic Systems 
Laboratories).
No significant difference was seen in IGF levels between pre and post - 
menopausal women, however there were slightly higher levels of IGF-1 in pre­
menopausal women at baseline (P=0.056) (Table 5.3.2.3)
For pre-menopausal subjects, while there was an effect of time on IGF-1 
(p=0.005), 1GF-BP1 (p=0.004), and IGF-BP3 (p<0.001) confirming that IGF 
profile is influenced by menstrual cycle, this did not differ between placebo and 
isoflavone supplement (Table 5.3.3.1) (Figures 5.3.3.1-5.3.3.3).
When the change in IGF-1 over the whole supplementation period was 
compared between the supplement and placebo phases, there was a non­
significant reduction in change in IGF-1 (p=0.06) on isoflavone supplement 
compared to placebo. However, this may be due to the non-significantly higher 
baseline concentrations of IGF-1 during the supplement phase.
In post-menopausal subjects, there was no effect of isoflavone supplementation 
in comparison with placebo on IGF-1, IGFBP-1 or IGFBP-3 (Table 5 3.3.2).
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Table 5.3.3.1: Effect of supplementation on insulin-like growth factor and binding protein concentrations in pre-menopausal women
Baseline
(Day 1-3)
Day 6-8 Day 12-15 Day 21-23 Day 26-28
IGF-1
(ng/ml)
Placebo
Supplement
169.6 (51.4)
193.7 (71.1)
170.3 (55.5)
175.3 (55.0)
159.7 (64.4) 
177.5 (57.1)
192.1 (50.2)^"
204.2 (46.0)'=*
194.5(49.5)3 
197.4 (52.1)
IGFBP-1
(ng/ml)
Placebo
Supplement
53.4 (39.9) 
59.1 (44.1)
49.9 (38.2) 
54.5 (36.1)
43.3 (28.8) 
63.5 (57.5)
46.6 (32.8) 
54.5 (48.3)
64.4 (50.0) 
72.9 (52.5)
IGFBP-3
(ng/ml)
Placebo
Supplement
3116(395) 
3275 (629)
3195 (425) 
3254 (478)
3237 (404) 
3305 (417)
3319 (446)3 
3343 (446)
3411 (419)3" 
3497 (484)"
Data presented as mean (SD). Repeated measures ANOVA revealed significant changes over the menstrual cycle during placebo 
phase in IGF-1 (p=0.005), IGF-BP1 (p=0.004) and IGF-BP3 (p<0.001) but no significant differences between treatment regimen in these 
changes (IGF-1 p=0.44; IGF-BP1 p=0.48; 1GF-BP3 p=0.81).
^(paired t test significantly different from placebo baseline)
(paired t test significantly different from supplement baseline)
(paired t test significantly different from follicular phase Day 6-8)
*(p<0.01)
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Table 5.3.3.2: Effect of supplementation on insulin-like growth factor and binding protein concentrations in post-menopausal women
Baseline 
Mean (SD)
28 d
Mean (SD)
Mean change from 
baseline (SD)
Difference in mean change 
from baseline (95% Cl)
P value
IGF-1
(ng/ml)
Placebo
Supplement
125.9(43.5) 
130.2 (34.9)
137.3 (40.5) 
141.1 (40.3)
11.37 (27.17) 
10.89 (28.93)
0.49 (-36.93, 37.90) 0.98
IGFBP-
1
(ng/ml)
Placebo
Supplement
47.9(16.6) 
44.3 (9.0)
48.7(18.0) 
54.7 (10.7)'
0.76 (22.60) 
10.37 (8.92)
-9.61 (-33.68, 14.46) 0.37
IGFBP-
3
(ng/ml)
Placebo
Supplement
2874 (418) 
2878 (467)
3005 (390) 
2971 (516)
92.7 (223.3) 
130.4 (225.6)
-37.7 (-263.8, 188.3) 0.70
n change 
ement), ar
From baseline calculated as (28 
id compared using a paired t-te
days- baseline). Difference in mean change from baseline calculated as (placebo-
3St.
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Figure 5.3.3.1: IGF-1 levels in pre-menopausal women on placebo or 
supplement. Mean (SE)
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Figure 5.3.3.2: IGFBP-3 levels in pre-menopausal women on placebo or supplement. 
Mean(SE)
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Figure 5.3.3.3: IGFBP-1 levels in pre-menopausal women on placebo or 
supplement. Mean (SE)
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5.3.4 Lipids and antioxidants
Total cholesterol and triacylglycerol were not affected by the supplement in 
either pre- or post-menopausal women. However, HDL-cholesterol 
concentrations were significantly elevated by isoflavone supplementation in the 
post-menopausal subjects. (Figure 5.3.4.1). There were no significant 
differences in any of the antioxidant endpoints assessed in either pre- or post­
menopausal women when compared using paired t test (Table 5.3.4.1) and 
(Table 5.3.4.2).
1.9
1.8
1.7 p<o;o5
1.6
1.5
— ♦ —  Pre-menopausal 
- - •  - - Post-menopausal
1.4
1.3
baseline post-supplement
Figure 5.3.4.1;HDL-cholesterol (mmol/L) in pre and post menopausal women 
after supplementation. Mean(SE).
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Baseline 
Mean (SD)
28 d
Mean (SD)
Mean change from 
baseline (SD)
Difference in mean change 
from baseline (95% Cl)
P value
Vitamin C 
(|imol/l)
Placebo
Supplement
93.6(47.1) 
69.3 (30.0)
68.7(34.1) 
70.4 (41.7)
-24.96 (54.24) 
1.05 (31.90)
-26.01 (-61.43, 9.40) 0.14
MDA
(^mol/l)
Placebo
Supplement
2.30 (1.08) 
2.22 (0.98)
2.26 (0.69) 
2.32 (0.74)
-0.04(1.03) 
0.10 (0.85)
"^.14 (-0.67, 0.39) 0.59
Total cholesterol 
(mmol/l)
Placebo
Supplement
4.65 (1.10) 
4.75 (0.72)
4.56 (0.76) 
4.75 (0.93)
-0.09 (0.57) 
0.001 (0.47)
-0.09 (-0.58, 0.41) 0.71
HDL-cholesterol
(mmol/l)
Placebo
Supplement
1.63 (0.58) 
1.57 (0.52)
1.61 (0.41) 
1.66 (0.46)
-0.03 (0.26) 
0.10 (0.18)
-0.12 (-0.28, 0.04) 0.13
Triacylglycerol
(mmol/l)
Placebo
Supplement
0.73 (0.93) 
0.72 (0.49)
0.63 (0.31) 
0.62 (0.30)
-0.10(0.69) 
-0.11 (0.30)
0.01 (-0.34, 0.36) 0.96
LDL- cholesterol 
(mmol/l)
Placebo
Supplement
2.68 (0.89) 
2.86 (0.69)
2.67 (0.67) 
2.81 (0.92)
-0.02 (0.41) 
-0.05 (0.44)
0.03 (-0.38, 0.44) 0.87
a-tocopherol
(pmol/l)
Placebo
Supplement
21.0 (7.0) 
18.4 (3.3)
18.9(4.1) 
19.2 (3.2)
-2.06 (8.44) 
0.72 (4.35)
-2.78 (-8.05, 2.49) 0.28
y-tocopherol
(pmol/l)
Placebo
Supplement
4.4 (1.4) 
4.2 (1.1)
3.8 (0.8)
3.9 (0.6)
-0.56(1.79) 
-0.25 (0.74)
-0.32 (-1.42,0.79) 0.55
Retinol
(pmol/l)
Placebo
Supplement
2.4 (0.7) 
2.2 (0.7)
2.1 (0.6) 
2.3 (0.5)
-0.31 (0.74) 
0.16(0.60)
-0.46 (-1.06, 0.13) 0.12
lutein Placebo 0.32 (0.15) 0.28 (0.12) -0.04 (0.14) -0.05 (-0.17, 0.07) 0.38
(pmol/l) Supplement 0.28 (0.12) 0.29 (0.12) 0.01 (0.11) ' ■
zeaxanthin
(pmol/l)
Placebo
Supplement
0.089 (0.046) 
0.076 (0.036)
0.082 (0.035) 
0.078 (0.029)
-0.007 (0.041) 
0.002 (0.036)
-0.087 (-0.044, 0.027) 0.61
p-cryptoxanthin
(pmol/l)
Placebo
Supplement
0.22 (0.11) 
0.22 (0.15)
0.20 (0.13) 
0.23 (0.14)
-0.02 (0.10) 
0.01 (0.15)
-0.03 (-0.15,0.09) 0.62
a-carotene
(pmol/l)
Placebo
Supplement
0.083 (0.062) 
0.070 (0.049)
0.074 (0.070) 
0.083 (0.063)
-0.012(0.043) 
0.009 (0.058)
-0.022 (-0.070, 0.027) 0.36
p-carotene
(pmol/l)
Placebo
Supplement
0.82 (0.60) 
0.60 (0.60)
0.64 (0.44) 
0.79 (0.61)
-0.18(0.45)
0.15(0.60)
-0.32 (-0.85, 0.21) 0.22
lycopene
(pmol/l)
Placebo
Supplement
0.43 (0.40) 
0.39 (0.32)
0.36 (0.39) 
0.49 (0.44)
-0.06 (0.55) 
0.11 (0.46)
-0.17 (-0.67,0.33) 0.48
Mean change from baseline calculated as (28 d -  baseline). Difference in mean change from baseline calculated as (placebo
-  supplement), and compared using a paired t-test.
Table 5.3.4.2: Elffect of isoflavone supplementtation on antioxidant and lipid status in post-menopausal subiects
Baseline 
Mean (SD)
28 d
Mean (SD)
Mean change from 
baseline (SD)
Difference in mean change 
from baseline (95% Cl)
P value
Vitamin C 
(|imol/l)
Placebo
Supplement
37,9 (8.9) 
46.8 (16.2)
34.9 (14.3) 
33.9(18.0)
1.13(16.41)
-11.17(16.77)
12.30 (-12.18,36.78) 0.25
MDA
(jamol/l)
Placebo
Supplement
2.47 (1.90) 
2.35 (0.51)
1.98 (0.99)
1.96 (0.47)^
-0.49(1.55) 
-0.39 (0.28)
-0.10 (-1.64, 1.43) 0.87
Total cholesterol 
(mmol/l)
Placebo
Supplement
6.12(0.96) 
5.57 (1.03)
6.04(1.10) 
6.01 (1.14)
-0.08 (0.51) 
0.44(1.04)
-0.52 (-1.38, 0.34) 0.19
HDL-cholesterol
(mmol/l)
Placebo
Supplement
1.58 (0.62) 
1.54 (0.60)
1.54(0.61) 
1.72 (0.64)2
-0.04(0.10)
0.18(0.22)
-0.22 (-0.40, -0.04) 0.02
Triacylglycerol
(mmol/l)
Placebo
Supplement
1.42(1.35)
1.15(0.95)
1.33(1.28)
1.18(0.87)
-0.09 (0.17) 
0.03 (0.39)
-0.12 (-0.58, 0.35) 0.56
LDL- cholesterol 
(mmol/l)
Placebo
Supplement
3.90(1.08)
3.52(1.12)
3.90(1.20)
3.76(1.04)
-0.00 (0.42) 
0.25 (0.94)
-0.25 (-1.05, 0.55) 0.48
a-tocopherol
(pmol/l)
Placebo
Supplement
28.0 (6.1) 
27.7 (5.0)
27.4 (5.2) 
26.8 (4.8)
-0.57 (3.48) 
-0.94 (3.95)
0.37 (-0.48, 1.21) 0.33
y-tocopherol
(pmol/l)
Placebo
Supplement
4.39 (0.60) 
4.36 (0.45)
4.18(0.54)
4.18(0.41)
-0.21 (0.31) 
0.25 (0.095)
-0.03 (-0.19, 0.13) 0.69
Retinol
(pmol/l)
Placebo
Supplement
2.89 (0.50) 
2.79 (0.48)
2.74 (0.33) 
2.83 (0.48)
-0.15(0.45) 
0.04 (0.31)
-0.20 (-0.66, 0.26) 0.33
lutein Placebo 0.27 (0.09) 0.26 (0.08) -0.01(0.07) -0.043 (-0.14, 0.06) 0.34
(pmol/l) Supplement 0.29 (0.10) 0.32 (0.18) 0.03 (0.145)
zeaxanthin
(pmol/l)
Placebo
Supplement
0.08 (0.030) 
.069 (0.033)
0.06 (0.016) 
0.05 (0.02)
-0.01 (0.02) 
-0.02 (0.02)
0.01 (-0.00, 0.02) 0.20
p-cryptoxanthin
(pmol/l)
Placebo
Supplement
0.40 (0.29) 
0.29 (0.12)
0.40 (0.25) 
0.32 (0.15)
0.01 (0.08) 
0.03 (0.06)
-0.02 (-0.10, 0.05) 0.49
a-carotene
(pmol/l)
Placebo
Supplement
0.10(0.06) 
0.09 (0.07)
0.12(0.08)
0.10(0.07)
0.02 (0.02) 
0.01 (0.02)
0.01 (-0.02, 0.04) 0.42
p-carotene
(pmol/l)
Placebo
Supplement
0.88 (0.56) 
0.88 (0.55)
1.03 (0.71) 
1.01 (0.67)
0.16(0.19)
0.13(0.17)
0.029 (-0.15. 0.21) 0.71
lycopene
(pmol/l)
Placebo
Supplement
0.39 (0.31) 
0.31 (0.27)
0.39 (0.26) 
0.34 (0.23)
0.00 (0.10) 
0.03 (0.10)
-0.03 (-0.11,0.06) 0.48
Mean change from baseline calculated as (28 d -  baseline). Difference in mean change from baseline calculated as (placebo
-  supplement), and compared using a paired t-test.
5.3.5 Nutrients
When nutrient intake was assessed by food frequency questionnaire (FFQ) or 
7-day food diary (FD), there was no significant difference in energy, 
carbohydrate, fat, protein (in grams), SFA, PUFA, MUFA, cholesterol, fibre 
(Southgate method), vitamin E or carotene intake between placebo or 
supplement phase, whether assessed by FFQ or food diary in pre- or post­
menopausal subjects (Table 5.3.5.1). For protein (in g) and vitamin C intake 
there was no significant difference between phases when assessed by FFQ. 
However, there was a decrease in the percentage of daily calories derived from 
protein in questionnaires from the supplement phase compared with the 
placebo phase in pre-menopausal subjects (15.0 (2.0) vs. 13.8 (1.7) placebo 
versus supplement, mean (SD) p<0.05), while vitamin C intake was lower 
during the supplement phase than the placebo phase in post-menopausal 
women when assessed by FD, (105 (41) vs. 74 (30) mg; placebo versus 
supplement, mean (SD) p<0.05). When compared with findings from the 
National Diet and Nutrition Survey 2000-1, percentage contribution of 
macronutrients to energy intake were similar to those of the national average for 
women (%total carbohydrate 48.5, %protein 16.6, %total fat 34.9)(Swan, 2004). 
Although the food diaries and FFQs showed good levels of association between 
assessed nutrient intake, lower levels were seen in FFQ for some 
micronutrients and estimated intakes of starch, energy and carbohydrate in pre­
menopausal women which would suggest a tendency for under reporting. 
However, the FFQs appeared to give a good indication of long-term dietary 
habits as caloric intake was positively correlated with height (supplement, 
r=0.48, P=0.029), cholesterol intake with hip, weight measurements and BMI 
(supplement r=0.48, P=0.032) (supplement r=0.51, P=0.018) (supplement.
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r=0.456, P=0.038), MUFA with hip measurements (supplement, r=0.0454, 
P=0.045) and percentage of fat negatively correlated with waist/hip ratio 
(placebo, r=-0.52, P=0.0189) (supplement, r=-0.456, P= 0.043). Intake of fibre 
as estimated by the Englyst method was correlated with w/hip ratio (r=0.45, 
P=0.047) showing that the greater the fibre intake the smaller the hips. Intake of 
protein correlated with waist and hip measurements in both phases; waist 
(placebo r=0.460, P=0.041), hip (placebo r=0.489, P=0.029), waist (supplement 
r=0.477, P=0.034), hip (supplement r=0.453, P=0.045).
With FDs only height correlated with caloric intake (r=0.551, P= 0.014) 
cholesterol (r=0.518, P= 0.023), fat (r=0.526, P=0.021) MUFA (r=0.539, 
P=0.017) and starch (r=0.570, P=0.011) on the supplement phase.
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Table 5.3.5.1: Dietary intake, on placebo and supplement in pre and post­
menopausal women. Mean (SD)
Nutrients
Unit / 
day
Pre-menopausal Postmenopausal
FFQ 7-FD FFQ 7-FD
Water
gm Placebo 2266 (848) 1907 (469)" 2692 (657) 2093 (600)
Supp 3240 (3361) 1729 (567) 2601 (1090) 2186 (641)
Protein
gm Placebo 67(17) 77(19) 76 (20) 70 (21)
Supp 66 (13) 69 (19) 74(18) 67 (22)
Fat
gm Placebo 74 (23) 96 (28) 83(17) 78 (23)
Supp 83 (21) 83 (22) 84 (23) 76 (33)
Carbohydrate
gm Placebo 204(61) 244 (57)" 264 (61) 239 (61)
Supp 211(64) 218(50) 264 (69) 233 (61)
Energy (kcal)
Cal Placebo 1791 (458) 2209 (485)" 2105 (417) 1940 (479)
Supp 2855 (3512) 1929 (431)"' 2086 (372) 1898 (603)
Energy (kj)
kJ
Placebo 7514(1923)
9268
(2025)d 8835(1758) 8173 (2018)
Supp
11970
(14737)
8098 (1796)
c* 8758(1560) 8005 (2537)
Total Nitrogen
gm Placebo 11 (3) 13(3) 1213) 11 (3)
Supp 17(23) 11 (3)"‘ 12(3) 11 (4)
Saturated fatty 
acids
gm Placebo 25 (9) 34(12) 30 (7) 29(10)
Supp 28 (8) 32(12) 29 (9) 27(14)
Mono­
unsaturated 
fatty acids
gm Placebo 26 (8) 32 (8) 30 (7) 25 (7)
Supp 28 (7) 28 (8) 29 (9) 25(12)
Poly­
unsaturated 
fatty acids
gm
Placebo 15(5) 18(6) 16(6) 15(4)
Supp 17(9) 15(5) 18(7) 14(5)
Cholesterol
mgm Placebo 198 (59) 279(105) 200 (64) 221 (87)
Supp 206 (38) 271 (122) 200 (42) 197 (106)
Starch
gm Placebo 97 (31) 135 (28)"^ 123 (40) 124 (37)
Supp 98 (28) 125 (29)" 124 (36) 121 (45)
Total Sugars
gm Placebo 103 (52) 103 (37) 139 (34) 112(42)
Supp 109 (43) 90 (46)" 139 (56) 107 (30)
Dietary fibre,
Southgate
method
gm Placebo 21 (7) 19(4) 29 (8) 21 (5)
Supp 21 (7) 17(4) 30 (9) 20 (7)
Dietary fibre,
Englyst
method
gm Placebo 16(6) 14(3) 24 (7) 16(4)"
Supp 16(5) 12 (3)b 24 (9) 15(6)
Sodium (Na)
mgm Placebo 2166 (722) 3225 (637)" 2450 (596) 2821 (742)
Supp 2261 (611) 2821 (840)" 2672 (541) 2732 (976)
Potassium (K)
mgm Placebo 3340(1369) 3117(543) 4045 (879) 3100 (609)
Supp 4660 (5481) 2748 (501)" 3899 (1080) 3081 (895)
Calcium (Ca)
mgm Placebo 816(288) 992 (322) 945 (275) 912(344)
Supp 929 (255f 861 (300) 896 (328) 874 (358)
Magnesium
(Mg)
mgm Placebo 286 (101) 297 (53) 371 (98) 294 (64)
Supp 278 (66) 255 (48)" 362(125) 284 (87)
Phosphorus
(P)
rngm Placebo 1168 (294) 1391 (291) 1377 (276) 1278 (341)
Supp 1203 (224) 1186 (288)" 1404 (376) 1241 (445)
Iron (Fe)
mgm Placebo 10(3) 13(3)"' 12(3) 12(3)
Supp 10(2) 11 (3)" 12(3) 13(4)
Copper (Cu)
mgm Placebo 1 (0.4) 1 (0.3)" 1 (0.3) 1 (0.3)
Supp 2(2) 1 (0.3) 1 (0.5) 1 (0.4)
Zinc (Zn)
mgm Placebo 7(2) 9(2)” 9 (2 ) . 8 (2 )
Supp 10(12) 8 (2 )” 9(2) 8 (3 )
Chloride (Cl)
mgm
Placebo 3449(1117)
4917
(1084^ 3946 (943) 4371 (1116)
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Supp
5608
(8026)
4409
(1375)"* 4191 (826) 4181 (1455)
Manganese
(Mn)
mgm Placebo 3(1) 6(1 ) 4(1 )
Supp 5(4) 3(1) 6(2) 4 (1 )
Selenium (Se)
ugm Placebo 45 (21) 54(15) 63 (21) 58(18)
Supp 66 (98) 50(15) 68(18) 58 (31)
Iodine (1)
ugm Placebo 100 (40) 110(39) 96 (21) 111 (62)
Supp 154(174) 96 (31) 96 (24) 128 (66)
Retinol
ugm Placebo 334(213) 668 (731)" 531 (245) 562 (347)
Supp 389(182) 444 (248) 540 (216) 459 (287)"
Carotene
ugm
Placebo 4038 (2282) 2520 (835)"d 3924 (1494)
2157
(1037)'
Supp 4314 (2429)
2749
(1212)d 3586 (1007) 2150(1746)
Vitamin D
ugm Placebo 2(1) 2(2 ) 2 (1 ) 3 i1 )
Supp 3(4) 2(1) 3 (1 ) 3 (1 )
Vitamin E
mgm Placebo 9(3) 9(3) 11 (6) 9 (3 )
Supp 12(10) 7(2) 12(6) 9(2 )
Thiamin
mgm Placebo 1 (0.4) 2 (3 ) . 2 (0.5) 2 (0.4)
Supp 1 (0.3) 1 (0.4) 2 (1 ) 3 (3 )
Riboflavin
mgm Placebo 2(0.5) 2 (1 ) 2 (1 ) 2 (1 )
Supp 2 (0.4) 2 (0.4)" 2(1 ) 2 (1 )
Niacin
mgm Placebo 21 (6) 19J4) 25 (7) 20 (5)
Supp 19 (5 f 16 (5)"" d 27(11) 18(6)
Tryptophan 
divided by 60
mgm Placebo 14(4) 16(4) 15(4) 15(4)
Supp 14(3) 15(4) 14(4) 14(5)
Vitamin B6
mgm Placebo 2(1) 2(0.5) 2 (1 ) .. 2 (1 )
Supp 2 (0.4) 2 (0.4)' 2(0.4) 2 (1 )
Vitamin B12
ugm Placebo 2(1) 3(1)" 2 (1 ) 3 (2 )
Supp 2(1) 3(1)" 2 (1 ) 4 (4 )
Folate
ugm Placebo 354 (129) 268 (84)' 393(123) 266 (83)
Supp 332 (73) 230 (68)" 408(154) 276(111)
Pantothenate
mgm Placebo 4(1 ) 4(1 ) 6(1 ) 4.4 (1.1)
Supp 4 (1) 4 (1 ) 6(1 ) 3.9(1.4)^
Biotin
ugm Placebo 35(11) 35 (9)" 46(15) 37(11)
Supp 35 (7) 31(9) 46 (19) 32(8)
Vitamin C
mgm Placebo 192 (123) 94 (36)" ' 231 (85) 105 (41)'"
Supp 168 (69) 93 (53)' 232 (99) 74 (30)""'
% Calories from
Protein
Placebo 15(2.0) 14(2) 14(2) 14 (2)"
Supp 13.8(1.7)" 14(2) 14(3) 14(2)
Carbohydrate
Placebo 43(6) 42 (7)" 47 (5) 47 (8)
Supp __41 (6) 43 (6) __ 47 (8) 47 (5)"
Fat
Placebo 37 (6) 39(5) 36 (4) 36(4)
Supp 3(4) 38(5) 36 (7) 35 (5)"'
Alcohol
Placebo 5(6) 5(5)" 3(3 ) 3(4)"
Supp 7(8) 5(4)" 2 (2 ) 4 (4)"'
a : mean values of FFQ on supplement significantly different from FFQ on placebo (P<0.05 
paired t test)
b : mean values of FD on supplement significantly different from FDs on placebo (P<0.05 
paired t test)
c : mean values of FFQ significantly correlated with FD on placebo and supplement.
(P<0.05 Pearsons correlation) 
d: mean values of FFQ significantly different from FD (P<0.05 paired t test)
*: P<0.01
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5.3.6 Associations between continuous variables
This study was a randomised, placebo-controlled intervention study, designed 
to determine the effect of isoflavone supplementation on a number of endpoints. 
A comparison of changes in the endpoints of interest between intervention and 
control groups therefore represents the main analysis of this study. However, 
secondary analysis, which due to the small numbers, multiple comparisons, and 
study design must be considered only as hypothesis-generating, has been 
carried out to assess cross-sectional associations between variables. These 
are presented as Tables in Appendix, and results that are consistent across 
more than one timepoint or method of assessment are presented here.
5.3.6.1 Associations with Isoflavone status
When Isoflavone excretion in pg/day was compared with serum lipid/antioxidant 
levels, dietary intake and anthropometric measurements (Tables 5.A.1 -  5.A.8), 
the following associations were found:
Baseline levels of equol excretion correlated positively with energy intake at 
baseline, assessed by both FFQ (p=0.019) and FD (p=0.022). This may have 
largely been due to alcohol intake, as there was also a strong positive 
correlation with alcohol consumption and equol excretion at baseline on both 
placebo and supplement of the FFQ (p<0.001 and p<0.001 respectively) and 
FD (p=0.037 and p=0.001 respectively).
Excretion of genistein (ug/day) at baseline correlated with serum levels of a 
number of antioxidants including retinol (p=0.025), a-carotene (p=0.046), lutein 
(p=0.011) and p-cryptoxanthin (p=0.034). Genistein at baseline also correlated 
with estimated intakes of carotene on placebo FFQ (p=0.020) (Table 5.A.4), 
and FD vitamin C (p=0.023), suggesting overall an association between 
genistein status and antioxidant intake and status. However, as presented
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earlier, there was no direct effect of isoflavone supplementation, leading to 
increased genistein excretion, on antioxidant status.
When isoflavone excretion in pg/day in pre-menopausal women was compared 
with serum levels of IGF-1, BP3 and BP1, there were strong positive 
associations between enterolactone and BP-1 throughout the cycle on both 
placebo and supplement (Table 5.A.7).
In post-menopausal women there was a strong positive correlation between 
levels of daidzein post supplement and levels of IGF-1 post-supplement 
(p=0.004), although this was not seen at other timepoints. Enterolactone at 
baseline was positively associated with IGF-1 both on placebo (p=0.029) and 
supplement (p=0.034) (Table 5.A.8). These observations suggest some 
association between status of the lignan enterolactone and the IGF system.
5.3.6 2 Associations with hormonal status
When hormone concentrations were compared with isoflavone excretion in 
pg/day (Tables 4.A.9-4.A.10) the following associations were found:
In pre-menopausal women (Table 5.A.10) baseline levels of equol were 
negatively associated with levels of SHBG throughout the cycle on placebo and 
on days 1-3, 21-23 and 26-28 of the supplement phase.
Daidzein excretion at baseline, was positively correlated with concentrations of 
LH, particularly in the follicular (p<0.001) and luteal (p<0.001) phase of the 
cycle, and with FSH concentrations throughout the cycle on both placebo and 
supplement. Baseline excretion of genistein was also positively correlated with 
FSH and LH throughout the cycle.
In post-menopausal women (Table 5.A.9) baseline levels of genistein 
excretion correlated negatively with SHBG and FSH levels at baseline whilst on 
supplement.
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Again, however, we saw no effect of supplementation with these compounds on 
hormonal status.
5.3.6 3 Associations with IGF-1 and BPs
The associations between IGF-1 and binding proteins and hormonal status are 
presented in Tables 5.A.11-5.A.13. When pre-menopausal hormone levels 
were compared with IGF-1 and BP levels (Table 5.A.11) there were significant 
negative correlations between IGF-1 and oestradiol in the Luteal phase (day 21- 
23) both on placebo and supplement. There were also strong positive 
correlations between progesterone and BP-1 at baseline and mid cycle. SHBG 
levels were also significantly positively correlated to BP-1 levels throughout the 
menstrual cycle with some weaker negative correlations with IGF-1 at baseline 
(Table 5.A.12).
In post-menopausal subjects, there were some correlations with hormone levels 
(Table 5.A.13) with SHBG showing positive correlations with IGF-1 levels, 
which were not seen in pre-menopausal women.
Correlations between IGF-1, BP-3 and BP-1 levels and Isoflavone 
concentrations are found in Table 5.A.6 - 5.A.8. Correlations between IGF-1, 
BP1 and BPS and serum lipids and serum antioxidants can be found in Tables 
5.A.14 - 5.A.17 for premenopausal subjects and Tables 5.A.19 - 5.A.20 for 
post menopausal subjects. The following results are the strongest associations 
seen in pre and post-menopausal women.
BP-1 was positively associated with HDL on both placebo and supplement in 
pre-menopausal women.
In pre-menopausal women correlations with concentrations of BP-1 and BP-3 
and serum antioxidants were as follows; BP-1 was associated with levels of a-
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carotene (r=0.606, p=0.013, n=16)and p-Carotene (r=0.580, p=0.018, n=16) at 
supplement baseline.
Correlations between concentrations of IGF-1, BP1 and BPS and dietary intake 
assessed by FFQ/FD can be found in Tables 5.A.23-5.A.27. The following 
correlations were of note;
In pre-menopausal women BP1 concentrations showed positive correlation with 
vitamin E intake throughout when assessed by FD, while in post-menopausal 
women there was a positive association between BPS and BP1 with vitamin E 
intake, although this was not consistent at all timepoints, and BP1 and BPS 
were not associated with vitamin E status.
5.3.6 4 Associations with lipid and antioxidant status
Pearson correlation coefficients comparing serum lipid levels with the intake of 
fat in FDs and FQs (Table 5.A.21) showed some significant correlations with 
serum levels of LDL, cholesterol and MDA with estimated intakes of Fat, PU FA, 
MUFA, cholesterol and % of calories from fat assessed using the FFQ in the 
placebo phase, although this was not shown for dietary data from food diaries. 
Pearson correlations comparing serum concentrations of antioxidants with 
FFQ/FD intake (Table 5.A.22) showed strong correlations between serum 
levels of carotenoids and carotene intake when assessed by both FFQ and FD 
but especially strong correlations seen when comparing levels of a- and p- 
carotene with FD estimates of carotene.
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5.4 Discussion
5.4.1 Isoflavones
Supplementation for 28 days with 80 mg/day red clover isoflavones significantly 
increased the excretion of isoflavones although levels were highly variable 
between individuals. As equol is a product of intestinal bacterial metabolism 
formed from its isoflavone precursors daidzin and daidzein (Coward et al., 1993; 
Setchell et al., 2002), the large range of equol’s excretion after supplementation 
(0-27587 nmol/day) may be explained by individual differences in isoflavone 
metabolic pathways (Rowland et al., 2003). Feeding studies would suggest that 
-30-40% of the western population excrete equol in urine when challenged with 
soy foods (Karr et al., 1997; Kelly et al., 1995; Rowland et al., 2000); (Lampe et 
al., 1998). In vitro and animal in vivo studies show equol to be more estrogenic 
and have greater antioxidant activity than other isoflavones (Kostelac et al., 
2003; Setchell et al., 2002), with recent clinical studies finding greater benefits 
for equol producers, in the areas of lipid profiles, bone density, hormone profiles 
and IGF-1 profiles (Duncan et al., 2000; Lydeking-Olsen et al., 2004; Meyer et 
al., 2004; Vrieling et al., 2007; Wu et al., 2006) decreased risk of prostate 
cancer (Akaza et al., 2004) and inhibition of prostate cancer in animals (Lund et 
al., 2004).
As the proportion of metabolites excreted may be a result of differential 
absorption and variation in gut microflora (Atkinson et al., 2004), the influence of 
habitual dietary intake on excretion of equol has been a subject of considerable 
interest.
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5.4.2 Equol metabolism and diet
The dietary habits that promote equol production still remain unclear. Animal 
studies have showen that the inability of some subjects to produce equol is a 
consequence of the lack of specific components of the gut microflora (Bowey et 
al., 2003). Some studies have suggested that high fibre and low fat diets are 
conducive to equol production. In a study which classified 30 men and women 
into "excreters or non- excreters" (Lampe et al., 1998), there was no difference 
in fat intake but rather increased calories from carbohydrate and greater 
amounts of plant protein and dietary fibre in the diet of excrete rs. Another found 
that equol excreters consumed significantly less fat and more carbohydrate 
(Rowland et al., 2000).
In theory, this type of diet may promote the growth or activity of certain strains 
of bacteria shown to convert Daidzein from Dihydrodaidzein (DHD) to equol in 
vitro (Decroos et al., 2005; Ueno, 2001). However, one month supplementation 
with 16g fibre daily in the form of wheat bran in pre-menopausal women did not 
increase Equol production (Lampe et al., 2001) and a recent study found that 
chornic soy consumption does not induce major changes to gut metabolism of 
isoflavones, suggesting that the bacteria and enzymes responsible for equol or 
O-DMA production are not inducible (Wiseman et al., 2004). Other results 
suggest that high fiber intake could actually decrease bioavailability of 
isoflavones (Tew et al., 1996). Some feeding studies done with soy milk in a 
metabolic unit have suggested that the consumption of soy itself can induce 
equol production (Lu & Anderson, 1998; Lu et al., 1996b). However, this finding 
was not seen in a more recent study of one month exposure to 100mg 
isoflavones in the form of cereal bars and yoghurts in post-menopausal women 
(Vedrine et al., 2006).
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In this study, we did not see consistent associations between fibre intake and 
equol excretion, although it was not originally designed to examine this. We did 
find significantly higher levels of MDA, triglycerides and a- and y-tocopherol 
levels in equol producers compared to non producers, and consistent 
associations between equol excretion and energy intake. We also found some 
associations between equol excretion and levels of total cholesterol (p=0.0090), 
triglycerides (p=0.0012), LDL (p=0.034), MDA (p=0.0015) concentrations and 
the fat soluble vitamins a- tocopherol (p=0.0039), y-tocopherol (1.07 x 10'®) and 
retinol (p=0.034), but this was not consistent at all timepoints and therefore 
these observations are probably artefactual.
Although a study comparing soy intake assessed through FFQ in 478 post­
menopausal Japanese women, found no significant differences in serum lipids 
between soy intake groups (Somekawa et al., 2001), other studies have not 
compared equol excretion with serum lipid levels. However, some studies have 
found correlations between fat intake as assessed through dietary 
questionnaires and equol excretion. A study of 19 Japanese men and women 
consuming their traditional diet (Adlercreutz et al., 1991) reported that equol 
excretion correlated positively with intake of total fat (p<0.01), fat-fiber ratio 
(p<0.05) and meat (p<0.05) which was not the case with other isoflavonoids. 
They proposed that the individuals consuming more meat and fat had intestinal 
flora that metabolised daidzein into equol more readily. Two other more recent 
and larger studies (Hedlund et al., 2005; Ozasa et al., 2005) have also shown 
associations with fat intake. A study in 45 Caucasian men (Hedlund et al., 2005) 
showed that those who had consumed >30mg soy for at least 2 years and 
consumed animal meat regularly had a higher probability of producing equol, 
while a study of western diets by (Lampe et al., 1999) also found isoflavone and
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in particular equol excretion had strong associations with high fat and 
processed meat intake, and found no associations between equol excretion and 
soy intake. Associations examined in a Japanese population (Ozasa et a!., 
2005) found equol concentrations were not associated with dietary intake of tofu 
or miso soup (like genistein and daidzein) but with foods containing fat (butter, 
margarine, cheese), meat (including pork, ham) and coffee.
However, equol is actually being consumed directly from processed meats that 
contain soy products (Fletcher, 2003; Murphy et al., 1999) and possibly 
Indirectly through the meat and dairy of animals consuming alfalfa, clover, or 
soy, supplemented feed (King et al., 1998; Lampe et al., 1999; Nilsson et al., 
1967)
Certainly, within the UK population, the main contributors of isoflavones in the 
non-soy consuming population, were found to be bread/ bread rolls, meat 
products and then vegetable dishes (Mulligan et al., 2006). There is limited data 
on Isoflavone content of meat, milk, dairy products and fish products (King et 
al., 1998), (Antignac et al., 2003; Clarke et al., 2004). However, recent analysis 
of UK foods has found isoflavones in beers (traces of daidzein, genistein and 
biochanin A), fish and fish products including Indian foods (Clarke et al., 2004), 
with a single portion of vindaloo curry containg 11 mg of genistein. Certainly, we 
did find strong consistent positive correlations between excretion of equol and 
alcohol consumption.
Analysis of Australian milk samples (King et al., 1998) found that, in areas 
where clover represents a significant potential source of isoflavonoids in cows 
milk, samples contain equol concentrations of 293± 52 ng/ml compared with 
90ng/ml in Finish milk (Adlercreutz, 1985). Although the authors concluded 
these amounts were not clinically significant (Cassidy et al., 1994) large
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quantities of milk and dairy products could account for baseline levels of equol 
excreted in the non soy consuming population and certainly free equol has a far 
greater binding affinity for SHBG (Martin et al., 1996) and oestrogen receptors 
alpha and beta (Muthyala et al., 2004) than its precursor daidzein.
Enterediol and enterolactone are metabolites of plant lignans and their excretion 
has been associated with higher levels of dietary fibre intake (Adlercreutz, 
2002a). Adlercreutz showed differences in lignan excretion, with vegetarians 
excreting significantly higher amounts than omnivores (Adlercreutz et al., 1986; 
Adlercreutz et al., 1995b). Lignan excretion in the western diet is also related to 
fruit intakes of squash, melons, stone fruits and berries (Hutchins et al., 1995; 
Lampe et al., 1999). However, we were unable to show consistent associations 
between fibre intake and lignan excretion in this study.
5.4.3 Isoflavones and hormones
It has been proposed that isoflavones exert their cancer preventative effects in 
part as a result of hormonal actions. To investigate the influence of the 
isoflavone supplement on regulation of the menstrual cycle and hormonal 
status, serum concentrations of oestradiol, progesterone, LH, FSH and SHBG 
were measured in all 16 pre and 7 post-menopausal women.
Hormones in pre-menopausal women followed normal menstrual cycle patterns 
and serum concentrations were within expected ranges for both age groups, 
given within kit instruction manuals and laboratory normal ranges. Analysis of 
pre-menopausal hormones (paired t test) showed SHBG concentrations were 
higher in the luteal phase on supplement compared with the luteal phase on 
placebo (p=0.003). However using repeated measure AN OVA (for multiple time 
point comparisons), Isoflavone supplementation had no effect on circulating
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hormone concentrations in either pre- or post-menopausal subjects. Other 
intervention studies that have looked at the hormonal effects of soy have had 
varying results (Kurzer, 2002) (Table 1.2.4.1). For oestradiol concentrations, 
some have shown increases in the follicular phase (Cassidy et al., 1994), 
(Duncan et al., 1999a; Kumar et al., 2002) and overall increases throughout 
(Petrakis et al., 1996) while others have seen decreases in the luteal phase (Lu 
et al., 2000a; Lu et al., 1996a; Maskarinec et al., 2002; Wu et al., 2000) and 
follicular phase (Lu et al., 2000a; Lu et al., 1996a; Martini et al., 1999; Nagata et 
al., 1998) (Nicholls et al., 2002). Only two studies have shown a significant 
reduction in oestradiol (Lu et al., 1996a; Wu et al., 2000). All of these mentioned 
studies showed a reduction in total progesterone or concentrations measured in 
the luteal phase but only one found this to be a significant reduction (Lu et al., 
1996a). SHBG levels measured in these intervention studies also varied with 
only two studies showing increases in the follicular and luteal phase (Nagata et 
al., 1998; Wu et al., 2000). A smaller number of intervention studies have 
looked at the effects of soy/isofalvones on FSH and LH levels. Studies done in 
a metabolic unit on six pre-menopausal women (Cassidy et al., 1995; Cassidy 
et al., 1994) found significantly decreased FSH and LH levels in response to 45 
mg isoflavones (in the form of a textured soybean product) daily, while 
increasing the follicular phase length of the menstrual cycle. However, in 
another study, 36 oz of soy milk had no effect on LH or FSH levels in 10 pre­
menopausal women with no change in mean menstrual cycle length (Lu et al., 
2000a), (Lu et al., 2001). Another study (Maskarinec et al., 2002) saw no 
significant changes in hormone levels when comparing 17 premenopausal 
women on 100mg soy isoflavones for a year compared to the same size control 
group. Studies testing three different doses of soy protein powder in 14 pre­
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menopausal women (Duncan et al., 1999a; Duncan et a!., 2000), found that 
only the low Isoflavone dose significantly decreased LH and FSH levels 
mid cycle. A cross-sectional study by (Verkasalo et al., 2001) looked at 636 pre­
menopausal women on the EPIC study who were consuming soy milk and 
separated them into a < 142ml or >284ml vs control group. Although FSH and 
LH concentrations were -25% higher in < 142ml group, they found no 
statistically significant associations of hormones with soy milk intake in pre or 
post menopausal women. When subjects were stratified into equol excreters 
(n=5) vs non excreters (n=9), they found that over all three different isoflavone 
doses, excreters had lower levels of oestrone and higher concentrations of 
SHBG and midluteal progesterone (Duncan et al., 2000). (Setchell et al., 2002) 
has hypothesised that the effects of soy may lie with an individuals ability to 
metabolise daidzein to the more estrogenic metabolite equol, but (Maskarinec 
et al., 2002) did not find a difference in oestrone or oestradiol concentrations in 
equol excreters after 6 and 12 months of 100mg soy isoflavone intake. 
Intervention with lactobacillus and birfidobacterium (Bonorden et al., 2004) was 
also unable to verify this hypothesis as there was no significant difference in 
homone concentrations in equol excreters vs non excreters with no significant 
alteration in equol or hormone concentrations after 2 months probiotic 
intervention. In a more recent randomised intervention study with 220 pre­
menopausal women (Maskarinec et al., 2004), there appeared to be no 
significant difference in the oestrone, oestradiol, prgesterone and SHBG levels 
of the intervention group consuming ~50mg isoflavones daily versus the control 
group in samples taken in the luteal phase (day 19) after 3, 6,12 and 24 
months. The author concluded that the effects of soy on the breast, if they exist,
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are mediated by mechanisms other than the lowering of circulating oestrogen
levels in pre-menopausal women.
A one-month crossover intervention study using soy milk (113-202 mg/day 
isoflavone content) or an isoflavone-free soymilk (<4.5 mg/day isoflavones), 
with a 4-month washout between phases, looked at the effect on the 
metabolism of 17p-oestradiol (Lu et al., 2000b). Higher levels of two putative 
carcinogenic metabolites of l7p-oestradiol, 4- and 16a-hydroxy oestrogen, and 
lower amounts of anti-carcinogenic metabolites, 2-hydroxyoestrogens, have 
been associated with a greater risk of breast cancer. The diet rich in 
isoflavones increased the cycle mean daily urinary excretion of 2- 
hydroxyestrone, while the mean daily excretion of 16a-hydroxy-estrone did not 
change. The ratio of 2-hydroxyestrone to 16a-hydroxy-estrone was higher 
during the isoflavone-rich diet (2.6 + 0.34) than during the isoflavone-free diet 
(2.0 ±  0.32; p=0.01). These results suggest that isoflavones increase the 
metabolism of endogenous oestrogens to the protective 2-hydroxylated 
oestrogens in women, and this may play a role in lowering 17p-oestradiol levels 
and therefore reducing breast cancer risk (Lu et al., 2000b).
In post-menopausal women most soy intervention studies have shown few 
differences in levels of oestradiol, LH, or FSH (Table 1.2.4.2) (Baird et al., 1995; 
Berrino et al., 2001; Brooks et al., 2004; Brzezinski, 1997; Duncan et al., 1999b; 
Foth & Nawroth, 2003; Murkies et al., 1995; Nicholls et al., 2002; Persky et al., 
2002; Petrakis et al., 1996; Pino et al., 2000). In the post-menopausal arm of a 
study with three different doses of soy protein, there was a small decrease in 
oestrone and oestradiol concentrations with a significant increase in SHBG on 
the high isoflavone diet containing ~132mg/per day for 93 days (Duncan et al., 
1999b). Other studies have also seen an increase in SHBG (Berrino et al.,
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2001; Kaaks et al., 2003; Pino et al., 2000). A study containing large quantities 
of isoflavones (Brzezinski, 1997) saw an increase in SHBG and a decrease in 
the strength of hot flushes, while (Nicholls et al., 2002) saw a decrease in LH 
peaks after discontinuation of soy containing 60mg isoflavones suggesting a 
residual effect post supplementation. In the large EPIC -Oxford cross-sectional 
study (Verkasalo et al., 2001), there were no differences seen in oestradiol or 
SHBG levels in 456 postmenopausal women consuming daily soy milk. Another 
arm of the EPIC study (Norfolk) found that urinary and serum levels of daidzein 
and genistein were negatively correlated with plasma oestradiol (Low et al., 
2005), but that when women with certain genotypes were excluded these 
correlations were no longer significant. The author concluded that 
polymorphisms in genes encoding for enzymes involved in oestradiol 
metabolism (i.e, ESR1 Pvull CC genotype) may affect the concentration of 
plasma oestradiol, suggesting diet-gene interactions.
A study looking at correlations between levels of soy intake (assessed through 
FFQ) in 50 pre-menopausal Japanese women found negative correlations with 
oestradiol levels on day 11 and 22 of the cycle and no associations with SHBG 
(Nagata et al., 1997). Positive correlations were found between urinary 
phytoestrogens and plasma SHBG in other studies (Adlercreutz et al., 1987; 
Adlercreutz et al., 1992). More recent cross sectional studies of post­
menopausal women (Low et al., 2005; Shoff et al., 1998; Thomas et al., 1999; 
Verkasalo et al., 2001 ) assessed phytoestrogen intakes through dietary 
questionnaires and found correlations between intake and SHBG or oestradiol 
were not significant.
Certainly in this study we did not see any significant change in hormone 
concentration in pre or post-menopausal women when on supplement.
160
However, the almost significant luteal increase in SHBG has been seen in other 
studies (Duncan et al., 2000; Wu et al., 2000). We saw no consistent 
association of lignan status with SHBG, in contrast with(Adlercreutz et al.,
1987), who found that intake of total fibre correlated with enterolactone, 
enterediol and plasma SHBG.
Further investigations are needed to determine whether isoflavones can cause 
hormonal changes and whether these are length of intervention and dose 
dependant. However data from this and other short term feeding studies 
suggest that Isoflavone effects on serum hormones and the menstrual cycle are 
unlikely to be the primary mechanisms by which isoflavones may prevent 
cancer in pre-menopausal women and certainly do not appear to have 
estrogenic-like effects in post-menopausal women.
Longer term supplementation than that carried out in this study, with thought 
given to the type of supplement (whole food or extracted supplement) and the 
subjects selected, may be required to fully elucidate this matter. This matter is 
of considerable importance in terms of the possible role of isoflavones in breast 
cancer prevention, where two early intervention studies focusing on the effects 
of phytoestrogens on the breast have both found evidence of a possible 
oestrogenic effect (McMichael-Phillips et al., 1998; Petrakis et al., 1996). It may 
be that the anti-cancer effects of isoflavones/soybeans are non-hormonal 
(Anderson, 1999).
5.4.4 IGF-1 and binding protein concentrations
Red clover isoflavone supplementation had no effect on IGF-1, lGFBP-1 or 
IGFBP-3 in post menopausal women. In pre-menopausal women, isoflavone 
supplementation had no effect when multiple time points over the menstrual
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cycle were considered, although there seemed to be a slight protective effect of 
isoflavone supplementation when the analysis was carried out simply before 
and after the supplementation period. This is likely to be due, however, to the 
large difference in IGF-1 levels at baseline and cannot be attributed to the 
isoflavone supplement. The effect of isoflavone supplementation on IGF status 
would therefore appear to be relatively weak. The clinical relevance of this small 
change may, in fact, be negligible. Our numbers were small, and the variance 
observed in IGF-1 and its binding proteins was high, so the area requires further 
study.
5.4.5 IGF and menstrual cycle
IGF-1 appears to be influenced by stages of the menstrual cycle. We observed 
a significantly higher concentration of IGF-1 and IGF-BP3 in pre-menopausal 
subjects on placebo in the luteal phase (days 21-23) compared to the menstrual 
phase (days 1-3). These changes over the menstrual cycle between the luteal 
and follicular phase are of a small magnitude (12.8% for placebo and 16.5% for 
supplement) and are in agreement with other studies (Gaufriez et al., 1986; Juul 
et al., 1997; Lavigne et al., 2004). An early study in 5 premenopausal women 
(Gaufriez et al., 1986) showed higher levels in the luteal (+4-+9) vs follicular (-3 
- - 8) phases of the menstrual cycle and (Juul et al., 1997) also showed that, in 
ten healthy pre-menopausal women, there were significantly higher levels of 
IGF-1 in the luteal (0 - +10) vs follicular (-10 - 0) phase of the cycle (P<0.01). 
There were no cyclic changes in BP-3, while BP-1 had a pre-ovulation peak and 
was negatively correlated with SHBG levels. A more recent study in 37 pre­
menopausal women (Lavigne et al., 2004) also found that IGF-1 increased by 
7.6% in the luteal phase (days 21-23) and 3.3% in the preovulatory phase (days
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12-15), compared with the follicular phase (days 5-7) (p=0.004), and saw no 
change in BP-3 levels. These small changes may explain why several other 
studies have not seen any significant cyclic variation in IGF-1, BP-1 or BP-3 
(Blake et al., 1997; Guidoux et al., 1986; Helle et al., 1998; Thierry van Dessel 
et al., 1996; Wang et al., 1995).
A study in 9 pre-menopausal women (Helle et al., 1998) found IGF-1 and BP-3 
levels to be highest in the follicular phase in 8 out of 9 women studied.
However, the differences between the follicular and luteal phase were minimal 
with the major difference in plasma IGF-1 due to lower levels in the menstrual 
phase. As discussed previously (Duncan et al., 1999a), a feeding study in 14 
pre-menopausal women (Wangen et al., 2000) found that IGF-1 was lower in 
the menstrual phase compared with the mid-follicular and mid-luteal phases 
(p=0.03 and p=0.05 respectively) whilst on the control ISP powder.
In this study, there were some consistent associations observed between IGF 
and binding proteins and hormones at certain stages of the menstrual cycle, but 
numbers were small, and the study not originally designed to examine this. In 
other studies, results for this have been conflicting. Positive correlations 
between oestradiol and IGF-1 have been seen (Helle et al., 1998; Ho et al., 
1987; Massa et al., 1993) however others have found no correlations (Juul et 
al., 1997; Thierry van Dessel et al., 1996). A study by (Kelly et al., 1993) found 
that levels of serum oestrogen in post-menopausal women receiving exogenous 
oestrogens was actually negatively correlated with IGF-1 levels.
Certainly the positive correlations found in this study between BP-1 and SHBG 
levels throughout the menstrual cycle on both placebo and supplement reflects 
findings that both are regulated by insulin under various physiological conditions
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(Holly, 1991) and has been seen in studies of post-menopausal breast cancer 
patients (Lonning et al., 1995).
These results therefore indicate that controlling closely for menstrual cycle 
phase may be necessary to observe IGF changes of small magnitude.
5.4.6 Isoflavones and IGF
To our knowledge this is the first published randomised controlled trial to 
examine the effects of isolated isoflavones on IGF-1 status in humans 
(Campbell et al., 2004). Since conducting this study between 1998-1999, other 
intervention studies have also published their findings on the effects of soy 
supplementation on IGF status (Table 1.3.5.1), including one recent study that 
has also looked at isolated isoflavone supplementation in men.
Of the twelve studies published to date, half have seen a significant increase in 
serum IGF-1 concentrations while the others have seen no effect (Table
1.3.5.1). The discrepancy in results may be due to differences in endogenous 
estrogen levels between subjects studied i.e the study of males versus females, 
and pre or post-menopausal women or may be explained by the increased 
kilocalorie/ protein intake (Clemmons & Underwood, 1991) from the actual soy 
supplement used which may be masking the IGF lowering effects of isoflavones 
alone (Voskuil et al., 2005).
In animal studies, soy protein resulted in reduced IGF-1 in both normal and 
polycystic kidney disease affected male animals (Aukema & Housini, 2001), 
while Isoflavones reduced IGF-1 and inhibited growth of prostate cancer in mice 
(Zhou et al., 1999). It should be noted however that rodents convert most of 
their daidzein to equol (Setchell et al., 2002).
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In our one week study using a soy, rye and linseed bar (see chapter 4) 
(Woodside et al., 2006), both IGF-1 and IGF-BP3 were significantly elevated 
after intervention.
Two studies were conducted using soy protein with a milk protein control. In 
men, serum IGF-1 was higher in those supplemented with soy protein than 
those consuming milk protein (Khalil et al., 2002). The same supplements given 
to post menopausal women (Arjmandi et al., 2003) resulted in significant 
increases in IGF-1 on both soy protein (p<0.0001) and the milk protein control 
(p=0.0045). However like the men, the greatest increases in IGF-1 (97%) was 
seen in women on the Soy protein especially those who were not on HRT. 
These two studies would suggest that protein itself does increase IGF-1 but that 
soy protein had an effect on IGF-1 independent of its protein content. Calcium 
was not involved as both supplements had similar calcium content.
By contrast, in a three month study looking at markers of bone turnover 
(Wangen et al., 2000), in pre-menopausal women, IGF-1 and IGF-BP3 were 
increased by a low isoflavone diet, while in post-menopausal women, there 
were trends towards decreased IGF-1 and IGF-BP3 concentrations with 
increasing isoflavone concentration. The authors concluded that, although soy 
isoflavones do affect markers of bone turnover, the changes observed were of 
small magnitude and were not likely to be clinically relevant. In a study looking 
at soy protein supplementation with or with out 83 mg isoflavones (Adams et al.,
2003), It was found that changes in serum IGF-1 and BP3 were similar in both 
groups and there appeared to be no effect of soy isoflavones on IGF-1 when 
compared to the protein supplement alone.
Similarly, a one year soy protein supplementation in post menopausal women 
(n=62) (Arjmandi et al., 2005), found that both soy and dietary protein
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supplements significantly increased serum IGF-1, however only those 
consuming soy protein had a significant increase in IGF-BP3.
In a 2 year soya intervention (~30mg isoflavones) in pre-menopausal women 
(Maskarinec et al., 2005b), there was also no significant change in serum IGF-1 
or BP-3 throughout. They did see a positive correlation between total isoflavone 
excretion and IGF-1 (p=0.004). The author concluded that adding soya foods to 
the diet of pre-menopausal women does not appear to lower serum levels of 
IGF-1 and BP-3, if anything the greater protein intake from soy may lead to a 
small increase in IGF-1 serum levels.
There have recently been a few studies that have examined the effects of soy 
supplementation in combination with low fat/high fibre diets. A study in 17 
prostate cancer patients (Spentzos et al., 2003) found that a low fat diet with the 
subsequent addition of a soy protein supplement (containing 114mg 
isoflavones), significantly increased serum IGF-1 levels from baseline (p=0.02), 
while a study by (Gann et al., 2005) found that in 153 pre-menopausal women 
randomised to the consumption of a low fat high fibre diet followed by soy 
protein with or without isoflavones vs the usual diet, there was no difference in 
the LFHF diet groups vs the usual diet. There were also no differences in IGF 
levels between those on soy with or without isoflavones. However, there was a 
small but significant decrease in BP-3 in both groups post soy protein 
supplementation regardless of isoflavone presence. In a recent study in post­
menopausal women (Kaaks et al., 2003) involving five month dietary 
intervention with foods rich in dietary fibre/phytoestrogens (~45mg isoflavones) 
and a reduction in total fat and refined carbohydrate intake, there were also no 
significant changes in serum IGF-1 levels. However the intervention group did 
have increased levels of IGF-BP1, BP-2 and SHBG.
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In all of the studies mentioned above it is difficult to disentangle the effects of 
isoflavones from soy protein (Voskuil et al., 2005) especially in those studies 
which have looked at soy supplementation as part of an overall healthy dietary 
intervention (Gann et al., 2005; Kaaks et al., 2003; Spentzos et al., 2003).
Only our study (Campbell et al., 2004) and to our knowledge one subsequent 
study published recently (Vrieling et al., 2007), has looked at the effects of 
isoflavone supplementation on its own. The study by (Vrieling et al., 2007) also 
used a supplement derived from red clover (by the same manufacturer) and 
found that in the 37 men, with a family history of colorectal cancer or a personal 
history or adenomas, 84mg/d Isoflavone supplementation did not significantly 
affect serum IGF-1, BP-3 or BP-1 serum concentrations. However, they did find 
that the change in serum IGF-1 concentrations post supplement were 
negatively correlated to serum equol concentrations (r=-0.49, p=0.002). This 
requires further investigation in larger studies and as our numbers were small 
we cannot corroborate this finding in the 4 subjects who were classified as 
equol producers.
The results from our study and the intervention studies above are inconclusive 
but would point to there being little clinical effect of soy and isoflavones on 
serum levels of IGF-1. The results possibly show opposing effects of 
Isoflavones and soy protein, with IGF-1 decreased by isoflavones but increased 
by soy protein and possibly protein in general. Certainly feeding studies 
(Clemmons et al., 1985; Smith et al., 1995) have shown that a diet restricted of 
certain essential amino acids reduces IGF-1 levels possibly by decreasing 
production of GH which in turn reduces hepatic production of IGF-1 
(Ketelslegers et al., 1995) and increases BP-1 (Jousse et al., 1998). The status 
of endogenous oestrogen concentrations may also contribute to the differences
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seen with IGF-1 association between men and women, pre and post­
menopausal, HRT vs none, etc.
However further larger and long-term intervention studies using isolated 
isoflavone supplementation should determine whether the isoflavone content of 
soy is beneficial to IGF status.
Since this study was conducted there have also been a number of cross- 
sectional studies published that have looked at links between dietary intake and 
IGF-1 concentrations (Table 1.3.4.1). Some of the studies have been reviewed 
(Voskuil et al., 2005) and a few of them have also examined associations with 
intake of Soy/phytoestrogens (Nagata et al., 2003; Probst-Hensch et al., 2003; 
Vrieling et al., 2004). No correlations were seen between soy product intake 
and IGF-1 or BP-3 levels in 261 Japanese pre-menopausal women (Nagata et 
al., 2003) or the 386 pre and post-menopausal Dutch women (Vrieling et al.,
2004) assessed using food frequency questionaires. However, there was a 
positive association found between soy intake and IGF-1 in 321 Chinese men 
studied (Probst-Hensch et al., 2003) and a positive association with plant 
lignans and BP1 concentrations in 162 post menopausal Dutch women (Vrieling 
et al., 2004). It would appear then that the findings from the cross-sectional 
studies are in agreement with results from our study and the other intervention 
studies, i.e. there appears to be very little effect of soy/isoflavones on IGF-1 
concentrations and that, rather than reducing levels of IGF-1, consumption of 
soy may in fact be increasing levels particularly in men and post-menopausal 
women who are not on HRT (Arjmandi et al., 2003; Khalil et al., 2002).
Other nutritional factors that have been associated with IGF-1 levels are energy 
and protein intake, with malnutrition and fasting states resulting in significant 
reductions of serum IGF-1 levels (Thissen et al., 1994). The physiological
168
mechanisms are thought to be linked to low levels of insulin, resulting in 
consistently high levels of GH, which leads to hepatic resistance and binding of 
GH, with decreased production of hepatic IGF-1 (Thissen et al., 1994).
However, these correlations only appear to apply with extreme dietary 
restictions as only a few cross-sectional studies, done in well-nourished 
individuals, have shown positive associations with energy intake (Heald et al.,
2003) where subjects with BMI<25 kg/m  ^are analysed separately (Giovannucci 
et al., 2003; Holmes et al., 2002). We did not see a positive association 
between IGF-1 and total energy intake but we did find a number of positive 
correlations with anthropometric data (Table 5.A.18) including correlations 
between IGF-1 and waist, weight and hip measurements. We also did not 
detect any correlations with protein intake and IGF-1 in pre-menopausal 
women. Ten of the seventeen crossectional studies done to date (Table
1.3.4.1) did not see any significant correlations between IGF-1 and protein 
intake. Seven saw positive associations with protein intake (Allen et al., 2002; 
Devine et al., 1998; Holmes et al., 2002), (Giovannucci et al., 2003; Heald et al., 
2003; Larsson et al., 2005; Norat et al., 2007) and only one study (Maskarinec 
et al., 2005a) saw a suggestive negative corrieation with IGF-1 and protein in 
the form offish intake.
This study showed some associations between serum levels of triglycerides, 
total cholesterol and IGF-1 concentrations in pre-menopausal women, which is 
consistent with findings by (Probst-Hensch et al., 2003) which also found strong 
positive associations between IGF-1 concentrations and serum levels of 
cholesterol, LDL and triglycerides. Other cross-sectional studies have examined 
fat intake through dietary questionnaires and have found significant positive 
correlations with IGF-1 concentrations (Baibas et al., 2003; Gunnell et al., 2003;
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Heald et al., 2003; Kakiamani et al., 1999), with one study shoing a negative 
association between intake of fat from meat and IGF-1 (DeLellis et al., 2004). 
Interestingly we found that, in pre-menopausal women, BP-1 levels were 
consistently positively associated with HDL levels and as there have been no 
other studies to examine this link it would be worth further investigation.
Studies linking the IGF system with the development of cardiovascular disease 
(Bayes-Genis et al., 2000), have been examined fairly recently, finding 
associations between insulin like growth factors and its binding protiens with 
serum lipid levels, (Fischer et al., 2004; Harrela et al., 2002; Janssen et al., 
1998; Juul et al., 2002; Laughlin et al., 2004).
The positive associations seen in our pre-menopausal women between BP-1 
and HDL, agree with findings by (Janssen et al., 1998) and (Laughlin et al.,
2004), while the positive associations for IGF-1 with triglycerides and 
cholesterol (although not consistent at all timepoints) appear to agree with 
findings by (Laughlin et al., 2004) but not (Harrela et al., 2002; Juul et al., 2002). 
The links are not entirely clear, however, with (Juul et al., 2002) showing that 
low IGF-1 levels puts patients at significantly higher risk of developing ishaemic 
heart disease (IHD), while recent findings by (Fischer et al., 2004) suggest a 
postive association with IGF-1, BP-3 levels and CVD. A review by (Juul, 2003) 
suggesting that the controversy around clinical studies of IGF-1 being either 
cardioprotective or a risk fator for IHD may reflect that IGF-1 was studied at 
different time points in relation to the ishaemic heart event.
Although none of the cross-sectional studies done to date have looked at 
associations with serum levels of antioxidants, the negative correlations we 
found between IGF-1 and its binding proteins and serum levels of carotenoids 
are similar to findings by the recent large EPIC crossectional study examining
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diets of women in Europe (Norat et al., 2007) which saw negative correlations 
with dietary intake of p-carotene, while an earlier study of 112 Greek men 
(Mucci et al., 2001) showed that greater consumption of cooked tomatoes (the 
largest source of lycopene) was associated with lower concentrations of IGF-1 
(p=0.041 ). However, positive correlations have also been observed in cross- 
sectional studies (Holmes et al., 2002; Maskarinec et al., 2005a).
There also appears to be a strong suggestion that milk and/or dairy 
consumption is associated with higher levels of IGF-1, with many of the 
crossectional studies showing positive correlations with IGF-1 concentrations 
and milk/dairy foods (Gunnell et al., 2003; Ma et al., 2001 ; Norat et al., 2007) 
and/or calcium and vitamin D intake (Giovannucci et al., 2003; Gunnell et al., 
2003; Holmes et al., 2002; Nagata et ai., 2003; Norat et al., 2007; Probst- 
Hensch et al., 2003). While consumption of % pint of soya milk daily in vegan 
women significantly increased IGF-1 concentrations (Allen et al., 2002), these 
increases in IGF-1 could be attributable to increased levels of protein (including 
essential amino acids and possibly ingestion of bovine IGF-1 contained in milk 
(Giovannucci, 2003). Other nutrients that have been shown to be positively 
associated with IGF-1 include intake of vitamin B6 and B12 (Norat et al., 2007). 
(Maskarinec et al., 2005a), found that women in the top quartiles of dietary fiber 
intake had 5.7% higher IGF-1 levels than women in the bottom quartiles 
(p=0.004).
We did not see any associations with IGF levels and alcohol consumption unlike 
other studies (Probst-Hensch et al., 2003; Vrieling et al., 2004), nor did we find 
any associatons between Zinc intake and IGF-1 (Devine et al., 1998; 
Giovannucci et al., 2003; Holmes et al., 2002; Larsson et al., 2005).
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Due to the small numbers in our study it is difficult to draw conclusions from the 
correlations found between serum levels of lipids and antioxidants, dietary 
intake and IGF-1, BP3 and BP1 levels. Further larger studies and intervention 
studies should be done to determine if there is a causal effect and what the 
relationships are with these dietary components, including analysis of serum 
concentrations of these nutrients which may give a more accurate assessment 
of dietary intake.
5.4.7 Isoflavones and lipids
We have shown an effect of isoflavone supplementation within one month on 
HDL-cholesterol in post-menopausal subjects. Several studies have provided 
evidence that phytoestrogens in general can modulate plasma lipid and 
lipoprotein concentrations, but the data are not entirely consistent (Anderson et 
al., 1995). A recent overview concluded that soy could improve blood lipid 
parameters in both normocholesterolaemic and hypercholesterolaemic subjects, 
although the use of soy alone may not allow patients with hyperlipidaemia to 
achieve target lipid parameters (Costa & Summa, 2000). Soy, with which most 
of the studies have been carried out, has a variety of properties unrelated to 
isoflavone content that may contribute to its lipid-modulating properties (Potter, 
1995). Our post-menopausal subjects had normal lipid levels, but displayed an 
increase in HDL-cholesterol during the isoflavone supplementation phase. This 
may be pertinent in light of the fact that, a short-term study using the same 
purified red clover isoflavone pills found no effect on plasma lipids and 
lipoprotein concentrations (Nestel et al., 1999) and another found only small 
changes in levels of triglycerides (Schult et al., 2004). However other longer 
term studies using this supplement have demonstrated an effect of isoflavones
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on HDL3 (Samman et al., 1999) in pre-menopausal women and total HDL 
(Clifton-Bligh et a!., 2001; Knight et al., 1999) in pre-menopausal and post­
menopausal women. A recent study in post-menopausal women with a different 
isoflavone supplement not derived from red clover (containing 47mg as 
aglycone form) found that HDL cholesterol significantly increased from baseline 
in the combination of walking and supplement but not on supplement alone (Wu 
et al., 2006). The apparent difference in these findings compared to those 
obtained with soy-derived isoflavones (Dewell et al., 2002; Gardner et al., 2001; 
Somekawa et al., 2001) could be accounted for by the high levels of biochanin 
and fomonomentin in red clover isoflavone extracts.
5.4.8 Isoflavones and antioxidants
Isoflavones can act as antioxidants (Bingham et al., 1998), both in vitro and test 
systems. (Kapiotis et al., 1997) observed that LDL oxidation products, assayed 
as thiobarblturic acid-reactive substances, were strongly inhibited by genistein, 
somewhat inhibited by daidzein, but not affected by genistin (the glycosylated 
form of genistein) or control. Furthermore, both genistein and daidzein were 
found to protect against cytotoxic effects of oxidised LDL as assessed by 
cellular morphologic features and lactate dehydrogenase release by cultured 
endothelial cells. Genistein has also been shown to inhibit hydrogen peroxide 
production and increase the activity of antioxidant enzymes, such as catalase, 
superoxide dismutase, glutathione peroxidase and glutathione reductase (Lissin 
& Cooke, 2000). A protective/antioxidant effect has been shown by 
phytoestrogen supplementation on the susceptibility of LDL to oxidation in 
another study (Tikkanen et al., 1998). Six healthy volunteers received 19 mg 
isoflavones/day for 2 weeks. Lag phases of LDL oxidation curves were reduced
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post-supplement compared with baseline values. Another study, however, 
failed to show an inhibition of lipid peroxidation after 8 weeks of isoflavonoid 
supplementation in subjects with high-normal blood pressure (Hodgson et al., 
1999), measuring urinary F-2-isoprostanes. Another study in 24 subjects 
showed that consumption of soy containing burgers containing 21 mg Daidzein 
and 35mg genistein isoflavones, reduced lipid peroxidation in plasma in the 
form of plasma F(2)isoprostane and increased the resistance of LDL to 
oxidation (Wiseman et al., 2000). We found little effect of isoflavone 
supplementation on markers of antioxidant status. Our subjects were healthy 
and had normal antioxidant levels; it may be that isoflavones will exert marked 
antioxidant effects in vivo only in those with an already compromised 
antioxidant status.
5.4.9 Diet
Background diet did not seem to affect the findings of this study, with the 
magnitude of any differences observed being unlikely to affect our conclusions. 
Overall analysis of dietary intake showed that mean intakes were comparable to 
national averages in the UK (Swan, 2004). The percentage of calories from 
protein, carbohydrate, fat and alcohol were very similar between FFQs and 
FDs. In terms of biomarkers, overall serum levels of carotenoids appeared to 
correlate strongly with both FFQ and FDs. Serum lipid levels of LDL, cholesterol 
and MDA showed some correlation with FFQ estimated intakes of fats but not at 
all with intakes estimated from FDs. The FFQ estimated intake of calories, 
cholesterol, % fat and fibre also showed some interesting correlations with 
anthropometric data.
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Thus, it would appear that both methods of dietary assessment showed a 
reasonable level of agreement. However the FFQ appeared to perform better 
when compared with biomarkers and anthropometric data. Therefore the FFQ 
may well give a better indication of long-term dietary habits.
5.5 Conclusion
Red clover-derived isoflavone supplementation over one month has no effect on 
IGF status in post-menopusal women, and at most has a small effect on IGF-1 
in pre menopausal women. Red clover isoflavones seem to increase HDL- 
cholesterol in post-menopausal women, but have little or no effect on other 
lipids or antioxidant status. It must be remembered, in the interpretation of these 
data, that the study was small and had low power to detect a difference 
between placebo and supplement, particulary when multiple comparisons were 
being carried out. Further work in larger numbers will determine whether these 
dietary compounds may play a role in endocrine-responsive cancer and 
Cardiovascular disease prevention.
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CHAPTER SIX -  THE EFFECT OF ISOFLAVONES ON DNA 
SYNTHESIS IN MCF-7 AND MDA-MB-231 HUMAN BREAST 
CANCER CELLS
6.1 Introduction
In vitro, isoflavones inhibit the growth of both oestrogen dependent and 
independent breast cancer cells by a number of different mechanisms (Dampier 
et al., 2001 ; Magee & Rowland, 2004; Peterson & Barnes, 1991 ; Sarkar & Li, 
2003).
Isoflavones bind to mammalian oestrogen receptors with between 1 x 10'  ^ and 
1 X 10  ^ the activity of 17p-oestradiol and are conventionally considered weak 
oestrogenic compounds (Markiewicz et al., 1993). However the discovery of the 
oestrogen receptor p subtype (ERP) (Kuiper et al., 1996; Kuiper & Gustafsson, 
1997) has added a new dimension to the understanding of oestrogen and anti- 
oestrogenic actions of these compounds. The relative binding affinities and 
transcription activities of isoflavones compared to oestrogen, in both a and p 
subtypes have been investigated (Kuiper et al., 1997; Kuiper et al., 1998). 
Isoflavones, and in particular genistein and equol, have 30-100 fold higher 
binding affinities and transcription activities for ERp compared with ERa (An et 
al., 2001; Barkhem et al., 1998; Kostelac et al., 2003) (McCarty, 2006).
Normal and malignant breast tissue express both receptors (Kuiper et al., 
1997). Studies suggest that ERp is the principle oestrogen receptor in normal 
breast tissue with decreasing expression in poorly differentiated cancerous and 
metastatic tissue (Palmieri et al., 2002), with others finding that ERp is 
upregulated in breast tumours that develop antioestrogen resistance (Speirs &
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Kerin, 2000). Although the precise role of ERp activation is unclear (Park et al., 
2003) there is evidence that it opposes the proliferative effects of ERa in vitro 
(Caetano et al., 2006; Paruthiyil et al., 2004; Strom et al., 2004).
Expression of the oestrogen receptors in breast cancer cell lines, shows that the 
ER positive MCF-7 cells strongly express ERa, while both MCF-7 and the ER 
negative MDA-MB-231 cells express low levels of ERp (Dampier et al., 2001; 
Fuqua et al., 1999; Tong et al., 2002; Vladusic et al., 2000).
Genistein and daidzein bind to ERa with 4% and 0.1% affinitiy of oestradiol 
respectively (Kuiper et al., 1998). Equol has similar binding affinity to genistein 
but a much stronger ability to induce transcription (Morito et al., 2001). In ERa 
positive MCF-7 cells, isoflavone concentrations <1pM increase cell proliferation, 
with genistein shown to be a strong oestrogenic agonist for both ER isoforms 
(Maggiolini et al., 2001). However, higher concentrations (>10pM) have been 
shown to inhibit hormone dependent growth by oestrogen antagonistic activity, 
and these biphasic effects on cell growth are now well documented (Fioravanti 
et al., 1998; Hsieh et al., 1998; Hsu et al., 1999; Le Bail et al., 1998; Power & 
Thompson, 2003; Wang & Kurzer, 1997; Wang et al., 1996; Zava & Du we,
1997). Research by (Hsieh et al., 1998) found that concentrations as low as 
lOnM of genistein could have proliferative effects in MCF-7 cells, with lOOnM 
achieving proliferative effects similar to InM of oestradiol. Others have also 
found that genistein and equol induced oestrogen regulated pS2 expression at 
concentrations of InM to IpM, with their growth stimulation linked to the binding 
affinity for ERa (Zava & Duwe, 1997). They also found that genistein’s ability to 
override the growth inhibitory effects of tamoxifen helped demonstrate that the 
inhibitory mechanisms of isoflavones may not be the same as classical 
oestrogen agonists like tamoxifen. (Le Bail et al., 1998) found that, in the
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presence of 0.1 nM oestradiol, the proliferative effects of isoflavones at lower 
concentrations were no longer present while their inhibitory effects at higher 
concentrations (~50pM) were unaffected by oestradiol.
Oestradiol and IGF-1 appear to work together in the proliferation of breast 
cancer cells with increasing suppport for cross talking between the ER and IGF- 
1R signalling pathway (Kato et al., 2000; Laban et al., 2003). Oestradiol has 
been showen to stimulate expression of IGF-1, the IGF-1 R, IRS-1 and down 
regulate expression of the IGF binding proteins (Ruan et al., 1995; Stewart et 
al., 1990), (Huynh et al., 1996b; Lee et al., 1999). The cytotoxic effects of 
tamoxifen are partially mediated through IGF-1 receptor (IGF-1 R) signalling 
(Guvakova & Surmacz, 1997), while genistein has recently been shown to 
enhance the IGF-1 signalling pathway in proliferation of MCF-7 cells at low 
concentrations (Chen & Wong, 2004).
In ERa negative cells, isoflavones do not appear to cause biphasic effects on 
cell proliferation. A study comparing the effects of genistein in different breast 
cancer cell types, found that growth promotion at low concentrations of 1-1 OpM 
were only apparent in MCF-7 cells, and that different mechanisms were found 
to promote growth depending on breast cell type (Dampier et al., 2001). 
Whether these antiproliferative effects are mediated through binding to ERp has 
yet to be fully examined. However research by (Caetano et al., 2006) has 
recently found that in MDA-231 cells, genistein increases expression of all 
genes involved in cell cycle control, apoptosis and DNA repair including 
BRAC1, p53, p21, RadSI, BARD, Bax GADD45 and RF1, suggesting it may 
decrease the inhibition exerted by oestrogens on the transcription of these 
genes by antagonising ERp.
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A recent study using cDNA miocroarray technology has shown that 50|jM 
Genistein can also upregulate genes such as HSP, involved in cell salvage 
response, and down regulate SRF transcription factor, involved in cell growth 
/differentiation through oestrogen receptor independent pathways (Chen et al., 
2003). Other oestrogen independent mechanisms have been reviewed 
(Middleton et al., 2000; Sarkar & Li, 2003), and include: inhibition of AKt 
signalling and activation of nuclear fator KB DNA binding activity needed for cell 
survival, inhibition of antiproliferative enzymes such as topoisomerase I and II 
and 5a reductase, inhibition of protein tyrosine kinase mediated signalling 
pathway, inhibition of angiogenesis and metastasis, simulation of immunity and 
antioxidant activity (Akiyama et al., 1987; Akiyama & Ogawara, 1991; Chen et 
al., 2003; Kim et al., 1998; Ruiz-Larrea et al., 1997; Shao et al., 1998a; Shao et 
al., 1998b; Sierens et al., 2001; Su et al., 2005; Zhang et al., 1999).
However, caution is warranted in the Interpretation of some of these effects, as 
they have been observed at higher concentrations than may be found in vivo. 
Reports on plasma concentrations of isoflavones do vary, with levels reported to 
reach no higher than 18.5pM (Barnes & Peterson, 1995). Soy rich Japanese 
diets can result in total concentrations above 5pM (Morton et al., 1994) with 
mean concentrations of genistein in Japanese men (493nM) compared with 
men from UK (33nM). It was found that 58% of Japanese men and 38% of 
women had serum equol concentrations above 20nM compared with none and 
2.2% of comparable samples in the UK population (Morton et al., 2002). Total 
levels of isoflavones following moderate consumption of soy are reported to be 
~2pM (Franke et al., 1998) with studies following consumption of genistein rich 
foods, finding that plasma concentrations are generally <1pM of genistein 
(Barnes et al., 1996), (Adlercreutz et al., 1995a; Gooderham et al., 1996;
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Wiseman et al., 2004; Xu et al., 1994). Recent bioavailbilty studies looking at 
the American Caucasian female population have found peak plasma genistein 
concentrations of 0.5-2.2 pM after 4-8 hours of ingestion (Setchell et al., 2003), 
with the bioavailability from aglycone forms higher than glycosides for daidzein 
with no difference seen for genistein (Zubik & Meydani, 2003). Studies suggest 
that as little as -0.5-2% of genistein in serum is actually available as the 
unbound unconjugated form of genistein (Barnes, 1995; Nagel et al., 1998) 
which may be equivalent to -lOnM genistein concentrations in vitro (McCarty, 
2006).
However, cellular concentrations may in fact be higher than this, with oestrogen 
concentrations found to be up to 40 fold higher in breast ductal fluid than in 
serum (Ernster et al., 1987). A study by (Hargreaves et al., 1999) also found 
significantly higher isoflavone levels in nipple aspirate fluid than in serum, in 
both control and soy supplemented pre-memopausal women, suggesting 
accumulation of phytoestrogens within breast ducts. Similar concentrated 
effects have also been seen in prostatic fluid (Morton et al., 1997). However, 
(Pumford et al., 2002) found that breast tissue levels of phytoestrogens are 
comparable to serum levels, and increase with isoflavone supplementation.
In vitro studies in breast cancer cells can improve our understanding of the 
possible therapeutic benefits that isoflavone compounds may have. Thus, the 
present study was designed to investigate the effects of isoflavones on DNA 
proliferation in the oestrogen dependent, non-invasive MCF-7 breast carcinoma 
cell line and the oestrogen-independent, invasive MDA-MB-231 breast 
carcinoma cell line. Interactions between the isoflavones, antiestrogen 
Tamoxifen and IGF-1 were also examined to investigate possible mechanisms
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of action. To examine the mechanisms by which isoflavones inhibit cell growth, 
concentrations of 10|jM (-IC50) of isoflavones were combined with:
• 1nM Oestradiol to imitate levels seen in plasma for premenopausal 
women (Pike et al., 1993),
• lOnM IGF-1 which gave near maximum promotion of DNA synthesis in 
both cell lines
• IpM tamoxifen to imitate levels in women receiving tamoxifen for 
prevention/treatment of breast cancer (Lien et al., 1989) and can inhibit 
ER and IGF-1 mediated proliferation of MCF-7 cells (Jordan, 1994) 
(Wosikowski et al., 1993).
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6.2 Materials and methods
6.2.1 Cell Culture
MCF-7 and MDA MB -231 cells (kindly donated by Ludwig cancer research 
group) were maintained in Phenol Red IMEM (GIBCO) supplemented with 5% 
PCS (GIBCO), 1% L-Glutamine (sigma) and 1% Fungizone (GIBCO) in 5% CO2 
at 37°C. Conditions involved growing cells in phenol red free IMEM 
supplemented with 5%FCS for 72 hours prior to plating. Cells were then seeded 
in 96 well plates (NUNC) at 1x lO'^  cells per well in 5% DCC-FCS (Dextran 
charcoal coated foetal calf serum) phenol red free IMEM and incubated for 24 
hours. Medium was changed to serum free IMEM for another 24 hours before 
the compounds were added. Stock solutions of tamoxifen, genistein (4,5,7- 
thhydroxyisoflavone), daidzein (4,7-dihydroxyisoflavone), equol and 17p- 
oestradiol (Sigma) in ethanol were used to produce the required concentrations 
of compounds in culture medium. Control conditions also contained the 
appropriate amount of ethanol (0.1%).
6.2.2 BrdU assay
The principle of the assay is to determine cell proliferation by measuring 5- 
bromo-2-deoxyuridine (BrdU) incorporation during DNA synthesis in 
proliferating cells. This assay indicates growth rate as opposed to cumulative 
cell growth. Conventional methods use thymidine, however this technique is 
based on the incorporation of the pyrimidine analogue 5-bromo-2’-deoxyuridine 
(BrdU). The BrdU assay was performed using a colorimetric ELISA kit 
(Amersham-Pharmacia-Biotech, 1998). Results were from five replicate wells 
with experiments performed two to three times.
See Chapter two for further detail on Methods.
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6.3 Results
Because we have not directly compared DNA synthesis with other assays, such 
as cell number or protein content, we cannot assume that these results are 
directly comparable. However, previous studies have compared assays and 
found DNA synthesis to parallel other assays and directly correlate with the 
pH]thymidine incorporation assay (Amersham-Pharmacia-Biotech, 1998).
The work presented here does appear to correlate quite closely with results 
from studies that have used thymidine to analyse DNA synthesis in these cell 
types, and could therefore be considered as a useful and safer alternative.
6.3.1 Effects of E2 and IGF-1 on DNA synthesis
DNA synthesis was significantly stimulated with E2 after 24 hour incubations in 
MCF-7 cells (Table 6.3.1.1 and Fig 6.3.1.1). Induction was 16%, 173%, 187% 
and 159% of the 0% control at 0.01 nM, 0.1 nM, InM and lOnM, respectively. 
(P<0.01). In MDA-MB-231 cells E2 did not stimulate DNA synthesis but 
appeared to inhibit cells to between 87 and 89% of the control at higher 
concentrations (P<0.05) (Table 6.3.1.2 and Fig 6.3.1.2).
IGF-1 significantly increased DNA synthesis in MCF-7 cells to 123%, 149%, 
198% and 214% of the control at 0.1 nM, InM, lOnM and lOOnM, respectively 
(P<0.01) (Table 6.3.1.1 and Fig 6.3.1.1). In MDA-231 cells IGF-1 did not 
stimulate DNA synthesis but inhibited to 92 and 89% of the control at higher 
concentrations (P<0.05) (Table 6.3.1.2 and Fig 6.3.1.2).
6.3.2 Effects of Isoflavones and Tamoxifen on DNA synthesis
The isoflavones genistein, daidzein and equol all stimulated DNA sunthesis to a 
maximum of 207%, 198% and 209% at IpM respectively. Both genistein and
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equol caused significant stimulation between concentration of 0.01^M-10p,M, 
(P<0.01), while daidzein significantly increased stimulation between 0.1|aM- 
100)^M, (P<0.01). Biphasic effects, meant that at higher concentrations, 
genistein and equol were able to inhibit DNA synthesis, with IC50 values of 93 
and 55pM respectively. Tamoxifen did not have biphasic effects and inhibited 
DNA synthesis from O.IpM (P<0.05) through to lOOpM (P<0.01) with an IC50 
value of 1.17pM (Table 6.3.1.1 and Fig 6.3.2.1).
In MDA-MB-231 cells the isoflavones did not stimulate DNA synthesis at any 
concentration but significantly inhibited induction as concentrations increased. 
Genistein inhibited DNA synthesis from concentrations of 0.1 pM (P<0.01) 
upwards with an IC50 value of 14pM. Daidzein and equol inhibited DNA 
synthesis at concentrations greater than 1pM (P<0.01) with an IC50 value of 
15pM for equol. Tamoxifen inhibited synthesis form concentrations of O.IpM 
(P<0.01) onwards with an IC50 value of 1.35pM (Table 6.3.1.2 and Fig 6.3.2.2).
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Table 6.3.1.1: Dose response of MCF-7 cells incubated with Isoflavones, 
Tamoxifen, IGF-1 and oestradiol for 24 hours.
O.OIuM O.luM I.OuM lOuM lOOuM IC50
Daidzein 96.4(15.6) 153.5(34.6)* 198.0(50.5)* 161.2(60.2)* 133.8(41.2)* >100fiM
Genistein 163.8(29.7)* 197.7(25.3)* 207.1(43)* 156.3(39.2)* 41.0(27.4)* 93nM
Equol 122.4(14.6)* 193.8(43.2)* 209.1(54.2)* 141.5(45.4)* 14.7(1.9)* 54.8|jM
Tamoxifen 92.5(9.4) 91.5(8.0)* 59.7(11.6)* 7.45(0.7)* 9.11(0.8)* 1.17^M
IpM O.OInM O.InM InM lOnM lOOnM
IGF-1 102.9(14.4) 123.3(26.0)* 149.2(18.0)* 197.6(45.2)* 214.3(46.5)*
Oestradiol 97.4(17.7) 160.9(22.9)* 172.9(25.9)* 187.4(45.8)* 159.3(39.2)*
Levels given as percentage of the control. Mean (SD) *P<0.01 Mann Whitney U 
test.
Table 6.3.1.2: Dose response of MDA-231 cells incubated with Isoflavones, 
Tamoxifen, IGF-1 and oestradiol for 24 hours.
O.OipM 0 .1  pM I.OpM lOpM lOOpM IC50
Daidzein 100.4(9.3) 104.5(11.2) 98.3(12.1) 80.4(8.1)* 54.0(7.9)* 113pM
Genistein 96.4(10.3) 89.5(5.7)* 85.6(7.8)* 59.7(10.5)* 19.5(5.4)* 14.1pM
Equol 94.0(7.0) 100.8(7.7) 97.4(14.9) 65.2(11.0)* 9.0(1.7)* 14.55pM
Tamoxifen 96.1(5.6) 86.9(6.8)* 74.5(12.4)* 4.7(0.3)* 5.1 (0.5)* 1.35pM
IpM O.OInM O.InM InM lOnM lOOnM
IGF-1 101.3(6.2) 106.7(12.3) 101.1(10.5) 91.7(9.2)* 89.3(5.8)*
Oestradiol 97.4(13.0) 91.5(13.5)* 88.7(8.4)* 92.6(9.4)* 86.7(15.0)*
Levels given as percentage of the control. Mean (SD) * P<0.01 Mann Whitney 
test.
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Figure 6.3.1.1: Dose response of MCF-7 cells incubated with IGF-1 and 
oestradiol for 24 hours before labelling with BrDU. Mean (SE)
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Figure 6.3.1.2: Dose response of MDA-MB-231 cells incubated with IGF-1 and 
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Figure 6.3.2.1: Dose response of MCF-7 cells incubated with isoflavones and 
Tamoxifen for 24 hours before labelling with BrDU. Mean (SE)
120
100
2 80
C
8 60
o 40
20
0
"♦—  Daidzein 
# — Genistein 
A - ■ Equol 
A — Tamoxifen
A -----------------1
0 O.OIuM O.luM I.OuM
concentration
lOuM 100uM
Figure 6.3.2.2: Dose response of MDA-MB-231 cells incubated with isoflavones 
and Tamoxifen for 24 hours before labelling with BrDU. Mean (SE)
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6.3.3 Interactions between isoflavones and Tamoxifen with Oestradiol
In MCF-7 cells maximal stimulation of DNA synthesis with 1nM Ea alone was 
187% of the control. When incubated in combination with lOpM genistein, 
daidzein and equol, synthesis induced by InM Ea was decreased by 51%, 41% 
and 43% respectively (P<0.01).
When incubated in combination with IpM tamoxifen, the decrease of Ea induced 
synthesis was 28% (P<0.01 ) (Table 6.3.3.1)
In MDA-231 cells the inhibition caused by isoflavones alone was counteratcted 
by the addition of InM Estradiol such that the inhibition of DNA synthesis was 
reduced by 10%, 7% and 11% for genistein, daidzein and equol respectively
(p<0.01).
This was not the case with tamoxifen as there was very little difference seen 
between inhibition with or without Ea (Table 6.3.3.2).
6.3.4 Interactions between Isoflavones with Tamoxifen
In MCF-7 cells, IpM tamoxifen inhibited DNA synthesis by 60% (P<0.01). 
However, when added to lOpM genistein and daidzein, tamoxifen increased 
DNA synthesis by a further 22% and 15% (P<0.05). This increase was not seen 
when tamoxifen was added to equol (Tabie 6.3.3.1).
In MDA-231 cells, IpM tamoxifen inhibited DNA synthesis to 74.5% of the 
control. Unlike the MCF-7 cells, the addition of genistein and equol reduced this 
inhibition further by 11% (P<0.01) and 22% (P<0.01) (Table 6.3.3 2).
6.3.5 Interactions between Isoflavones and Tamoxifen with IGF-1
Stimulation of DNA synthesis with lOnM IGF-1 was 198% of the control 
(P<0.01). When incubated with isoflavones, induction was decreased. With
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equol, this was a significant reduction of 46.2% (P<0.01). Tamoxifen also 
reduced IGF-1 induced synthesis but this was not significant. No significant 
increase in DNA synthesis was seen with the addition of E2 to IGF-1 (Table
6.3.3.1).
In MDA-231 cells the addition of lOnM IGF-1 reduced the ability of genistein, 
daidzein and equol to inhibit DNA synthesis by 11%, 20% and 17%, 
respectively (P<0.05). However, this was not the case with tamoxifen as there 
was no difference seen in the amount of DNA inhibition between tamoxifen on 
its own or combined with IGF-1. There was a small yet significant increase in 
DNA synthesis with the addition of E2 to IGF-1 (P<0.01) (Table 6 3.3.2).
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Table 6.3.3.1 Response of MCF-7 cells incubated for 24 hours with different 
combinations of Isoflavones, oestradiol, Tamoxifen and IGF-1.
Oestradiol(lnM) Tamoxlfen(lnM) IGF-l(IOnM)
Genistein(IO^M) 156.3(39.2) 136.9(7.9) 178.6(17.2) 168.7(9.2)
Daidzein(IO^M) 161.2(60.2) 146.5(12.9) 176.2(17.6) 181.3(12.4)
Equol(IOi^M) 141.5(45.4) 144.6(13.4) 143.2(15.2) 151.4(22.3)
Tamoxlfen(l)^M) 59.7(11.6) 159.0(49.8) - 169.6(41.0)
Oestradiol(lnM) 187.4(45.8) - 159.0(49.8) 190.2(9.6)
IGF-1 (10nM) 197.6(45.2) 190.2(9.6) 169.6(41.0) -
Levels given as a percentage of the control. Mean (SD)
Table 6.3.3.2: Response of MDA231 cells incubated for 48 hours with different 
combinations of Isoflavones, oestradiol, Tamoxifen and IGF-1.
Oestradiol(1 nM) Tamoxifen(lnM) IGF-l(IOnM)
Genistein(IO^M) 59.7(8.1) 69.9(4.3) 63.4(6.0) 70.2(12.8)
Daidzeln(IOjiM) 80.4(10.5) 87.0(6.8) 91.4(6.6) 100.2(18.6)
Equol(10|iM) 65.2(11.0) 76.4(4.0) 52.9(5.1) 81.9(14.2)
Tamoxifen(lfaM) 74.5(12.4) 68.2(12.9) - 71.1(9.1)
Oestradlol(lnM) 92.6(9.4) - 68.2(12.9) 102.1(11.2)
IGF-l(IOnM) 91.7(9.2) 102.1(11.2) 71.1(9.1) -
Levels given as a percentage of the control. Mean (SD)
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6.4 Discussion
6.4.1 Isoflavones
DNA synthesis was significantly increased by E2 in MCF-7 (ERa+/ERp+) cells 
but not MDA-MB-231 (ERa-/ERp+) cells. These results confirm the role of ERa 
in facilitating the dose dependent proliferation effects of E2 in MCF-7 cells 
(Dampier et al., 2001). The isoflavones genistein, daidzein and its metabolite 
equol also significantly stimulated DNA synthesis in a dose dependant manner 
in MCF-7 cells. Maximal stimulation for all three isoflavones tested was reached 
at 1.0 uM, with an increase of 207%, 198% and 209% for genistein, daidzein 
and equol respectively. However, genistein and equol concentrations >10pM 
inhibited DNA synthesis with IC50 values of 93pM and 54.8pM respectively. 
This biphasic response of MCF-7 cells to increasing concentrations of 
isoflavones has also been reported in other studies looking at DNA synthesis. 
Incubation for 24 hours with luM genistein and lOuM daidzein in the presence 
of 5% DCC-fCS, maximized DNA synthesis to 215% and 210% of the control 
while, inhibition occurred between 50-1 OOpM with an IC50 value for genistein of 
41 pM (Liu & Wang, 1997; Wang & Kurzer, 1998). (Hoffman, 1995) found 
genistein IC50 values of 12.6pM in the presence of no growth factors and an 
IC50 of 5.9pM in the presence of lOng/ml IGF-1. Studies using BRDU 
incorporation to assess DNA synthesis have also shown biphasic effects in 
MCF-7 cells. (Hsu et al., 1999) found that in MCF-7 cells, biochanin A (the 
precursor to genistein) concentrations of less than lOpg/ml increased DNA 
synthesis by up to 280% of the control while greater than 30pg/ml significantly 
reduced DNA synthesis with an IC50 value of 40pg/ml.
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The biphasic effects on DNA synthesis caused by increasing concentrations of 
isoflavones in MCF-7 cells agrees with results from other studies done in 
variying assays including:
• direct cell counting with a Coulter Counter (Dampier et al., 2001 ; Schmitt 
et al.,2001)
• cell doubling time after 7 days incubation (Matsumura et al., 2005)
• cell number-colorimetric M IT assay (Le Bail et al., 1998)
• protein content-sulphorhodamine colorimetric assay (Sathyamoorthy & 
Wang, 1997; Sathyamoorthy et al., 1994; Wang et al., 1996)
• DNA content- diphenylamine assay (Fioravanti et al., 1998)
• DNA content- Krishans propidium iodide stain (Zava & Duwe, 1997)
• DNA content- Hoeshst reagent (Hsieh et al., 1998).
Studies examing MCF-7 cell number, found genistein IC50 values of 36pM 
(Monti & Sinha, 1994), 39pM (Peterson & Barnes, 1991) and 24-38pM 
(Matsukawa et al., 1993). Our comparatively high IC50 values could well be 
lowered if concentratiosn beween 10 and lOOpM had been examined, as 
inhibition appears to increase steeply in the cells between these concentrations. 
A recent paper examining DNA synthesis using the BRDU assay and 
expression of ERa/ERp in MCF-7 and T47D cells (Power & Thompson, 2003) 
found biphasic effects in both cell lines, with maximal proliferation of -250%  
control at lOpM genistein which then decreased at lOOpM in MCF-7 cells. 
Western blot analysis showed that 1 pM genistein caused a down-regulation of 
ERa while having no effect on ERa in T47D cells and an upregulation of ERp in 
both cell types. This pattern of differential regulation of the ERs between the two 
cell lines was also seen with oestradiol stimulation at InM. This suggests that 
proliferation of DNA synthesis by genistein at this concentration is using similar
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mechanisms to that of oestradiol, while the inhibitory action at higher 
concentrations appears to be only partially mediated through ER dependent 
pathways (Chen et al., 2003).
In the ERa negative MDA-MB 231 cells, isoflavones did not cause proliferation 
of DNA synthesis at lower concentrations but showed significant inhibition at 
higher concentrations. The IC50 values of 14 pM, 113pM and ISplVI for 
genistein, daidzein and equol respectively are consistent with findings reported 
by other studies in other assay types.
The IC50 for DNA synthesis, as determined through thymidine incorporation, for 
genistein and daidzein, were 27|iM and 81|iM respectively (Liu & Wang, 1997). 
Assays of cell number in MDA-231 cells found IC50 of 15pM for genistein (Monti 
& Sinha, 1994) and in MDA-468 cells 24|liM  and 134|aM for genistein and 
daidzein, respectively (Peterson & Barnes, 1991). Genistein concentrations 
>1pM markedly inhibited MDA-468 cell growth measured as DNA content (Zava 
& Duwe, 1997) and genistein concentrations of 0.01-1 OpM were inhibitory of 
DNA conentent In MDA-231 cells (Wang et al., 1996). (Fioravanti et al., 1998) 
also found that > IpM genistein inhibited cell growth as measured through DNA 
content with 5pM giving 20% inhibition and significant counteraction of IGF-1 
stimulation (p<0.01). A lOpM concentration of genistein significantly inhibited 
cell number in MDA-MB 231 cells (Dampier et al., 2001). (Tanos et al., 2002) 
also showed inhibition of MDA-MB 231 cells between the genistein 
concentrations of 0.4-4pM with 54.6% of cell growth at 4pM using methylene 
blue staining method. (Shao et al., 1998a) found a genistein IC50 for cell growth 
of 20pg/ml (74pM) for both MCF-7 and MDA-231 cells, while (Schmitt et al., 
2001) showed that concentrations of Daidzein and Equol >10pM inhibited cell 
proliferation in this cell line.
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6.4.2 Interactions between Isoflavones and oestradiol
In the ERa positive MCF-7 cells, the three isoflavones studied at 10pM 
concentrations all significantly inhibited 1nM oestradiol induced synthesis.
These results agree with other studies which have shown that, like the biphasic 
effects seen when isoflavones are given on their own, low concentrations 
enhance oestradiol proliferation and high concentrations (>10pM) inhibit 
oestradiol induced proliferation (Harris et al., 2005; Le Bail et al., 1998; Power & 
Thompson, 2003; Wang & Kurzer, 1998). (Kuiper et al., 1998) investigated the 
induction of gene expression by a combination of oestradiol with genistein and 
found that low concentrations of 10'^M and 10'^M had additive effects on the 
activation of transcription in both ERa and ERp.
At higher concentrations (Zava & Duwe, 1997) found that the pronounced 
growth-inhibitory actions of genistein over the 10-20pM concentration were not 
modified by O.SnM E2. (So et al., 1997) showed that inhibition in cell growth 
caused by 18.5pM genistein in MCF-7 cells was restored by lOOnM oestradiol, 
while (Schmitt et al,, 2001) also found that 1-1 OpM of daidzein and equol in 
combination with lOOpM oestradiol reduced cell proliferation compared to the 
treatment with oestradiol alone. (Matsumura et al., 2005) also showed an 
inhibition of oestradiol stimulated growth after 7 days when combined with 
genistein and equol concentrations of 10'^M.
(Power & Thompson, 2003) found that when genistein was combined with 1 nM 
oestradiol and compared to cells treated with oestradiol alone it significantly 
decreased cell proliferation at concentrations > lOpM in MCF-7 and >1pM in 
T47D cells. They found that ERp was upregulated when IpM genistein or InM 
oestradiol was given alone but not when given in combination.
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These results could be explained by a competitive reaction of the test 
compounds with oestradiol for the receptor subtypes, as genistein competes 
strongly with oestradiol, with (Kuiper et al., 1998) showing that at concentrations 
of IpM, genistein has a greater oestrogenic potency (in the form of trans 
activation activity for ERa and Erg).
(Zava & Duwe, 1997) suggests that genistein, while mediating its actions via ER 
as an estrogen agonist, apparently also cross talks with other ER-independent 
cellular mechanisms at higher concentrations to inhibit cell proliferation induced 
by genistein through ER pathways. However, whether this activity may 
potentially be due to extragenomic actions of these ligands as concluded by 
(Harris et al., 2005) such as antioxidant activity G2M arrest of the cell cycle 
and/or possibly the result of ER|3 exerting an inhibitory action on ERa mediated 
gene expression, still remains to be elucidated (Matthews & Gustafsson, 2003). 
A recent study by (Chen et al., 2003) showed that genistein at high 
concentrations down regulates the SRF response element, which is involved in 
both ER and IGF-R mediated pathways (Duan et al., 2001). However this 
occurred in the presence of a pure antiestrogen ICI 182, 780 which suggests 
this is not purely an ER dependent mechanism.
In MDA-231 cells however, the addition of InM oestradiol appeared to rescue 
the cells slightly from the inhibitory effects of the isoflavones with an increase in 
synthesis of 10%, 7.9% and 11% of gensitein, daidzein and equol respectively. 
The reason for this may be due to competitive binding for ERp, however the 
combinatory effects of isoflavones with oestradiol have not been investigated by 
others in ER negative cell lines and thus requires further investigation.
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6.4.3 Interactions between oestradiol and Isoflavones with Tamoxifen
In MCF-7 cells, tamoxifen inhibited DNA synthesis and this inhibition was 
significant from O.IpM onwards with an 1050 of 1.2|jM. These results agree with 
other studies in this cell line (Faye et al., 1987; Jordan et al., 1985; Power & 
Thompson, 2003; Tanos et al., 2002; Taylor et al., 1984).
Concentrations of IpM tamoxifen also inhibited InM oestradiol induced 
synthesis by 28% (P<0.01). This is consistent with results by (Wang & Kurzer,
1998) who showed a decrease in DNA synthesis of 23% at these 
concentrations. Other studies have also shown inhibitory effects of tamoxifen on 
oestradiol induced proliferation at varying concentrations (Power & Thompson, 
2003; Schmitt et al., 2001 ) The combination of 1 pM tamoxifen and 1 nM 
oestradiol induced the same pattern of ERo/p regulation as tamoxifen alone in 
MCF-7 cells (Power & Thompson, 2003). Tamoxifen has been showen to 
counteract oestradiol induced synthesis in part by binding and causing 
transcriptional activation of ERp (Paech et al., 1997).
Conversely, in this study the antiestrogenic actions of IpM tamoxifen which 
inhibited DNA synthesis to 60% when given alone or by 28% when given with 
oestradiol, was completely counteracted when combined with lOpM genistein 
and daidzein such that DNA synthesis actually increased by 22% and 15% 
respectively (P<0.05) compared with isoflavones given alone.
This is consistent with findings by (Wang & Kurzer, 1998) who showed that 
tamoxifen at concentrations of 0.1-1 pM enhanced the oestrogenic effects of low 
concentrations (0.1-1 OpM) of gensitein.
In contrast, others have found that although genistein may override the growth 
inhibitory actions of tamoxifen at concentrations of lOnM-lpM, tamoxifen still 
reduces genistein induced protein content when compared with genistein given
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alone (Zava & Duwe, 1997). While at 0.01 pM tamoxifen can further inhibit cell 
proliferation of 0-37pM genistein concentrations (Tanos et al., 2002) and 
decrease expression of genistein stimulated pS2 mRNA expression (Wang et 
al., 1996).
It is interesting to note that the increase we saw In DNA synthesis with genistein 
and daidzein was not seen when tamoxifen was combined with lOpM equol and 
the reasons for this requires further investigation. Studies by (Sathyamoorthy & 
Wang, 1997) have found equol to be 100 fold more potent than daidzein in 
stimulating pS2 expression in MCF-7 cells. They found that 1 pM tamoxifen was 
able to completely inhibit pS2 expression by 0.1 pM daidzein but could only 
partially inhibit equol stimulation (55%) at this concentration. Equol was far 
more effective at inhibiting the binding of oestradiol to ER with 0.05pM resulting 
in 50% inhibition compared to 20% for Daidzein at the same concentration. A 
study by (Magee et al., 2006) has also found that R and S-equol enantiomers 
have different biological properties with the Racemic equol responsible for 
antioxidant effects preventing DNA damage in MCF-7 cells.
In the ERa negative MDA 231 cells, the opposite was true. The addition of 
genistein and equol caused a further inhibtion of 11% and 22% respectively 
than antiproliferative effects seen with IpM tamoxifen alone (74.5%) or with 
1 nM Estradiol alone (68.2%). This synergistic inhibition has also been reported 
by (Shen et al., 1999) who found that 5pM tamoxifen and genistein decreased 
cell inhibition to 44% of the control in MDA-435 cells and agrees with results by 
(Schmitt et al., 2001; Tanos et al., 2002). An explanation for the observed 
synergistic anti-proliferative action may be the result of tamoxifen and genistein 
attacking different targets in signal transduction at different phases in the cell 
cycle (G1 and G2M respectiveiy)(Shen et al., 1999). Why this synergism was
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not seen in MCF-7 cells is a matter for discussion, however, it would seem that 
the presence of ERa complicates the non-estrogenic actions of these 
compounds. We should note that we did not see this synergism in inhibition with 
daidzein and this may be explained by some reports which have showen that 
daidzein does not bind with any great affinity to ERp compared with genistein 
and equol (Kuiper et al., 1998; Matsumura et al., 2005).
6.4.4 Interatctions between isoflavones and Tamoxifen with IGF-1
Early studies showed that genistein inhibited tyrosine kinase activity of growth 
factor receptors EGF, PDGF, insulin and IGF-1 (Akiyama et al., 1987; Akiyama 
& Ogawara, 1991; Kawase et al., 1995). Studies have also shown that 
antiestrogens can inhibit the IGF-1 induced transcriptional activation of the ER 
(Clayton et al., 1997; Lee et al., 1997a; Newton et al., 1994; Westley & May, 
1994) with increasing substantiation of interactions between the ER and IGF-1 R 
pathways in ERa positive breast cancer cells (Cascio et al., 2007; Kato et al., 
2000; Martin & Stoica, 2002; Mendez et al., 2003; Surmacz & Bartucci, 2004). 
To investigate these effects, DNA synthesis was measued in both MCF-7 cells 
and MDA-231 cells after incubation with isoflavones in the presence of IGF-1. 
The stimulation of IGF-1 in MCF-7 cells was reduced by the addition of all three 
isoflavones and tamoxifen. However, although reductions of 29%, 16% and 
28% were seen for genistein, daidzein and tamoxifen respectively, only the 
equol reduction of 46.2% (P<0.01) was significant.
These results compare with two previous studies examining genistein inhibition 
of IGF-1 or insulin stimulated growth. (Hoffman, 1995) found an IC50 value of 
5.9pM genistein for inhibition of 10 ng/ml IGF-1 stimulated DNA synthesis of 
MCF-7 cells. (Fioravanti et al., 1998) found that 5pM genistein significantly
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counteracted 10ng/ml IGF-1 stimulation of DNA content (p<0.001). (Pagliacci et 
al., 1994) also found that lOOpM genistein inhibited insulin induced tyrosine 
phosphorylation and a strong increase in the percentage of S phase cells.
(Wang & Kurzer, 1998) found that 0.1 pM and I.OpM genistein significantly 
increased insulin induced DNA synthesis, while 10pM genistein inhibited DNA 
synthesis induced by 1-2 pg/ml insulin and > 25pM genistein inhibited DNA 
synthesis induced by 0.5-2pg/ml insulin (p<0.01). (Panno et a!., 1996) found 
that >37pM Genistein inhibited insulin induced growth in MCF-7 cells. However, 
to our knowledge there are no other studies that have examined the effects of 
daidzein and equol on IGF-1 induced DNA synthesis in MCF-7 cells.
The tamoxifen reductions in IGF-1 induced DNA synthesis also agree with other 
studies, which have shown that IpM tamoxifen can significantly inhibit IGF-1 
induced proliferation in ERa positive cell lines by inhibiting IGF-1 mediated 
transcriptional activation of the endogenous ER (Lee et al., 1997a), down 
regulate IGF-1 induced tyrosine phosphorylaltion of IGF-1 R and inhibit IRS-1 
(Guvakova & Surmacz, 1997). Antiestrogens such as tamoxifen, have also 
been shown to down regulate the expression of IGF binding proteins (Winston 
et al., 1994). Certainly the interaction between oestrogens and the IGF-1 
signaling pathway could explain some of the isoflavone biphasic effects seen in 
ER postive cell lines and possibly the synergistic effects seen with combinations 
of tamoxifen and isoflavones.
Oestradiol has been showen to upregulate IGF-1 receptor mRNA expression 
(Stewart et al., 1990), enhance IGF-1 signalling through IRS-1 expression (Lee 
et al., 1999; Surmacz & Bartucci, 2004), activate MAP Kinase pathway 
(Migliaccio et al., 1996) and prevent apoptosis through a synergistic increase in 
Akt protein activity (Ahmad et al., 1999), with studies by (Martin & Stoica, 2002),
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showing that IGF-1 regulates both the expression and the activity of ERa in part 
through the phos-phatidylinositol-3-kinase/Akt pathway. More recent studies by 
(Cascio et al., 2007) show that both oestradiol and IGF-1 differentially regulate 
ER transcription at ERE and AP-1 sites. A recent study by (Chen & Wong,
2004) has looked directly at the effects of genistein at low concentrations (IpM) 
on the IGF-1 signalling pathway. They found that IpM genistein like lOnM 
oestradiol increases protein, mRNA expression and enhances tyrosine 
phosphorylation of the IGF-1 R and downstream signalling protein IRS-1. These 
effects were completely counteracted by the antiestrogens ICI 182,780 and 
tamoxifen, sugesting that ER and more specifically the AF-2 domain of the ER 
is most likely involved in mediating these effects. The author concluded that the 
IGF signalling pathway is at least partly responsible for the growth promoting 
effects of genistein in MCF-7 cells at low concentrations. However, further 
investigation should be done to determine if higher doses of genistein cause 
inhibition of the IGF-1 signalling pathway or mediate their antiproliferative 
actions through other mechanisms. It would also be valuable to conduct these 
experiments with other isoflavones and antiestrogens in combination and in cell 
lines that do not express ERa, such as MDA-231 cells, to understand more fully 
the mechanisms involved.
In MDA-231 cells the addition of IGF-1 actually reduced the ability of genistein, 
daidzein and equol to inhibit DNA synthesis alone by 11%, 20% and 17% 
respectively (P<0.05). Genistein inhibited IGF-1 stimulated growth by 22% 
compared with IGF-1 alone, which is similar to the findings of (Fioravanti et al., 
1998) who found that 5pM genistein was able to inhibit IGF-1 stimulated DNA 
content by 20%. However, we did not see this with tamoxifen, which showed no
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difference in the amount of DNA inhibition with or without IGF-1 at the 
concentrations used.
The synergistic increase in DNA synthesis when oestradiol and IGF-1 were 
combined (P<0.01) is in line with studies that have looked at these effects in ER 
a positive cell lines (Stewart et al., 1990) but have not been investigated with 
the MDA-231 ERa negative cell line.
These results suggest that the isoflavones are working differently to tamoxifen 
in that part of the isoflavone inhibitory action (possibly through ER-p) is 
counteracted by the addition of IGF-1 and stimulation of the IGF-1 R mediated 
pathway. To our knowledge there are as yet no published studies that have 
examined the interactions of daidzein and equol with IGF-1 in MCF-7 or MDA- 
231 ERa negative cell lines.
6.5 Conclusion
In conclusion, the most plausible explanation for the biphasic effects of these 
isoflavone compounds in MCF-7 cells is that, while mediating their actions via 
ER as oestrogen agonists, they can also cross talk with the IGF-1 signalling 
pathway using this and other ER independent cellular mechanisms at higher 
concentrations to inhibit cell proliferation. Certainly the presence of ERa is not 
required for the isoflavones to inhibit tumor cell growth as seen by the results in 
the MDA-231 cells. The isoflavones themselves also appear to have different 
qualities with the metabolite equol showing greater inhibition than the parent 
compound daidzein in both cell lines.
Isoflavones do appear to be inhibitory in concentrations >10pM and the 
synergism of tamoxifen especially with equol in the ERa negative MDA-231 
cells is certainly worth further investigation. The clinical concern is whether
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physiological concentrations could be sustainable at these levels and the 
evidence for this is conflicting. Reports also indicate that not everyone produces 
equol as a metabolite and thus it may need to be provided in supplement form. 
Finally, to our knowledge, this is the first report to assess the effect of 
isoflavones daidzein and equol on IGF-1 induced DNA synthesis in MCF-7 and 
MDA-231 cells and although the results do not provide direct biochemical 
evidence for antagonism of the IGF-1 R signalling pathway they do show that 
biological effects of IGF-1 on MCF-7 and MDA-231 cells are counteracted by 
isoflavones, especially equol.
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CHAPTER SEVEN -  CONCLUSION
The potential role for isoflavones in the prevention of breast cancer is yet to be 
fully established, whilst the mechanisms involved also remain to be further 
elucidated.
Certainly the intervention studies conducted here and others published to date 
show that these compounds have only moderate effects on hormonal status 
and little impact in lowering endogenous levels of IGF-1, unlike pharmacological 
compounds such as tamoxifen. Further well-designed and controlled 
intervention studies using isolated isoflavones are required to determine any 
differences when compared with soy protein, which appears to increase 
circulating levels of IGF-1 and its binding proteins.
The heterogeneity of response to isoflavone exposure, which depends on gut 
microflora activity, necessitates an increase in the numbers of subjects required 
for an adequately powered study (Bingham et al., 1998) as increasing evidence 
suggests that equol producers may have greater clinical benefits. Differences in 
lipid and antioxidant status in equol excretors versus non-excretors in our one 
month supplementation study would appear to support this. The effect of 
habitual dietary intake on the proportion of metabolites excreted remains to be 
determined. Further studies are also needed to determine the amounts of equol 
ingested directly from meat and dairy products as opposed to created through a 
conducive microflora environment. It may also be of interest to study 
supplementation with isolated equol supplements to reduce study 
complications.
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Certainly other dietary components may well be more effective in altering IGF-1 
status and this requires further investigation. In particular it may be more 
effective to intervene with more global dietary changes such as a low fat high 
fibre diet as seen with recent large long term intervention studies, rather than 
supplementing with isolated compounds.
With isoflavone effects on endogenous levels of IGF apparently minimal it may 
be that their benefits are more localised to the breast. In vitro results from our 
studies in breast cancer cell lines and others suggest that isoflavones, 
especially equol, may be useful in establishing the pharmacological qualities of 
compounds needed to overcome resistance to antiestrogens which may be 
occurring through the IGF-1 R and ER cross-talking mechanisms. Whether or 
not the isoflavones' greater affinity for ER|3 may be conferring an ability to act 
synergistically with tamoxifen remains to be examined. Further investigation 
should also be done to examine the isoflavones’ ability to increase signal 
transduction of the IGF-1 R pathway, which occurs at low concentrations and 
could well explain the biphasic effects seen with these compounds.
Certainly the ability of isoflavones to increase proliferation in ERa positive 
breast cancer cell lines at lower concentrations should not be ignored, with 
current opinion that breast cancer survivors and those at risk should avoid 
excess consumption of these “weak estrogenic compounds ' until further 
research has been carried out. Further studies should be done to fully establish 
concentrations at the cellular level in populations who already consume soy 
isoflavones, while future intervention studies in subpopulations at higher risk of 
breast cancer, and in those with breast cancer, may give us the answers 
required.
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Emerging animal study evidence suggests that short-term neonatal and pre­
pubertal exposure to dietary isoflavones decreases carcinogen-induced breast 
cancer by increasing the proportion of differentiated cells in the mammary gland 
(Lamartiniere et al., 1995; Miller et al., 1994). This would support a concept that 
the protective effect of the traditional Asian diet occurs early in life, (Colditz & 
Frazier, 1995) and may explain why epidemiological studies and intervention 
studies, focussing on adult intake, have to date been unimpressive. Future 
prospective studies examining outcomes of adults who received soy based 
formula as infants may be of interest although a recent study comparing infants 
and children on cows’ milk vs soya formula suggested no lasting effect of early 
life isoflavone exposure on isoflavone metabolism (Hoey et al., 2004). Finally, 
further epidemiological evidence coming from large prospective studies should 
point to nutritional links with breast cancer but may not be able to disentangle 
the beneficial effects of higher fibre/lignans/flaxseed or low fat diets that go 
hand in hand with soy consumption and an overall healthier diet pattern. Long 
term larger intervention studies with isolated isoflavones including equol, in 
populations at higher risk of developing breast cancer, will hopefully add to the 
evidence base. Certainly IGF-1 and its signalling pathway appear to be 
prominent targets for future treatments given they have such an important role 
in protecting tumour cells from apoptosis. Lowering physiological levels and 
expression of the IGF-1 R and its ligand IGF-1 also appear to be important 
components in the prevention of metastasis, with antiestrogenic treatment 
influencing levels in vivo. Just how effective natural antiestrogenic compounds 
like isoflavones are in lowering IGF-1 production, influencing the signalling 
pathway and ultimately breast cancer risk remains to be determined and 
certainly requires further research.
205
APPENDIX
Table 5.A.1: Correlations of equol excretion with serum lipids, serum 
antioxidants, dietary intake (pre and post-menopausal women) and
Equol (ug/day) 
P(1-3)
Equol (ug/day) 
P(26-28)
Equol (ug/day) 
S(1-3)
Equol (ug/day) 
5(26-28)
LDL P(1-3) R=0.487
P=0.034
N=19
LDL S{26-28) R=0.571
P=0.011
N=19
MDAP(1-3) R=0.676
P=0.001
N=19
CHOL P(1-3) R=0.579
P=0.009
N=19
CHOL 5(26-28) R=0.528
P=0.020
N=19
TRIG P(1-3) R=0.685
P=0.001
N=19
TRIG 5(1-3) R=0.486
P=0.030
N=20
R=0.577
P=0.010
N=19
RET P(1-3) R=0.487
P=0.034
N=19
g-TOG P(1-3) R=0.873
P=0.000
N=19
g-TOC P(26-28) R=0.469
P=0.037
N=20
a-TOC P(1-3) R=0.630
P=0.004
N=19
a-TOC 5(1-3) R=0.475
P=0.035
N=20
LYCO P(1-3) R=0.593
P=0.007
N=19
Iodine PFFQ R=0.590
P=0.016
N=16
% Alcohol PFFQ R=0.823
P=0.000
N=17
Garbo SFFQ R=0.498
P=0.036
N=18
Energy Kcal 
SFFQ
R=0.548
P=0.019
N=18
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Starch SFFQ R=0,639
P=0.004
N=18
Sodium SFFQ R=0.500
P=0.035
N=18
Iron SFFQ R=0.548
P=0.019
N=18
%Protein SFFQ R=0.555
P=0.017
N=18
%alcohol SFFQ R=0.815
P=0.000
N=17
Water PFD R=-0.583
P=0.014
N=17
Fat PFD R=0.552
P=0.022
N=17
«
Energy Kcal 
PFD
R=0.508
P=0.037
N=17
PUPA PFD R=0.528
P=0.029
N=17
R=0.551
P=0.022
N=17
Choi PFD R=0.615
P=0.009
N=17
Starch PFD R=0.518
P=0.033
N=17
Selenium PFD R=0.482
P=0.050
N=17
R=0.576
P=0.016
N=17
Vit D PFD R=0.516
P=0.034
N=17
Niacin PFD R=0.497
P=0.042
N=17
%alcohol PFD R=0.508
P=0.037
N=17
Vit DSFD R=0.577 !
P=0.019
N=16
% alcohol SFD R=0.748
P=0.001
N=17
...............  1
Weight R=0.503
P=0.028 ! 
N=19 f
Waist R=0.588
p=o.oi3 ;
N=17
BMI R=0.517
P=0.023
N=19 1
Data compared using pearson correlation and presented {r,P )
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Table 5.A.2; Correlations of Enterolactone excretion with serum lipids, serum
Enterolactone
P(1-3)
Enterolactone
P(26-28)
Enterolactone
8(1-3)
Enterolactone
8(26-28)
b-Cryp P(26-28) R=0.506
P=0.019
N=21
R=0.554
P=0.009
N=21
a-Caro P(1-3) R=0.531
P=0.013
N=21
a-Caro P(26-28) R=0.580
P=0.006
N=21
a-Caro S(1 -3) R=0.573
P=0.007
N=21
R=0.530
P=0.014
N=21
R=0.644
P=0.002
N=21
a-Caro 8(26-28) R=0.453
P=0.039
N=21
R=0.553
P=0.009
N=21
R=0.586
P=0.005
N=21
b-Caro P(1-3) R=0.440
P=0.046
N=21
b-Caro P(26-28) R=0.466
P=0.033
N=21
b-Caro 3(1-3) R=0.501
P=0.021
N=21
R=0.467
P=0.033
N=21
R=0.620
P=0.003
N=21
b-Caro 8(26-28) R=0.484
P=0.026
N=21
R=0.441
P=0.045
N=21
Manganese PFD R=0.487
P=0.035
N=19
Carotene
PFD
R=0.459
P=0.048
N=19
Zinc
SFD
R=0.546
P=0.024
N=T7
Retinol
8FD
R=0.579
P=0.009
N=19
R=0.511
P=0.030
N=18
R=0.517
P=0.028
N=18
Thiamin
8FD
R=0.504
P=0.039
N=17
Riboflavin
8FD
R=0.518
P=0.033
N=17
Data compared using pearson correlation and presented (r ,P )
208
Table 5.A.3: Correlations of Ente rod iol excretion with serum lipids, serum
Enterodiol P(1-3) Enterodiol P(26- 
28)
Enterodiol 3(1-3) Enterodiol 8(26- 
28)
MDA P(1-3) R=0.437
P=0.048
N=21
Choi S(26-28) R=0.436
P=0.048
N=21
VitCP(1-3) R=0.483
P=0.027
N=21
g-TOC P(1-3) R=0.581
P=0.006
N=21
R=0.555
P=0.009
N=21
R=0.706
P=0.000
N=21
a-TOC P(1-3) R=0.450
P=0.041
N=21
Zeax P(1-3) R=0.457
P=0.037
N=21
R=0.515
P=0.017
N=21
Iodine PFFQ R=0.611
P=0.007
N=18
Protein PFD R=0.552
P=0.014
N=19
Carbohydrate
PFD
R=0.502
P=0.034
N=18
Energy Kcal 
PFD
R=0.482
P=0.037
N=19
Nitrogen PFD R=0.553
P=0.014
N=19
PUFA PFD R=0.471
P=0.042
N=19
Choi PFD R=0.501
P=0.029
N=19
Sugar PFD R=0.482
P=0.043
N=18
Fibre 1 PFD R=0.578
P=0.012
N=18
Fibre2 PFD R=0.594
P=0.009
N=18
Potassium PFD R=0.692
P=0.001
N=18
Magnesium PFD R=0.605
P=0.008
N=18
Phosphorous
PFD
R=0.515
P=0.029
N=18
Iron PFD R=0.473
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P=0.041
N=19
Carotene PFD R=0.547
P=0.019
N=18
Vitamin D 
PFD
R=0.659
P=0.002
N=19
R=0.646
P=0.004
N=18
Vitamin E 
PFD
R=0.610
P=0.006
N=19
Niacin PFD R=0.533
P=0.019
N=19
Tryptophan
PFD
R=0.543
P=0.016
N=19
Vit B6 
PFD
R=0.648
P=0.004
N=18
VitB12
PFD
R=0.682
P=0.002
N=18
Pantothenic
PFD
R=0.469
P=0.050
N=18
R=0.634
P=0.004
N=19
Biotin
PFD
R=0.508
P=0.031
N=18
Retinol
SFD
R=0.538
P=0.017
N=19
Vit D SFD R=0.644
P=0.004
N=18
%Fat SFD R=0.511
P=0.025
N=19
%A!cohol SFD R=0.519
P=0.033
N=17
Data compared using pearson correlation and presented (r ,P )
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Table 5.A.4; Correlations of Genistein excretion with serum lipids, serum
Gensitein
P(1-3)
Genistein
P(26-28)
Gensitein
S(1-3)
Genistein
8(26-28)
HDL P(26-28) R=-0.479
P=0.038
N=19
TRIG P(1-3) R=0.525
P=0.021
N=19
TRIG P(26-28) R=0.457
P=0.049
N=19
TRIG S{26-28 R=0.532
P=0-019
N=19
Retin P(1-3) R=0.486
P=0.025
N=21
Vit 0  S(26-28) R=-0.482
P=0.043
N=18
Lutein P(T3) R=-0.451
P=0.046
N=20
Lutein P(26-28) R=0.492
P=0.023
N=21
Lutein S(1-3) R=0.544
P=0.011
N=21
Lutein 8(26-28) R=0.501
P=0.021
N=21
Zeax P(26-28) R=-0.463
P=0.040
N=20
Zeax 8(26-28) R=-0.486
P=0.035
N=19
BCryp P(1-3) R=0.464
P=0.034
N=21
Bcryp P(26-28) R=0.467
P=0.033
N=21
a-Caro P(1-3) R=0-439
P=0.046
N=21
R=-0.542
P=0.013
N=20
b-Caro P(1-3) R=-0.630
P=0.003
N=20
b-Caro 8(26-28) R=-0.446
P=0.049
N=20
Lyoo P(1-3) R=-0.658
P=0.002
N=20
Carotene PFFQ R=0.527
P=0.020
N=19
% Alcohol PFFQ R=0.687
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P=0.002
N=18
Water PFD R=0.524
P=0.026
N=18
Iodine PFD R=0.483
P=0.043
N=18
Niacin PFD R=0.560
P=0.016
N=18
Vitamin C PFD R=0.517
P=0.023
N=19
% Alcohol PFD R=0.494
P=0.037
N=18
Carotene SFD R=-0.526
P=0.030
N=17
Thiamin SFD R=0.525
P=0.021
N=19
Riboflavin SFD R=0.462
P=0.046
N=19
%Protein SFD R=-0.478
P=0.045
N=18
R=-0.501
P=0.041
N=17
%Alcohol SFD R=0.540
P=0.021
N=18
Age R=0.512
P=0.025
N=19
Weight R=0.648
P=0.003
N=19
Waist R=0.579
P=0.015
N=17
Hip R=0.659
P=0.004
N=17
BMI R=0.574
P=0.010
N=19
Data compared using pearson correlation and presented (r ,P )
212
Table 5.A.5; Correlations of Daidzein excretion 
antioxidants, dietary intake and anthropometric
with serum lipids, serum
measurements (pre and
Daidzein
P(1-3)
Daidzein
P(26-28)
Daidzein
8(1-3)
Daidzein
5(26-28)
RETIN P(26-28) R=0.449
P=0.041
N=21
G-Toc S(1-3) R=0.498
P=0.022
N=21
G-Toc 5(26-28) R=0.485
P=0.026
N=21
A-Toc 8(1-3) R=0.464
P=0.034
N=21
b-Cryp P{26-28) R=0.445
P=0.043
N=21
b-Cryp 5(26-28) R=0.539
P=0.012
N=21
a-Caro P(26-28) R=0.469
P=0.032
N=21
Garbo PFD R=0.710
P=0.001
N=19
Energy Kcal 
PFD
R=0.548
P=0.015
N=19
5tarch PFD R=0.589
P=0.008
N=19
5ugar PFD R=0.54-
P=0.017
N=19
Fibre 1 
PFD
R=0.550
P=0.018
N=18
R=0.478
P=0.039
N=19
R=0.811
P=0.000
N=19
Fibre 2 
PFD
R=0.627
P=0.005
N=18
R=0.512
P=0.025
N=19
R=0.689
P=0.001
N=19
Potassium
PFD
R=0.595
P=0.009
N=18
R=0.574
P=0.010
N=19
Magnesium
PFD
R=0.584
P=0.011
N=18
R=0.620
P=0.005
N=19
Phosphorous
PFD
R=0.479
P=0.038
N=19
Iron
PFD
R=0.527
P=0.025
N=18
R=0.565
P=0.012
N=19
Copper
PFD
R=0.619
P=0.006
N=18
Zinc
PFD
R=0.558
P=0.016
R=0.493
P=0.032
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N=18 N=19
Manganese
PFD
R=0.604
P=0.006
N=19
R=0.780
P=0.000
N=18
R=0.70
P=0.001
N=19
R=0.630
P=0.004
N=19
Riboflavin
PFD
R=0.536
P=0.022
N=18
Nicain
PFD
R=0.522
P=0.026
N=18
VitB6
PFD
R=0.610
P=0.007
N=18
R=0.560
P=0.013
N=19
VitB12
PFD
R=0.607
P=0.001
N=18
Folate
PFD
R=0.562
P=0.015
N=18
R=0.528
P=0.020
N=19
Pantothenic
PFD
R=0.692
P=0.001
N=18
R=0.516
P=0.024
N=19
R=0.581
P=0.009
N=19
Biotin
PFD
R=0.557
P=0.016
N=18
R=0.508
P=0.026
N=19
Water SFD R=0.543
P=0.024
N=17
Protein SFD R=0.577
P=0.015
N=17
Fat SFD R=0,577
P=0.012
N=18
Cabo SFD R=0.474
P=0.047
N=18
R=0.584
P=0.011
N=18
Energy Kcal 
SFD
R=0.549
P=0.018
N=18
R=0.512
P=0.030
N=18
Nitrogen SFD R=0.577
P=0.015
N=17
SFA SFD R=0.468
P=0.050
N=18
MUFASFD R=0.588
P=0.010
N=18
Sugar SFD R=0.543
P=0.020
N=18
Fibre 1 SFD R=0.557
P=0.016
N=18
R=0.482
P=0.043
N=18
Fibre 2 SFD R=0.523
P=0.026
N=18
R=0.513
P=0.035
N=17
R=0.552
P=0.018
N=18
Magnesium SFD R=0.526
P=0.025
N=18
R=0.653
P=0.004
N=17
R=0.534
P=0.022
N=18
Phosphorous R=0.606 R=0.479
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SFD P=0.010
N=17
P=0.044
N=18
Iron SFD R=0.667
P=0.003
N=18
R=0.644
P=0.005
N=17
R=0.559
P=0.016
N=18
Copper SFD R=0.544
P=0.01G
N=19
R=0.616
P=0.007
N=18
R=0.574
P=0.016
N=17
Zinc SFD R=0.485
P=0.041
N=18
R=0.670
P=0.003
N=17
Manganese
SFD
R=0.605
P=0.006
N=19
R=0.683
P=0.002
N=18
R=0.745
P=0.001
N=17
Selenium SFD R=0.621
P=0.006
N=18
R=0.635
P=0.006
N=17
R=0.668
P=0.002
N=18
Retinol SFD R=0.542
P=0.020
N=18
Vit D SFD R=0.493
P=0.038
N=18
Thiamin SFD R=0.614
P=0.007
N=18
R=0.541
P=0.025
N=17
Riboflavin SFD R=0.698
P=0.002
N=17
Niacin SFD R=0.649
P=0.005
N=17
R=0.551
P=0.018
N=18
Tryptophan SFD R=0.555
P=0.021
N=17
Vit B6 SFD R=0.541
P=0.025
N=17
R=0.471 
P=0 048 
N=18
Vit B12 SFD R=0.632
P=0.005
N=18
R=0.667
P=0.003
N=17
R=0.778
P=0.000
N=18
Folate SFD R=0.563
P=0.019
N=17
Pantothenic SFD R=0.461
P=0.047
N=19
R=0.533
P=0.023
N=18
R=0.611
P=0.009
N=17
Biotin SFD R=0.522
P=0.022
N=19
Age R=0.495
P=0.022
N=21
Data compared using pearson correlation and presented (r ,P)
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Table 5.A.6; Correlations of serum concentrations of Isoflavones (ug/day) in
Pre-menopausal women with Serum IGF-1, BP-3 and BP-1 throughout the
Genistein
Supp/post
Daidzein
Supp/post
Equol
Placeb/ba
se
Equol
Placeb/po
St
Equol
Supp/base
Equol
Supp/post
IGF1
Placebo(day1-3)
R=0.638
P=0.014
N=14
IGF1
Placebo(day 6-8)
R=0.736
P=0.015
N=10
IGF1
PIacebo(day12-15)
R=-0.741
P=0.002
N=15
IGF1
Placebo(day21-23)
R=0 548 
P=0.042 
N=14
IGF1
Supp(day1-3)
R=0.619
P=0.018
N=14
R=0.541
P=0.046
N=14
IGF1
Supp(day12-15)
R=0.600
P=0.030
N=13
BP3
Placebo(day6-8)
R=0 631 
P=0.016 
N=14
BP1
Placebo(day1-3)
R=-0.566
P=0.035
N=14
BP1
Supp(day12-15)
R=-0.597
P=0.031
N=13
Data compared using pearson correlation and presented {r ,P)
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Table 5.A.7: Correlations of serum concentrations of Enterolactone (ug/day) in
pre-menopausal women with Serum IGF-1, BP-3 and BP-1 throughout the
Enterolactone
Placebo/Base
Enterolactone
Placebo/post
Enterolactone
Supp/post
BP-1 Placebo (day1-3) R=0.590
P=0.026
N=14
R=0.505
P=0.055
N=15
R=0.655
P=0.011
N=14
BP-1 Placebo (day 6-8) R=0.639
P=0.019
N=13
R=0.574
P=0.032
N=14
R=0.733
P=0.007
N=12
BP-1 Placebo (day 12-15) R=0.528
P=0.052
N=14
R=0.454
P=0.089
N=15
R=0.716
P=0.004
N=14
BP-1 Placebo (day 21-23) R=0.731
P=0.003
N=14
R=0.59
P=0.021
N=15
R=0.741
P=0.002
N=14
BP-1 Placebo (day 26-28) R=0.664
P=0.010
N=14
R=0.525
N=0.045
N=15
R=0.709
P=0.005
N=14
BP-1 Supp (day 1-3) R=0.686
P=0.007
N=14
R=0.604
P=0.017
N=15
R=0.811
P=0.000
N=14
BP-1 Supp (day 6-8) R=0.652 
P=0.011 
N=14
R=0.550
P=0.034
N=15
R=0.775
P=0.001
N=14
BP-1 Supp (day 12-15) R=0.673
P=0.012
N=13
BP-1 Supp (day 21-23) R=0.684
P=0.007
N=14
R=0.578
P=0.024
N=15
R=0.782
P=0.001
N=14
BP-1 Supp (day 26-28) R=0.710
P=0.004
N=14
IGF-1 Supp (day 26-28) R=-0.670
P=0.009
N=14
Data compared using pearson correlation and presented {r ,P )
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Table 5.A.8: Correlations of serum concentrations o Isoflavones (ug/day) in post-menopausal women with Serum GF-1, BP-3 and BP-1.
Genistein
Placebo
base
Genistein
Placebo
post
Genistein
Supp
post
Daidzein
Placebo
base
Daidzein
Placebo
post
Daidzein
Supp
post
Equol
Placebo
Post
Equol
Supp
Base
Equol
Supp
Post
Enterelact
Placebo
base
IGF1
Placebo base
R=0.804
P=0.029
N=7
R=0.806
P=0.029
N-7
IGF1
Placebo Post
R=0.917
P=0.028
H=5
IGF1
Supp Base
R=0.98S
P=O.OOS
N=5
R=0.791
P=0.0S4
N=7
IGF1
Supp Post
R=0.967
P=0.002
N=6
R=0.914
P=0.004
N=7
R=0,313
R=0.034
N=7
BPS
Placebo Base
R=0.989
P=0.001
N=5
BPS
Placebo Post
R=0.898
P=0.0S8
N=5
R=0.912
P=0.0S1
N=5
BPS
Supp Base
R=0.9S8
P=0.018
N=5
BPS
Supp Post
R=0.920
P=0.009
N=6
R=0.93S
P=0.020
N=5
BP1
Placebo Base
R=0.931
P=0.021
N=5
BP1
Supp Base
R=-0.940
P=0.017
N=5
BP1
Supp Post
-
R=-0.776
P=0.040
N=7
R=0.804
P=0.029
N=7
R=-0.881
P=0.009
N=7 .
Data compared using pearson correlation and presented (r ,P )
Table 5.A.9: Correlations of hormones with excretion of Isoflavones (ug/day) in post-menopausal women.
Enterodiol
P(1-3)
Ug/day
Enterodiol
P(26-28)
Ug/day
Enterodiol
5(1-3)
Ug/day
Enterodiol
S(26-28)
Ug/day
Equol
P(1-3)
Ug/day
Equol
5(1-3)
Ug/day
Equol
S(26-28)
Ug/day
Daid
6(26-28)
Genistein
P(1-3)
Ug/day
Genistein
5(1-3)
Ug/day
Enterolactone
P(26-28)
Ug/day
Enterolactone
5(1-3)
Ug/day
Progesterone
P(1-3)
R=0.954
P=0.003
N=6
Progesterone
P(26-28)
R=0.919
P=0.003
N=7
Progesterone
8(26-28)
R=0.761
P=0.047
N=7
R=-0.970
P=0.006
N=5
SHBG
P(1-3)
R=0.834
P=0.039
N=6
R=0.875
P=0.010
N=7
R=0.836
P=0.019
N=7
R=0.906
P=0.005
N=7
SHBG
P(26-28)
R=0.809
P=0.027
N=7
R=0.837
P=0.019
N=7
R=0.852
P=0.015
N=7
R=-0.792
P=0.034
N=7
SHBG
S(1-3)
R=0.886
P=0.008
N=7
R=-0.841
P=0.018
N=7
SHBG
S(26-28)
R=0.817
P=0.025
N=7
R=-0.834
P=0.020
N=7
Estrodiol
5(1-3)
R=-0.890
P=0.043
N=5
Estrodiol
P(26-28)
R=0.939
P=0.018
N=5
LH
P(1-3)
R=0.713
P=0.042
N=7
LH
P(26-28)
R=0.787
P=0.036
N=7
LH R=0.797 R=0.760
8(1-3) P=0.032
N=7
P=0.047
N=7
FSH
P(1-3)
R=0.834
P=0.020
N=7
R=-0.797
P=0.032
N=7
FSH
8(1-3)
R=-0.839
P=0.018
N=7
F8H
8(26-28)
R=0.759
P=0.048
N=7
R=-0.763
P=0.046
N=7
Data compared using pearson correlation and presented {r,P )
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Table 5.A. 10: Correlations of hormones with excretion of Isoflavones (ug/day) in pre-menopausal women.
Enterodiol
P(1-3)
Ug/day
Enterodiol
P(26-28)
Ug/day
Equol
P(1-3)
Ug/day
Equol
P(26-
28)
Ug/day
Equol
S(1-3)
Ug/day
Daid
P(1-3)
Ug/day
Daid
S(1-3)
Ug/day
Daid
S(26-
28)
Ug/day
Genistein
P(1-3)
Ug/day
Enterolactone
P(1-3)
Ug/day
Enterolactone
P(26-28)
Ug/day
Enterolactone
S(1-3)
Ug/day
Enterolactone
8(26-28)
Ug/day
Progesterone
8(1.3)
R=0.653
P=0.011
N=14
R=0.617
P=0.014
N=
R=0.760
P=0.002
N=14
Progesterone
8(12-15)
Progesterone
8(21-23)
R=0.620
P=Q.018
N=14
R=0.588
P=0.034
N=13
R=0.589
P=0.027
N=14
R=0.669
P=0.012
N=13
Progesterone
3(26-28)
R=-0.708
P=0.007
N=13
R=-0.598
P=0.031
N=13
SHBG
P(1-3)
r=-0.626
P=0.017
N=14
SHBG
8(1-3)
R=-0.535
P=0.049
N=14
SHBG
P(6-8)
R=-0.580
P=0.038
N=14
R=0.645
P=0.017
N=13
R=0,539
P=0.047
N=14
R=0.696
P=0.008
N=13
SHBG
8(6-8)
R=-0.583
P=0.029
N=14
SHBG
P(12-15)
R=-0.654
P=0.011
N=14
R=-0.664
P=0.013
N=13
SHBG
8(12-15)
R=-0.599
P=0.030
N=14
SHBG
P(21-23)
R=-0.563
P=0.036
N=14
SHBG
8(21-23)
R=-0-578
P=0.03
N=14
R=-0.579
P=0.030
N=14
SHBG
P(26-281
R=-0.613
P=0.020
R=0.583
P=0.029
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N=14 N=14
SHBG
8(26-28)
R=-0.554
P=0.049
N=13
R=-0-534
P=0.049
N=14
Estrodiol
P(1-3)
R=0.564
P=0.028
N=15
Estrodiol
3(1-3)
Estrodiol
P{6-8)
R=0.796
P=0.001
N=13
R=0.539
P=0.047
N=14
R=0.950
P=0.000
N=13
R=0.907
P=0.000
N=14
R=0.959
P=0.000
N=12
Estrodiol
5(6-8)
R=0.568
P=0.027
N=15
Estrodiol
P(26-28)
R=-0.619
P=0.014
N=15
LH
P(1-3)
R=0.564
P=0.036
N=14
LH
P(6-8)
R=0.628
P=0.022
N=13
R=0.571
P=0.041
N=13
R=0.604
P=0.029
N=13
LH
8(6-8)
R=0.825
P=0.000
N=14
R=0.870
P=0,009
N=14
R=0.641
P=0.014
N=14
R=0.553
P=0.040
N=14
LH
P(12-15)
R=0,535
P=0.049
N=14
LH
8(12-15)
R=0.661
P=0.014
N=13
LH
P(21-23)
R=0.812
P=0.000
N=14
R=0,555
P=0.039
N=14
R=0.702
P=0.005
N=14
R=0.534
P=0.049
N=14
LH
8(21-23)
LH
P(26-28)
R=0.670
P=0.009
N=14
LH
8(26-28)
R=0.573
P=0.041
N=13
R=0.732
P=0.004
N=13
R=0.648
P=0.017
N=13
F8H
,222
P(1-3)
FSH
S(1-3)
R=0.706
P=0.005
N=14
R=0.820
P=0.000
N=14
FSH
P(6-8)
R=0.771
P=0.002
N=13
R=0.851
P=0.000
N=13
R=0.577
P=0.039
N=13
FSH
S(6-8)
R=0.744
P=0.002
N=14
R=0.866
P=0.000
N=14
R=0.540
P=0.046
N=14
FSH
P(12-15)
R=0.849
P=0.000
N=14
R=0.880
P=0.000
N=14
R=0.623
P=0.017
N=14
FSH
8(12-15)
R=0.796
P=0.001
N=13
R=0.B26
P=0.001
N=13
R=0.614
P=0.026
N=13
R=0.767
P=0.002
N=13
FSH
P(21-23)
R=0.871
P=0.000
N=14
R=0.829
P=0.000
N=14
R=0.562
P=0.036
N=14
R=0.645
P=0.013
N=14
FSH
S(21-23)
R=0.635
P=0.015
N=14
FSH
P(26-28)
R=0.690
P=0.004
N=15
R=0.671
P=0.009
N=14
R=0.688
P=0.005
N=14
R=0.677
P=0.008
N=14
R=0.576
P=0.031
N=14
FSH
8(26-28)
R=0.765
P=0.002
N=13
R=0.709
P=0.007
N=13
R=0.713
P=0.006
N=13
R=0.696
P=0.008
N=13
Data compared using pearson correlation and presented (r,P )
Table 5.A.11: Correlations of Estradiol and Progesterone with IGF-1, BP-3 and BP-
Estradiol
Placebo
(6-8)
Estradiol
Placebo
(21-23)
Estradiol
Supplement
(12-14)
Estradiol
Supplement
(21-23)
Proges
Supplement
(1-3)
Proges
Supplement
(6-8)
Proges
Supplement
(12-14)
IGF-1 (1-3) placeb -0.54, 0.031
supp -0.64. 0.008
IGF-1 (6-8) placeb
supp -0.61, 0.012 -0.72, 0.002
IGF-1 (12- 
14)
placeb
supp -0.76, 0.001
IGF-1 (21- 
23)
placeb -0.64, 0.008
supp -0.65, 0.006 -0.55, 0.032
IGF-1 (26- 
26)
placeb
supp -0.53, 0.04 -0.54, 0.038 -0.68, 0.008
BP-3 (1-3) Placeb
supp -0.51, 0.045
BP-3 (6-8) placeb -0.60, 0.030
supp -0.56, 0.023
BP-3 (12-
14)
Place
supp -0.53, 0.041 -0.58, 0.025
BP-3 (21- 
23)
Placeb
supp
BP-3 (26- 
28)
Placeb
supp
BP-1 (1-3) placebo 0.61, 0.020 0.508, 0.045 0.69, 0.004
supp 0.74, 0.003 0.79, 0.000 0.78, 0.001
BP-1 (6-8) placebo 0.66, 0.010 0.63, 0.016 0.75, 0.003
supp 0.68, 0.007 0.56, 0.023 0.65, 0.006 0.64, 0.01
BP-1 (12- 
_14)
placebo 0.56, 0.04 0.53, 0.034 0.67, 0.006 0.71, 0.003
supp 0.505, 0.055 0.59, 0.022 0.53, 0.043
BP-1 (21- 
23)
placebo 0.73, 0.003 0.55, 0.026 0.63, 0.009
supp 0.69, 0.006 0.511, 0.043 0.69, 0.003 0.66, 0.008
BP-1 (26- 
28)
Placebo 0.69,0.006 0.61,0.012 0.62,0.013
supp 0.63,0.012 0.49, 0.063 0.63, 0.016
in pre-menopausal women (n=16)
Data compared using pearson correlation and presented {r ,P )
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Table 5.A.12: Correlations of SHBG with IGF-1 and BP-1 in pre­menopausal women (n=16).
SHBG (Placebo phase) SHBG (Supplement phase)
1-3 6-8 12-14 21-23 26-28 1-3 6-8 12-14 21-23 26-28
IGF-1 (1-3) placebo -0.54,
0.036
-0.48, 0.061 -0.54, 0.036 -0.54, 0.039
supp -0.53,
0.044
IGF-1 (6-8) placebo
supp -0.55,
0.034
-0.56,
0.029
-0.54,
0.034
IGF-1 (12- 
14)
placebo
supp -0.57,
0.032
supp -0.62,
0.014
BP-1 (1-3) placebo 0.55,
0.027
0.74,
0.002
0.73,
0.002
0.6,
0.014
0.61,
0.011
0.61,
0.012
0.58,
0.022
0.58,
0.017
0.60,
0.019
supp 0.59.
0.016
0.75,
0.001
0.77,
0.001
0.63,
0.009
0.66,
0.005
0.60
0.015
0.59,
0.019
0.56,
0.023
0.62,
0.013
BP-1 (6-8) placebo 0.62,
0.019
0.76,
0.001
0.74,
0.002
0.63,
0.016
0.65,
0.011
0.60,
0.023
0.63,
0.022
0.57,
0.034
0.61,
0.028
supp 0.63,
0.009
0.78,
0.001
0.75,
0.001
0.67,
0.004
0.66
0.005
0.66,
0.005
0.51,
0.042
0.61,
0.017
0.61,
0.011
0.66,
0.008
BP-1 (12- 
14)
placebo 0.55,
0.027
0.62,
0.014
0.62,
0.014
0.56,
0.023
0.58,
0.019
0.49,
0.053
supp 0.50,
0.055
0.54,
0.050
0.57,
0.032
0.52,
0.048
0.57,
0.028
0.51,
0.051
BP-1 (21- 
23)
placebo 0.68,
0.005
0.66,
0.007
0.53,
0036
0.54,
0.031
0.53,
0.043
0.50,
0.051
0.57,
0.026
supp 0.59,
0.021
0.65,
0.09
0.50,
0.049
0.48,
0.07
BP-1 (26- 
28)
placebo 0.62,
0.013
0.56
0.037
0.50,
0.049
0.50,
0.06
supp 0.55,
0.033
0.57,
0.032
Data compared using pearson correlation and presen ed { r , P)
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Table 5.A.13: Correlations of hormones with IGF-1, BP-1 and BP-3 in post -
LH
(PI)
LH
(S28)
Prog
(P28)
Prog
(S28)
SHBG
(P1)
SHBG
(P28)
BP1
(PI) _
0.78,
0.037
BP1
(SI)
0.75,
0.050
BP3
(SI)
-0.78,
0.039
IGF-1
(PI)
0.81,
0.028
0.77,
0.043
IGF-1
(P28)
-0.85,
0.016
-0.93,
0.0023
IGF-1
(S28)
0.79,
0.033
Data compared using pearson corre ation and presented ( r ,P)
226
Table 5.A.14; Correlations of serum concentrations of IGF-1 & BP-1 and Serum
Lipids (no correlations seen with BP-3) in pre-menopausal women.
HDL
S(1-3)
HDL
P(26-
28)
HDL
S(26-
28)
Trig
P(1-3)
Trig
S(1-3)
Trig
P(26-
28)
Trig
S(26-
28)
Choi
P(1-3)
BP1
S(1-3)
R=0.622
P=0.010
N=16
R=0.584
P=0.018
N=16
R=0.549
P=0.028
N=16
BP1
S(6-8)
R=0.551
P=0.027
N=16
R=-
0.523
P=0.038
N=16
BP1
P(12-
15)
R=0.555
P=0.026
N=16
BP1
S(12-
15)
R=0.756
P=0.001
N=15
R=0,533
P=0.041
N=15
R=0.629
P=0.012
N=15
BRI
P(21-
23)
R=-
0.538
P=0.032
N=16
BP1
S(21-
23)
R=0.600
P=0.014
N=16
BP1
S(26-
28)
R=0.635
P=0.011
N=15
R=0.522
P=0.046
N=15
IGF-1
P(1-3)
R=0.748
P=0.001
N=16
R=0.676
P=0.004
N=16
R=0.699
P=0.003
N=16
R=0.504
P=0.046
N=16
IGF-1
S(1-3)
R=0.510
P=0.027
N=16
R=0.822
P=0.000
N=16
R=0.565
P=0.022
N=16
R=0.538
P=0.032
N=16
IGF-1
P(6-8)
R=0.608
P=0.023
N=14
IGF-1
S(6-8)
R=0.576
P=0.019
N=16
IGF-1
S(12-
15)
R=0.671
P=0.006
N=15
IGF-1
P(21-
23)
R=-
0.534
P=0.033
N=16
R=-
0.509
P=0.044
N=16
R=0.713
P=0.002
N=16
R=0.594
P=0.015
N=16
R=0.502
P=0.048
N=16
R=0.678
P=0.004
N=16
IGF-1
S(21-
23)
R=0.604
P=0.013
N=16
IGF-1
P(26-
28)
R=0.550
P=0.027
N=16
R=0.504
P=0.047
N=16
IGF-1
S(26-
28)
R=-
0.530
P=0.042
N=15
R=-
0.528
P=0.043
N=15
Data compared using pearson correlation and presented ( r , P)
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Table 5.A.15: Correlations of serum concentrations of IGF1 with Serum
antioxidants in pre menopausal women.
IGF-1
P(1-3)
IGF-1
S(1-3)
IGF-1
P(6-8)
IGF-1
S{6-8)
IGF-1
P(12-
_15)
IGF-1
S(12- 
.15)
IGF-1
P(21-
23)
IGF-1
P(26-
28)
Retinol
P(1-3)
R=0.503
P=0.047
N=16
R=0.586
P=0.017
N=16
Retinol
S(1-3)
R=-
0.655
P=0.006
N=16
R=- 
0.509 
P=0.044 
N=16
R=-
0.591
P=0.016
N=16
R=- s 
0.509 ' 
P=0.04 
N=16
Vite
S(1-3)
R=-
0.567
P=0.035
N=14
Vite
S(26-28)
R=-
0.540
P=0.046
N=14
G- Tocoph 
P(1-3)
R=0.600
P=0.014
N=16
G- Tocoph 
P(6-8)
R=-
0.501
P=0.046
N=14
A-Tocoph
P(26-28)
R=0.623
P=0.010
N=16
Lutein
pa-3)
R=0.503
P=0.047
N=16
R=0.533
P=0.041
N=15
Zeaxanthyn
P(1-3)
R=0.535
P=0.040
N=15
Bcryp
S(1-3)
R=-
0.519
P=0.040
N=16
R=-
0.557
P=0.025
N=16
Bcryp
P{26-28)
R=-
0.495
P=0.050
N=16
Lycopene
S(1-3)
r R=.
0.557
P=0.025
N=16
R=-
0.636
P=0.015
N=14
R=-
0.610
P=0.012
N=16
Lycopene
P{26-28)
R=-
0.585
P=0.028
N=14
MDA
P(1-3)
R=0.615
P=0.011
N=16
R=0.500
P=0.048
N=16
MDA
S(1-3)
R=0.533
P=0.033
N=16
Data compared using pearson correlation and presented (r , P)
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Table 5A 16: Correlations of serum concentrations of BP1 and Serum
antioxidanls in premenopausal women.
BP1
S(1-3)
BP1
P(6-8)
BP1
3(6-8)
BP1
3(21-23)
BP1
P(26-28)
B-Carotene
S(1-3)
R=0.580
P=0.018
N=16
R=0.635
P=0.015
N=14
R=0.655
P=0.006
N=16
R=0.570
P-0.021
N=16
B-Carotene
3(26-28)
R=0.575
P=0.020
N=16
R=0.540
P=0.046
N=14
A-Carotene
8(1-3)
R=0.606
P=0.013
N=16
R=0.587
P=0.027
N=14
R=0.656
P=0.006
N=16
R=0.631
P=0.009
N=16
A-Carotene
P(26-28)
R=0.519
P=0.039
N=16
A-Carotene
3(26-28)
R=0.661
P=0.005
N=16
R=0.569
P=0.034
N=14
R-0.585
P=0.017
N=16
Lycopene
3(1-3)
R=0.652
P=0.012
N=14
R=0.561
P=0.024
N=16
A-Tocoph
P(26-28)
R=0.532
P=0.034
N=16
Data compared using pearson correlation and presented (r ,P )
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Table 5.A.17: Correlations of serum concentrations of BP-3 and Serum antioxidants in pre-menopausal women.
BP3
P(1-3)
BP3
8(1-3)
BP3
P(6-8)
BP3
8(6-8)
BP3
P(12-14)
BP3
8(12-14)
BP3
P(21-23)
BP3
8(21-23)
BP3
P(26-28)
BP3
8(26-28)
Retinol
3(1-3)
R=0.540
P=0.031
N=16
R=0.576
P=0.020
N=16
R=0.718
P=0.002
N=16
R=0.738
P=0.002
N=15
Retinol
P(26-28)
R=0,635
P=0.008
N=16
R=0.626
P=0.017
N=14
R=0.499
P=0.049
N=16
R=0.586
P=0.022
N=15
R=0.589
P=0.016
N=16
R=0.638
P=0.008
N=16
R=0.697
P=0.004
N=15
Retinol
8(26-28)
R=0.565
P=0.028
N=15
G-tocoph
8(1-3)
R=0.589
P=0.027
N=14
G-tocoph
8(26-28)
R=0.552
P=0.027
N=16
R=0.520
P=0.039
N=16
R=0.633
P=0.015
N=14
R=0.50
P=0.049
N=16
R=0.584
P=0.017
N=16
R=0.573
P=0.026
N=15
R=0.519
P=0.039
N=16
R=0.574
P=0.020
N=16
R=0.536
P=0.040
N=15
a-tocoph
8(1-3)
R=0.582
P=0.018
N=16
Zeaxan
P(26-28)
R=0.575
P=0.20
N=16
B-cryp
P(1-3)
R=0.598
P=0.014
N=16
B-cryp
P(26-28)
R=0.545
P=0.044
N=14
R=0.539
P=0.031
N=16
R=0.666
P=0.007
N=15
R=0.595
P=0.015
N=16
R=0.548
P=0.028
N=16
R=0.649
P=0.006
N=16
R=0.579
P=0.024
N=15
B-cryp
8(1-3)
R=0.581
P=0.029
N=14
R=0.611
P=0.015
N=15
R=0.603
P=0.013
N=16
R=0.609
P=0.016
N=15
A-Caro
P(26-28)
R=0.570
P=0.021
N=16
R=0.546
P=0.035
N=15
B-Caro
P(26-28)
R=0.523
P=0.038
N=16
Lyco
P(26-28)
R=0.613
P=0.011
N=16
MDA
S(1-3)
R=-0.588
P=0.017
N=16
R—0.519
P=0.039
N=16
R=-0.503
P=0.047
N=16
MDA
8(26-28)
R=-0.590
P=0.016
N=16
R=-0.702
P=0.005
N=14
R=-0.550
P=0.027
N=16
R=-0.641
P=0.007
N=16
R=-0.676
P=0.004
N=16
R=-0.527
P=0.036
N=16
R=-0.514
P=0.050
N=15
Data compared using pearson correlation and presented (r,P  )
Table 5.A.18: Correlations of serum concentrations of IGF-1, & BP-1 with
anthropometric data in premenopausal women.
Waist Weight Height BMI Hip
IGF
P(1-3)
R=0.669
P=0.009
N=14
R=0.561
P=0.024
N=16
R=0.627
P=0.009
N=16
R=0.712
P=0.004
N=14
IGF-1
S(1-3)
R=0.538
P=0.047
N=14
R=0.626
P=0.009
N=16
R=0.527
P=0.036
N=16
R=0.615
P=0.019
N=14
IGF-1
P(6-8)
R=0.587
P=0.027
N=14
R=0.575
P=0.040
N=13
IGF-1
S(6-8)
R=0.501 
P=0 048 
N=16
IGF-1
P(21-23)
R=0.560
P=0.024
N=16
R=0.551
P=0.041
N=14
IGF-1
3(21-23)
R=0.513
P=0.042
N=16
IGF-1
3(26-28)
R=0.528
P=0.043
N=15
BP1
P(1-3)
R=-0.54
P=0.031
N=16
BP1
8(1-3)
R=-0.499
P=0.049
N=16
BP1
P(6-8)
R=-0.557
P=0.048
N=13
R=-0.59
P=0.026
N=14
R=-0.627
P=0.016
N=14
R=-0.615
P=0.025
N=13
BP1
8(6-8)
R=-0.625
P=0.010
N=16
R=-0.586
P=0.017
N=16
R=-0.551
P=0.041
N=14
BP1
P(12-15)
R=-0.534
P=0.033
N=16
BP1
P(21-23)
R=-0.604
P=0.013
N=16
R=-0.537
P=0.032
N=16
R=-0.600
P=0.023
N=14
BP1
3(21-23)
R=-0.642
P=0.007
N=16
R=-0.512
P=0.043
N=16
R=-0.512
P=0.043
N=16
BP1
3(26-28)
R=-0 639
P=0.010
N=15
Postmen 
IGF-1 
P(1-3) .
R=-0.766
P=0.046
N=7
Postmen
BP-1
P(26-28)
R=0.803
P=0.030
N=7
Data compared using pearson correlation and presented {r ,P )
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Table 5.A.19:Correlations of BP-1 with serum lipids in post-menopausal women.
N.B no correlations seen with BP-3 or IGF-1.
BP1 P(1-3) BP1 P(26-28) BP1 8(26-28)
LDL P(1-3) R=0.830
P=0.021
N=7
R=0.802
P=0.030
N=7
LDL P{26-28) R=0.964
P=0.000
N=7
LDL S(1-3) R=0.792
P=0.034
N=7
R=0-782
P=0.038
N=7
LDL 8(26-28) R=0.899
P=0.006
N=7
MDA P(26-28) R=0.769
P=0.043
N=7
Choi P(1-3) R=0.783
P=0.037
N=7
Choi P(26-28) R=0.925
P=0.003
N=7
Choi 8(1-3) R=0.782
P=0.038
N=7
Data compared using pearson correlation and presented (r ,P ).
Table 5.A.20: Correlations of IGF-1, BP-3 and BP-1 with serum antioxidants in
VitCP(1-
3)
Vit 0  8(1- 
3)
GtocP(1-
3)
Lutein
P(26-28)
Zeax P(1-
3)
Zeax P(26- 
28)
IGF P(1-3) R=-0.862
P=0.013
N=7
IGF P(26- 
28)
R=-0.776
P=0.040
N=7
IGF 8(26- 
28)
R=-0.760
P=0.048
N=7
BPS P(1-3) R=-0.777
P=0.040
N=7
BP3 P{26- 
28)
R=0.822
P=0.023
N=7
R=0.787
P=0.036
N=7
BP1 8(1-3) R=-0.815
P=0.026
N=7
R=-0.775
P=0.041
N=7
R=-0.932
P=0.002
N=7
BRI 8(26- 
28)
R=-0.8000
P=0.031
N=7
Data compared using pearson correlation.
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Table 5.A.21: Correlations of Serum Lipid concentrations and FFQ/FD dietary intake in pre and postmenopausal women (n=23).
Placebo Supplement
Serum Lipids PUFA FFQ Fat FFQ MUFA FFQ SFA
FFQ
CHOL
FFQ
PUFA FFQ Fat FFQ MUFA FFQ %Fat
LDL Placebo/baseline r= 0.461 
P=0.041
LDL
Placebo/post
r=0.533
P=0.016
LDL Supp/baseline r=0.589
P=0.006
r=0.447
P=0.048
Cholesterol
Placebo/baseline
r=0.451
P=0.046
Cholesterol
Placebo/post
r=0.547
P=0.013
r=0.480
P=0.032
r=0.479
P=0.033
Cholesterol
Supp/baseline
r-0.585
P=0.007
r=0.506
P=0.023
r=0.455
P=0.044
MDA Placebo/post r=0.485
P=0.030
r=0.448
P=0.048
r=0.461
P=0.041
r=0.506
P=0.023
r=0.483
P=0.026
MDA Supp/baseline r=0.460
P=0.041
r=0.522
P=0.015
r=0.515
P=0.017
r=0.437
P=0.048
Data compared using pearson correlation and presented ( r ,P)
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Table 5.A.22: Correlations of Serum concentrations of antioxidants with FFQ/FD intake in pre and postmenopausal women (n=23).
Vite VitD VitE Carotene Biotin Retinol
Serum P-ffq P-fd S-fd S-ffq P-fd S-fd S-ffq P-fd S-fd P-ffq S-ffq P-fd S-fd P-ffq S-ffq P-ffq
V ite
P-base
R=0.476
P=0.034
R=0.494
P=0.027
V ite
S-base
R=0.450
P=0.046
V ite
S-post
R=0.476
P=0.034
R=0.524
P=0.021
Retinol
P-base
R=-0.46
P=0.045
R=0.530
P=0.016
G-toc
P-base
R=0.657
P=0.002
R=0.502
P=0.029
R=0.481
P=0.032
G-toc
P-post
R=0.624
P=0.002
R=0.472
P=0.041
G-toc
S-base
G-toc
S-post
R=0-468
P=0.037
a-toc
P-base
R=0.631
P=0.003
R=0.634
P=0.004
a-toc
P-post
R=0.476
P=0.039
a-toc
S-base
a-toc
S-post
R=0.452
P=0.040
Lutein
P-post
R=0.716
P=0.000
R=0.613
P=0.004
Lutein
S-base
R=0.702
P=0.001
R=0.513
P=0.021
Lutein
S-post
R=0.458
P=0.042
R=0.507
P=0.022
R=0.69
P=0.001
R=0.54
P=0.017
R=0.522
P=0.018
Zeax R=0.445 R=0.485
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P-base P=0.049 P=0.03
Zeax
P-post
R=0.662
P=0.001
Zeax
S-base
R=0.654
P=0.002
Zeax
S-post
R=0.506
P=0.023
Bcryp
P-post
R=0.475
P=0.034
R=0.451
P=0.040
Bcryp
S-base
R=0.488
P=0.029
Acaro
P-base
R=0.635
P=0.003
Acaro
P-post
R=0.504
P=0.024
Acaro
S-base
R=0.487
P=0.029
R=0-682
P=0.001
Acaro
S-post
R=0.692
P=0.001
R=0.550
P=0.015
Bcaro
P-base
R=0.610
P=0.004
Bcaro
P-post
R=0.547
P=0.013
Bcaro
S-base
R=0.711
P=0.000
R=0.457
P=0.049
Bcaro
S-post
R=0.642
P=0.002
R=0.522
P=0.022
R=0.447
P=0.048
Lyco
P-post
R=0.542
P=0.014
Lyco
S-base
R=0.629
P=0.003
Lyco
S-post
R=0.627
P=0.002
R=0.50
P=0.022
R=0.468
P=0.038
Data compared using pearson correlation and presented (r ,P )
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Table 5.A.23: Correlations of IGF-1 concentrations with FFQ/FD intake in pre-
IGF-1
P(1-3)
IGF-1
S(1-3)
IGF-1
P(6-8)
IGF-1
S(6-8)
IGF-1
5(12-14)
IGF-1
P(21-23)
IGF-1
5(21-23)
IGF-1
P(26-28)
Carotene 
S FFQ
R=0.657
P=0.015
n=13
Vit B6 
S FFQ
R=0.604
P=0.022
n=14
R=0.545
P=0.044
n=14
VitB12 
S FFQ
R=0.537
P=0.048
n=14
Vit B12 
S FD
R=0.694
P=0.012
n=12
R=0.606
P=0.037
N=12
Biotin 
S FFQ
R=0.627
P=0.016
n=14
R=0.691
P=0.009
n=13
Vite  
S FFQ
R=0.610
P=0.027
n=13
R=0.594
P=0.025
n=14
R=0.557
P=0.038
n=14
PUFA
SFFQ
R=0.637
P=0.019
n=13
R=0.574
P=0.032
n=14
Fat
PFD
R=-0.652
P=0.012
N=13
SFA 
P FD
R=-0.612
P=0.026
N=13
MUFA 
P FD
R=-0.646
P=0.017
N=13
Energy 
P FD
R=-0.581
P=0.037
N=13
Starch 
P FD
R=-0.567
P=0.043
N=13
Sodium 
P FD
R=-0.621
P=0.023
N=13
R=-0.729
P=0.005
N=13
Copper 
P FD
R=-0.566
P=0.044
N=13
R=-0.631
P=0.021
N=13
Chloride 
P FD
R=-0.645
P=0.017
N=13
Selenium 
P FD
R=-0.602
P=0.029
N=13
R=-0,628
P=0.022
N=13
VitD 
P FD
R=0,625
P=0.022
N=13
R=0.605
P=0.037
N=12 1
Vit D 
SFD
R=0.755
P=0.005
N=12
R=0.592
P=0.042
N=12
R=0.630 1 
P=0.028 Î 
N=12 1
VitE 
S FD
R=-0.671
P=0.024
N=11
R=-0.587
P=0,045
N=12 i
Fibre
(Englyst)
SFD
R=-0.725
P=0.008
N=12
j
Data compared using pearson correlation and presented {r , P)
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Table 5.A.24: Correlations o1' BP-1 concentrations with FFQ/FD initake in pre-menopausal women.
BP1
P(1-3)
BRI
S(1-3)
BP1
P(6-8)
BP1
S(6-8)
BP1
P(12-14)
BP1
S(12-14)
BP1
P(21-23)
BP1
Sf21-23)
BP1
P(26-28)
BP1
S(26-28)
Carotene
PFFQ
R=0.557
P=0.048
N=13
%Carbo
PFFQ
R=0.668
P=0.018
N=12
Protein
SFFQ
R=-0.558
P=0.027
N=14
Magnesium
SFFQ
R=-0.575
P=0.031
N=14
Phosphorous
SFFQ
R—0.556
P=0.039
N=14
Tryptophan
SFFQ
R=-0.578
P=0.030
N=14
Water
PFD
R=-0.585
P=0.045
N=12
Manganese
PFD
R=-0.588
P=0.044
N=12
Selenium
SFD
R=-0.634
P=0.027
N=12
Iodine 
S FD
R=-0.597
P=0.041
N=12
R—-0.607
P=0.022
N=12
R=-0.651
P=0.022
N=12
VitE
SFD
R=0.626
P=0.029
N=12
R=0.635
P=0.027
N=12
R=0.742
P=0.009
N=11
R=0.7221
P=0.008
N=12
R=0.745
P=0.005
N=12
R=0.649
P=0.002
N=12
R=0.608
P=0.036
N=12
Vit B12 
SFD
R=-0.655
P=0.021
N=12
R -0.593
P=0.041
N=12
R=-0.664
P=0.026
N=11
Vit B6 
PFFQ
R=0.578
P=0.049
N=12
Data compared using pearson correlation and presented ( r , P)
Table 5.A.25; Correlations o ' BP-3 concentrations with FFQ/FD intake in pre-menopausal women.
BP3
P(1-3)
BP3
3(1-3)
BP3
P(6-8)
BP3
3(6-8)
BP3
P(12-14)
BP3
3(12-14)
BP3
P(21-23)
BP3
3(21-23)
BP3
P(26-28)
BPS
8(26-28)
Carbo
PFFQ
R=-Q.632
P=0.021
N=13
R=-0.577
P=0.049
N=12
R=-0.647
P=0.017
N=13
R=-0.580
P=0.038
N=13
R=-0.631
P=0.021
N=13
Starch
SFD
R=-0.705
P=0.015
N=11
Sugar
PFFQ
R=-0.565
P=0.044
N=13
R=-0.640
P=0.018
N=13
Fibre Southgate 
PFFQ
R=-0.643
P=0.018
N=13
R=-0.658
P=0.015
N=13
R=-0.674
P=0.012
N=13
R=-0.621
P=0.023
N=13
R=-0.611
P=0.035
N=12
R=-0,577
P=0.039
N=13
Fibre Southgate 
SFFQ
R=-0.546
P=0.043
N=14
R—0.566
P=0.035
N=14
R—0.553
P=0.040
N=14
Fibre 
Englyst 
P FFQ
R=-0.587
P=0.035
N=13
R=-0.597
P=0.031
N=13
R=-0.560
P=0.047
N=13
Fibre
Englyst
SFFQ
R=-0.541
P=0.046
N=14
Fibre
Southgate
SFD
R—0.632
P=0.028
N=12
Calcium
SFD
R=-0.725
P=0.008
N=12
R=-0.694
P=0.G12
N=12
R—0.688
P=0.013
N=12
Magnesium
PFFQ
R=-0.560
P=0.046
N=13
R=-0.567
P=0.043
N=13
Magnesium
SFFQ
R=-0.548
P=0.043
N=14
Phosphorous 
S FD
R-0.720
P=0.008
N=12
R=-0.684
P=0.014
N=12
R=-0.621
R=0.031
N=12
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Zinc 
S FD
R=-0.578
P=0.049
N=12
Manganese 
S FFQ
R=-0.556
P=0.039
N=14
Copper 
S FFQ
R=-0.545
P=0.044
N=14
VitD 
P FFQ
R=0.558
P=0.047
N=13
% Carbo 
P FFQ
R=-0.581
P=0.048
N=12
R—0.634
P=0.020
N=13
R=-0.651
P=0.016
N=13
% Fat 
PFFQ
R=0.584
P=0.046
N=12
R=0.616
P=0.025
N=13
% Protein 
SFFQ
R=0.536
P=0.048
N=14
% Protein 
S FD
R=-0.636
P=0.035
N=11
Choi 
S FFQ
R=0.608
P=0.027
N=13
Choi 
S FD
R=-0.657
P=0.020
N=12
R=-0.600
P=0.039
N=12
R=-G.644
R=0.024
N=12
R=-0.692
P=0.013
N=12
R=-0.629
P=0.038
N=11
VitE
SFFQ
R=-0.632
P=0.021
N=13
R=-0.560
P=0.037
N=14
R=-0.583
P=0.029
N=14
Vite  
P FD
R=0.608
P=0.028
N=13
R=0.555
P=0.049
N=13
Protein 
S FD
R=-0.694
P=0.012
N=12
R=-0.595
P=0.041
N=12
R=-0.666
P=0.025
N=11
Carbo R=-0.625
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SFD P=0.030
N=12
.........
Nitrogen 
S FD
R=-0.693
P=0.013
N=12
R=-0.585
P=0.046
N=12
R—0.656
P=0.028
N=11
Chloride
SFD
R=-0.584
P=0.046
N=12
R=-0.621
P=0.041
N=11
R=-0.579
P=0.048
N=12
Selenium
SFD
R=-0.616
P=0.033
N=12
R=-0.650
P=0.022
N=12
R=-0.613
P=0.034
N=12
R=-0,602
P=0.038
N=12
R=-0,722
P=0.008
N=12
R=-0.708
P=0.015
N=11
Tryptophan
SFD
R=-0.674
P=0.016
N=12
R=-0.637
P=0.026
N=12
R=-0.595
P=0.041
N=12
R=-0.585
P=0.046
N=12
R=-0.622
P=0.041
N=11
Energy Kcal 
SFD
R=-0.688
P=0.013
N=12
Sodium
SFD
R=-0.602
P=0.038
N=12
Fat 
S FD
R=-0.741
P=0.006
N=12
SFA 
S FD
R=-0.762
P=0.004
N=12
MUFA 
S FD
R—0.672
P=0.017
N=12
Data compared using pearson correlation and presented (r ,P )
241
Table 5.A.26: Correlations of IGF-1 with FFQ/FD in post-menopausal women
IGF-1
P(1-3)
IGF-1
8(1-3)
IGF-1
P(26-28)
IGF-1
8(26-28)
Water
PFFQ
R=-0.759
P=0.048
N=7
R=-0.861
P=0.013
N=7
Water
SFFQ
R=-0.828
P=0.021
N=7
Protein
PFFQ
R=-0.916
P=0.004
N=7
Protein
SFFQ
R=-0.809
P=0.028
N=7
R=-0.953
P=0.001
N=7
R=-0.840
P=0.018
N=7
Fat
PFFQ
R=-0.825
P=0.022
N=7
Carbo
PFFQ
R=-0.788
P=0.035
N=7
Energy
PFFQ
R=-0.961
P=0.001
N=7
Energy
SFFQ
R=-0.846
P=0.016
N=7
R=-0.863
P=0.012
N=7
Nitrogen
PFFQ
R=-0.960
P=0.003
N=7
Nitrogen
SFFQ
R=-0.820
P=0.024
N=7
R=-0.961 
P=0 001 
N=7
R=-0.836
P=0.019
N=7
MUFA
PFFQ
R=-0.932
P=0.002
N=7
PUFA
SFFQ
R=-0.810
P=0.027
N=7
Starch
PFFQ
R=-0.903
P=0.005
N=7
Starch
PFD
R=0.793
P=0.034
N=7
Fibre
(south)
PFD
R=0.768
P=0.044
N=7
Fibre
(engly)
PFD
R=0.813
P=0.026
N=7
Sodium
PFFQ
R=-0.865
P=0.012
N=7
Potass
PFFQ
R=-0.777
P=0.040
N=7
Potass
SFFQ
R=-0.809
P=0.028
N=7
R=-0.784
P=0.037
N=7
Calcium R—0.818
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SFFQ P=0.025
N=7
Phosph
PFFQ
R=-0.814
P=0.026
N=7
R=-0.979
P=0.000
N=7
R=-0.791
P=0.034
N=7
Phosph
SFFQ
R=-0.785
P=0.037
N=7
R=-0.830
P=-0.021
N=7
R=-0.898
P=0.006
N=7
Iron
PFFQ
R=-0.876
P-0.010
N=7
Copper
PFD
R=0.776
P=0.040
N=7
Zinc
PFFQ
R=-0.792
P=0.034
N=7
R=-0.971
P=0.000
N=7
Zinc
SFFQ
R=-0.870 
P=0 011 
N=7
R=-0.871
P=0.011
N=7
Chloride
PFFQ
R=-0.890
P=0.007
N=7
Mangan
PFFQ
R=-0.755
P=0.050
N=7
Mangan
PFD
R=0.795
P=0.033
N=7
Selen
PFD
R=0.772
P=0.042
N=7
Iodine
SFFQ
R=-0.827
P=0.022
N=7
Thiamin
PFFQ
R=-0.875
P=0.010
N=7
Riboflav
PFFQ
R=-0.779
P=0.039
N=7
Niacin
PFFQ
R=-0.846
P=0.016
N=7
Tryptop
PFFQ
R=-0.901
P=0.006
N=7
Tryptop
SFFQ
R=-0.799
P=0.031
N=7
R=-0.949
P=0.001
N=7
R=-0.826
P=0.022
N=7
Vit B6 
SFFQ
R—-0.876
P=0.010
N=7
R=-0.794
P=0.033
N=7
R=-0.885
P=0.008
N=7
Pantoth
PFFQ
R=-0.874
P=0.010
N=7
Pantoth
SFFQ
R=-0.816
P=0.025
N=7
R=-0.945
P=0.001
N=7 i
R=-0.874
P=0.010
N=7
Data compared using pearson correlation and presented (r , P)
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Table 5.A.27: Correlations of BP-3 and BP-1 with FFQ/FD in post-menopausal
women
BP3
P(1-3)
BPS
S(1-3)
BP3
P(26-28)
BP3
3(26-28)
BP1
P(1-3)
BP1
8(1-3)
BP1
P(26-28)
BP1
8(26-28)
Water
SFD
R=-0.843
P=0.017
N=7
Fat
PFFQ
R=0.878
P=0.009
N=7
Fat
SFFQ
R=0.800
P=0.031
N=7
Carbo
PFFQ
R=0.760
P=0.048
N=7
Energy
PFFQ
R=0.869
P=0.011
N=7
Energy
SFFQ
R-0.791
P=0.034
N=7
R=-0.807
P=0.028
N=7
R—-0.755
P=0.05
N=7
R=0.780
P=0.039
N=7
Nitrogen
SFD
R=-0.758
P=0.049
N=7
R=-0.758
P=0.048
N=7
SFA
PFFQ
R—0.775
P=0.041
N=7
R=-0.779
P=0.039
N=7
MUFA
PFFQ
R=0.803
P=0.030
N=7
MUFA
SFFQ
R=0.755
P=0.050
N=7
PUFA
SFFQ
R=0.804
P=0.029
N=7
Choi
PFD
R=-0.795
P=0.033
N=7
Starch
PFFQ
R=0.850
P=0.015
N=7
Starch
SFD
R=-0.785
P=0.037
N=7
Sugar
SFFQ
R=-0.804
P=0.029
N=7
R=-0.755
P=0.050
N=7
Sugar
SFD
R=-0.762
P=0.047
N=7
Fibre
(south)
PFD
R=-0.764
P=0.046
N=7
Fibre
(south)
SFD
R=-0.853
P=0.015
N=7
Sodium
PFFQ
R=0.852
P=0.015
N=7
Sodium
PFD
R=-0.861
P=0.013
N=7
Sodium
SFD
R—0.802
P=0.030
N=7
R=-0.755
P=0.050
N=7
Potass
SFFQ
R=-0.755
P=0.050
N=7
Potass
SFD
R=-0.831
P=0.020
N=7
Magnes R=-0.792
P=0.034
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SFD N=7
Phos
SFD
R=-0.771
P=0.042
N=7
Iron
SFD
R=-0.850
P=0.015
N=7
Copper
SFFQ
R=-0.833
P=0.020
N=7
R=-0.757
P=0.049
N=7
Copper
SFD
R=-0.840
P=0.018
N=7
R=-0,811
P=0.027
N=7
Chloride
PFFQ
R=0.855
P=0.014
N=7
Chloride
PFD
R=-0.855
P=0.014
N=7
Chloride
SFD
R=-0.772
P=0.042
N=7
Selenium
PFFQ
R=0.902
P=0.005
N=7
R=0.755
P=0.050
N=7
Iodine
SFFQ
R=0.763
P=0.046
N=7
Iodine
SFD
R=-0.766
P=0.044
N-7
Carotene
PFFQ
R=-0,774
P=0.041
N=7
R=-0,760
P=0.047
N=7
Carotene
SFFQ
R=-0.826
P=0.022
N=7
Carotene
PFD
R=-0.777
P=0.040
N=7
Carotene
SFD
R=-0.795
P=0.033
N=7
VitE
SFFQ
R=0.817
P=0.025
N=7
VitE
SFD
R=0.767
P=0.044
N=7
Riboflavin
SFD
R=-0.791
P=0.034
N=7
Niacin
SFD
R=-0.913
P=0.004
N=7
Folate
PFD
R=-0.763
P=0.046
N=7
Folate
SFD
R=-0.874
P=0,010
N=7
Vit B6 
PFFQ
R=0.836
P=0.019
N=7
Biotin
PFD
R=-0.938
P=0.002
N=7
Vite
PFD
R=-0.756
P=0.049
N=7
%carbo
SFD
R=0.803
P=0.03
N=7
%Fat
PFD
R=-0.804
P=0.029
N=7 , , ........... ..
Data compared using pearson correlation and presented { r , P
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